BindingDB Reactant_set_id Ligand SMILES Ligand InChI Ligand InChI Key BindingDB MonomerID BindingDB Ligand Name Target Name Target Source Organism According to Curator or DataSource Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) kon (M-1-s-1) koff (s-1) pH Temp (C) Curation/DataSource Article DOI BindingDB Entry DOI PMID PubChem AID Patent Number Authors Date of publication Date in BindingDB Institution Link to Ligand in BindingDB Link to Target in BindingDB Link to Ligand-Target Pair in BindingDB Ligand HET ID in PDB PDB ID(s) for Ligand-Target Complex PubChem CID PubChem SID ChEBI ID of Ligand ChEMBL ID of Ligand DrugBank ID of Ligand IUPHAR_GRAC ID of Ligand KEGG ID of Ligand ZINC ID of Ligand Number of Protein Chains in Target (>1 implies a multichain complex) BindingDB Target Chain Sequence 1 PDB ID(s) of Target Chain 1 UniProt (SwissProt) Recommended Name of Target Chain 1 UniProt (SwissProt) Entry Name of Target Chain 1 UniProt (SwissProt) Primary ID of Target Chain 1 UniProt (SwissProt) Secondary ID(s) of Target Chain 1 UniProt (SwissProt) Alternative ID(s) of Target Chain 1 UniProt (TrEMBL) Submitted Name of Target Chain 1 UniProt (TrEMBL) Entry Name of Target Chain 1 UniProt (TrEMBL) Primary ID of Target Chain 1 UniProt (TrEMBL) Secondary ID(s) of Target Chain 1 UniProt (TrEMBL) Alternative ID(s) of Target Chain 1 BindingDB Target Chain Sequence 2 PDB ID(s) of Target Chain 2 UniProt (SwissProt) Recommended Name of Target Chain 2 UniProt (SwissProt) Entry Name of Target Chain 2 UniProt (SwissProt) Primary ID of Target Chain 2 UniProt (SwissProt) Secondary ID(s) of Target Chain 2 UniProt (SwissProt) Alternative ID(s) of Target Chain 2 UniProt (TrEMBL) Submitted Name of Target Chain 2 UniProt (TrEMBL) Entry Name of Target Chain 2 UniProt (TrEMBL) Primary ID of Target Chain 2 UniProt (TrEMBL) Secondary ID(s) of Target Chain 2 UniProt (TrEMBL) Alternative ID(s) of Target Chain 2 BindingDB Target Chain Sequence 3 PDB ID(s) of Target Chain 3 UniProt (SwissProt) Recommended Name of Target Chain 3 UniProt (SwissProt) Entry Name of Target Chain 3 UniProt (SwissProt) Primary ID of Target Chain 3 UniProt (SwissProt) Secondary ID(s) of Target Chain 3 UniProt (SwissProt) Alternative ID(s) of Target Chain 3 UniProt (TrEMBL) Submitted Name of Target Chain 3 UniProt (TrEMBL) Entry Name of Target Chain 3 UniProt (TrEMBL) Primary ID of Target Chain 3 UniProt (TrEMBL) Secondary ID(s) of Target Chain 3 UniProt (TrEMBL) Alternative ID(s) of Target Chain 3 BindingDB Target Chain Sequence 4 PDB ID(s) of Target Chain 4 UniProt (SwissProt) Recommended Name of Target Chain 4 UniProt (SwissProt) Entry Name of Target Chain 4 UniProt (SwissProt) Primary ID of Target Chain 4 UniProt (SwissProt) Secondary ID(s) of Target Chain 4 UniProt (SwissProt) Alternative ID(s) of Target Chain 4 UniProt (TrEMBL) Submitted Name of Target Chain 4 UniProt (TrEMBL) Entry Name of Target Chain 4 UniProt (TrEMBL) Primary ID of Target Chain 4 UniProt (TrEMBL) Secondary ID(s) of Target Chain 4 UniProt (TrEMBL) Alternative ID(s) of Target Chain 4 BindingDB Target Chain Sequence 5 PDB ID(s) of Target Chain 5 UniProt (SwissProt) Recommended Name of Target Chain 5 UniProt (SwissProt) Entry Name of Target Chain 5 UniProt (SwissProt) Primary ID of Target Chain 5 UniProt (SwissProt) Secondary ID(s) of Target Chain 5 UniProt (SwissProt) Alternative ID(s) of Target Chain 5 UniProt (TrEMBL) Submitted Name of Target Chain 5 UniProt (TrEMBL) Entry Name of Target Chain 5 UniProt (TrEMBL) Primary ID of Target Chain 5 UniProt (TrEMBL) Secondary ID(s) of Target Chain 5 UniProt (TrEMBL) Alternative ID(s) of Target Chain 5 BindingDB Target Chain Sequence 6 PDB ID(s) of Target Chain 6 UniProt (SwissProt) Recommended Name of Target Chain 6 UniProt (SwissProt) Entry Name of Target Chain 6 UniProt (SwissProt) Primary ID of Target Chain 6 UniProt (SwissProt) Secondary ID(s) of Target Chain 6 UniProt (SwissProt) Alternative ID(s) of Target Chain 6 UniProt (TrEMBL) Submitted Name of Target Chain 6 UniProt (TrEMBL) Entry Name of Target Chain 6 UniProt (TrEMBL) Primary ID of Target Chain 6 UniProt (TrEMBL) Secondary ID(s) of Target Chain 6 UniProt (TrEMBL) Alternative ID(s) of Target Chain 6 BindingDB Target Chain Sequence 7 PDB ID(s) of Target Chain 7 UniProt (SwissProt) Recommended Name of Target Chain 7 UniProt (SwissProt) Entry Name of Target Chain 7 UniProt (SwissProt) Primary ID of Target Chain 7 UniProt (SwissProt) Secondary ID(s) of Target Chain 7 UniProt (SwissProt) Alternative ID(s) of Target Chain 7 UniProt (TrEMBL) Submitted Name of Target Chain 7 UniProt (TrEMBL) Entry Name of Target Chain 7 UniProt (TrEMBL) Primary ID of Target Chain 7 UniProt (TrEMBL) Secondary ID(s) of Target Chain 7 UniProt (TrEMBL) Alternative ID(s) of Target Chain 7 BindingDB Target Chain Sequence 8 PDB ID(s) of Target Chain 8 UniProt (SwissProt) Recommended Name of Target Chain 8 UniProt (SwissProt) Entry Name of Target Chain 8 UniProt (SwissProt) Primary ID of Target Chain 8 UniProt (SwissProt) Secondary ID(s) of Target Chain 8 UniProt (SwissProt) Alternative ID(s) of Target Chain 8 UniProt (TrEMBL) Submitted Name of Target Chain 8 UniProt (TrEMBL) Entry Name of Target Chain 8 UniProt (TrEMBL) Primary ID of Target Chain 8 UniProt (TrEMBL) Secondary ID(s) of Target Chain 8 UniProt (TrEMBL) Alternative ID(s) of Target Chain 8 BindingDB Target Chain Sequence 9 PDB ID(s) of Target Chain 9 UniProt (SwissProt) Recommended Name of Target Chain 9 UniProt (SwissProt) Entry Name of Target Chain 9 UniProt (SwissProt) Primary ID of Target Chain 9 UniProt (SwissProt) Secondary ID(s) of Target Chain 9 UniProt (SwissProt) Alternative ID(s) of Target Chain 9 UniProt (TrEMBL) Submitted Name of Target Chain 9 UniProt (TrEMBL) Entry Name of Target Chain 9 UniProt (TrEMBL) Primary ID of Target Chain 9 UniProt (TrEMBL) Secondary ID(s) of Target Chain 9 UniProt (TrEMBL) Alternative ID(s) of Target Chain 9 BindingDB Target Chain Sequence 10 PDB ID(s) of Target Chain 10 UniProt (SwissProt) Recommended Name of Target Chain 10 UniProt (SwissProt) Entry Name of Target Chain 10 UniProt (SwissProt) Primary ID of Target Chain 10 UniProt (SwissProt) Secondary ID(s) of Target Chain 10 UniProt (SwissProt) Alternative ID(s) of Target Chain 10 UniProt (TrEMBL) Submitted Name of Target Chain 10 UniProt (TrEMBL) Entry Name of Target Chain 10 UniProt (TrEMBL) Primary ID of Target Chain 10 UniProt (TrEMBL) Secondary ID(s) of Target Chain 10 UniProt (TrEMBL) Alternative ID(s) of Target Chain 10 BindingDB Target Chain Sequence 11 PDB ID(s) of Target Chain 11 UniProt (SwissProt) Recommended Name of Target Chain 11 UniProt (SwissProt) Entry Name of Target Chain 11 UniProt (SwissProt) Primary ID of Target Chain 11 UniProt (SwissProt) Secondary ID(s) of Target Chain 11 UniProt (SwissProt) Alternative ID(s) of Target Chain 11 UniProt (TrEMBL) Submitted Name of Target Chain 11 UniProt (TrEMBL) Entry Name of Target Chain 11 UniProt (TrEMBL) Primary ID of Target Chain 11 UniProt (TrEMBL) Secondary ID(s) of Target Chain 11 UniProt (TrEMBL) Alternative ID(s) of Target Chain 11 BindingDB Target Chain Sequence 12 PDB ID(s) of Target Chain 12 UniProt (SwissProt) Recommended Name of Target Chain 12 UniProt (SwissProt) Entry Name of Target Chain 12 UniProt (SwissProt) Primary ID of Target Chain 12 UniProt (SwissProt) Secondary ID(s) of Target Chain 12 UniProt (SwissProt) Alternative ID(s) of Target Chain 12 UniProt (TrEMBL) Submitted Name of Target Chain 12 UniProt (TrEMBL) Entry Name of Target Chain 12 UniProt (TrEMBL) Primary ID of Target Chain 12 UniProt (TrEMBL) Secondary ID(s) of Target Chain 12 UniProt (TrEMBL) Alternative ID(s) of Target Chain 12 BindingDB Target Chain Sequence 13 PDB ID(s) of Target Chain 13 UniProt (SwissProt) Recommended Name of Target Chain 13 UniProt (SwissProt) Entry Name of Target Chain 13 UniProt (SwissProt) Primary ID of Target Chain 13 UniProt (SwissProt) Secondary ID(s) of Target Chain 13 UniProt (SwissProt) Alternative ID(s) of Target Chain 13 UniProt (TrEMBL) Submitted Name of Target Chain 13 UniProt (TrEMBL) Entry Name of Target Chain 13 UniProt (TrEMBL) Primary ID of Target Chain 13 UniProt (TrEMBL) Secondary ID(s) of Target Chain 13 UniProt (TrEMBL) Alternative ID(s) of Target Chain 13 BindingDB Target Chain Sequence 14 PDB ID(s) of Target Chain 14 UniProt (SwissProt) Recommended Name of Target Chain 14 UniProt (SwissProt) Entry Name of Target Chain 14 UniProt (SwissProt) Primary ID of Target Chain 14 UniProt (SwissProt) Secondary ID(s) of Target Chain 14 UniProt (SwissProt) Alternative ID(s) of Target Chain 14 UniProt (TrEMBL) Submitted Name of Target Chain 14 UniProt (TrEMBL) Entry Name of Target Chain 14 UniProt (TrEMBL) Primary ID of Target Chain 14 UniProt (TrEMBL) Secondary ID(s) of Target Chain 14 UniProt (TrEMBL) Alternative ID(s) of Target Chain 14 BindingDB Target Chain Sequence 15 PDB ID(s) of Target Chain 15 UniProt (SwissProt) Recommended Name of Target Chain 15 UniProt (SwissProt) Entry Name of Target Chain 15 UniProt (SwissProt) Primary ID of Target Chain 15 UniProt (SwissProt) Secondary ID(s) of Target Chain 15 UniProt (SwissProt) Alternative ID(s) of Target Chain 15 UniProt (TrEMBL) Submitted Name of Target Chain 15 UniProt (TrEMBL) Entry Name of Target Chain 15 UniProt (TrEMBL) Primary ID of Target Chain 15 UniProt (TrEMBL) Secondary ID(s) of Target Chain 15 UniProt (TrEMBL) Alternative ID(s) of Target Chain 15 BindingDB Target Chain Sequence 16 PDB ID(s) of Target Chain 16 UniProt (SwissProt) Recommended Name of Target Chain 16 UniProt (SwissProt) Entry Name of Target Chain 16 UniProt (SwissProt) Primary ID of Target Chain 16 UniProt (SwissProt) Secondary ID(s) of Target Chain 16 UniProt (SwissProt) Alternative ID(s) of Target Chain 16 UniProt (TrEMBL) Submitted Name of Target Chain 16 UniProt (TrEMBL) Entry Name of Target Chain 16 UniProt (TrEMBL) Primary ID of Target Chain 16 UniProt (TrEMBL) Secondary ID(s) of Target Chain 16 UniProt (TrEMBL) Alternative ID(s) of Target Chain 16 BindingDB Target Chain Sequence 17 PDB ID(s) of Target Chain 17 UniProt (SwissProt) Recommended Name of Target Chain 17 UniProt (SwissProt) Entry Name of Target Chain 17 UniProt (SwissProt) Primary ID of Target Chain 17 UniProt (SwissProt) Secondary ID(s) of Target Chain 17 UniProt (SwissProt) Alternative ID(s) of Target Chain 17 UniProt (TrEMBL) Submitted Name of Target Chain 17 UniProt (TrEMBL) Entry Name of Target Chain 17 UniProt (TrEMBL) Primary ID of Target Chain 17 UniProt (TrEMBL) Secondary ID(s) of Target Chain 17 UniProt (TrEMBL) Alternative ID(s) of Target Chain 17 BindingDB Target Chain Sequence 18 PDB ID(s) of Target Chain 18 UniProt (SwissProt) Recommended Name of Target Chain 18 UniProt (SwissProt) Entry Name of Target Chain 18 UniProt (SwissProt) Primary ID of Target Chain 18 UniProt (SwissProt) Secondary ID(s) of Target Chain 18 UniProt (SwissProt) Alternative ID(s) of Target Chain 18 UniProt (TrEMBL) Submitted Name of Target Chain 18 UniProt (TrEMBL) Entry Name of Target Chain 18 UniProt (TrEMBL) Primary ID of Target Chain 18 UniProt (TrEMBL) Secondary ID(s) of Target Chain 18 UniProt (TrEMBL) Alternative ID(s) of Target Chain 18 BindingDB Target Chain Sequence 19 PDB ID(s) of Target Chain 19 UniProt (SwissProt) Recommended Name of Target Chain 19 UniProt (SwissProt) Entry Name of Target Chain 19 UniProt (SwissProt) Primary ID of Target Chain 19 UniProt (SwissProt) Secondary ID(s) of Target Chain 19 UniProt (SwissProt) Alternative ID(s) of Target Chain 19 UniProt (TrEMBL) Submitted Name of Target Chain 19 UniProt (TrEMBL) Entry Name of Target Chain 19 UniProt (TrEMBL) Primary ID of Target Chain 19 UniProt (TrEMBL) Secondary ID(s) of Target Chain 19 UniProt (TrEMBL) Alternative ID(s) of Target Chain 19 BindingDB Target Chain Sequence 20 PDB ID(s) of Target Chain 20 UniProt (SwissProt) Recommended Name of Target Chain 20 UniProt (SwissProt) Entry Name of Target Chain 20 UniProt (SwissProt) Primary ID of Target Chain 20 UniProt (SwissProt) Secondary ID(s) of Target Chain 20 UniProt (SwissProt) Alternative ID(s) of Target Chain 20 UniProt (TrEMBL) Submitted Name of Target Chain 20 UniProt (TrEMBL) Entry Name of Target Chain 20 UniProt (TrEMBL) Primary ID of Target Chain 20 UniProt (TrEMBL) Secondary ID(s) of Target Chain 20 UniProt (TrEMBL) Alternative ID(s) of Target Chain 20 BindingDB Target Chain Sequence 21 PDB ID(s) of Target Chain 21 UniProt (SwissProt) Recommended Name of Target Chain 21 UniProt (SwissProt) Entry Name of Target Chain 21 UniProt (SwissProt) Primary ID of Target Chain 21 UniProt (SwissProt) Secondary ID(s) of Target Chain 21 UniProt (SwissProt) Alternative ID(s) of Target Chain 21 UniProt (TrEMBL) Submitted Name of Target Chain 21 UniProt (TrEMBL) Entry Name of Target Chain 21 UniProt (TrEMBL) Primary ID of Target Chain 21 UniProt (TrEMBL) Secondary ID(s) of Target Chain 21 UniProt (TrEMBL) Alternative ID(s) of Target Chain 21 BindingDB Target Chain Sequence 22 PDB ID(s) of Target Chain 22 UniProt (SwissProt) Recommended Name of Target Chain 22 UniProt (SwissProt) Entry Name of Target Chain 22 UniProt (SwissProt) Primary ID of Target Chain 22 UniProt (SwissProt) Secondary ID(s) of Target Chain 22 UniProt (SwissProt) Alternative ID(s) of Target Chain 22 UniProt (TrEMBL) Submitted Name of Target Chain 22 UniProt (TrEMBL) Entry Name of Target Chain 22 UniProt (TrEMBL) Primary ID of Target Chain 22 UniProt (TrEMBL) Secondary ID(s) of Target Chain 22 UniProt (TrEMBL) Alternative ID(s) of Target Chain 22 BindingDB Target Chain Sequence 23 PDB ID(s) of Target Chain 23 UniProt (SwissProt) Recommended Name of Target Chain 23 UniProt (SwissProt) Entry Name of Target Chain 23 UniProt (SwissProt) Primary ID of Target Chain 23 UniProt (SwissProt) Secondary ID(s) of Target Chain 23 UniProt (SwissProt) Alternative ID(s) of Target Chain 23 UniProt (TrEMBL) Submitted Name of Target Chain 23 UniProt (TrEMBL) Entry Name of Target Chain 23 UniProt (TrEMBL) Primary ID of Target Chain 23 UniProt (TrEMBL) Secondary ID(s) of Target Chain 23 UniProt (TrEMBL) Alternative ID(s) of Target Chain 23 BindingDB Target Chain Sequence 24 PDB ID(s) of Target Chain 24 UniProt (SwissProt) Recommended Name of Target Chain 24 UniProt (SwissProt) Entry Name of Target Chain 24 UniProt (SwissProt) Primary ID of Target Chain 24 UniProt (SwissProt) Secondary ID(s) of Target Chain 24 UniProt (SwissProt) Alternative ID(s) of Target Chain 24 UniProt (TrEMBL) Submitted Name of Target Chain 24 UniProt (TrEMBL) Entry Name of Target Chain 24 UniProt (TrEMBL) Primary ID of Target Chain 24 UniProt (TrEMBL) Secondary ID(s) of Target Chain 24 UniProt (TrEMBL) Alternative ID(s) of Target Chain 24 BindingDB Target Chain Sequence 25 PDB ID(s) of Target Chain 25 UniProt (SwissProt) Recommended Name of Target Chain 25 UniProt (SwissProt) Entry Name of Target Chain 25 UniProt (SwissProt) Primary ID of Target Chain 25 UniProt (SwissProt) Secondary ID(s) of Target Chain 25 UniProt (SwissProt) Alternative ID(s) of Target Chain 25 UniProt (TrEMBL) Submitted Name of Target Chain 25 UniProt (TrEMBL) Entry Name of Target Chain 25 UniProt (TrEMBL) Primary ID of Target Chain 25 UniProt (TrEMBL) Secondary ID(s) of Target Chain 25 UniProt (TrEMBL) Alternative ID(s) of Target Chain 25 BindingDB Target Chain Sequence 26 PDB ID(s) of Target Chain 26 UniProt (SwissProt) Recommended Name of Target Chain 26 UniProt (SwissProt) Entry Name of Target Chain 26 UniProt (SwissProt) Primary ID of Target Chain 26 UniProt (SwissProt) Secondary ID(s) of Target Chain 26 UniProt (SwissProt) Alternative ID(s) of Target Chain 26 UniProt (TrEMBL) Submitted Name of Target Chain 26 UniProt (TrEMBL) Entry Name of Target Chain 26 UniProt (TrEMBL) Primary ID of Target Chain 26 UniProt (TrEMBL) Secondary ID(s) of Target Chain 26 UniProt (TrEMBL) Alternative ID(s) of Target Chain 26 BindingDB Target Chain Sequence 27 PDB ID(s) of Target Chain 27 UniProt (SwissProt) Recommended Name of Target Chain 27 UniProt (SwissProt) Entry Name of Target Chain 27 UniProt (SwissProt) Primary ID of Target Chain 27 UniProt (SwissProt) Secondary ID(s) of Target Chain 27 UniProt (SwissProt) Alternative ID(s) of Target Chain 27 UniProt (TrEMBL) Submitted Name of Target Chain 27 UniProt (TrEMBL) Entry Name of Target Chain 27 UniProt (TrEMBL) Primary ID of Target Chain 27 UniProt (TrEMBL) Secondary ID(s) of Target Chain 27 UniProt (TrEMBL) Alternative ID(s) of Target Chain 27 BindingDB Target Chain Sequence 28 PDB ID(s) of Target Chain 28 UniProt (SwissProt) Recommended Name of Target Chain 28 UniProt (SwissProt) Entry Name of Target Chain 28 UniProt (SwissProt) Primary ID of Target Chain 28 UniProt (SwissProt) Secondary ID(s) of Target Chain 28 UniProt (SwissProt) Alternative ID(s) of Target Chain 28 UniProt (TrEMBL) Submitted Name of Target Chain 28 UniProt (TrEMBL) Entry Name of Target Chain 28 UniProt (TrEMBL) Primary ID of Target Chain 28 UniProt (TrEMBL) Secondary ID(s) of Target Chain 28 UniProt (TrEMBL) Alternative ID(s) of Target Chain 28 BindingDB Target Chain Sequence 29 PDB ID(s) of Target Chain 29 UniProt (SwissProt) Recommended Name of Target Chain 29 UniProt (SwissProt) Entry Name of Target Chain 29 UniProt (SwissProt) Primary ID of Target Chain 29 UniProt (SwissProt) Secondary ID(s) of Target Chain 29 UniProt (SwissProt) Alternative ID(s) of Target Chain 29 UniProt (TrEMBL) Submitted Name of Target Chain 29 UniProt (TrEMBL) Entry Name of Target Chain 29 UniProt (TrEMBL) Primary ID of Target Chain 29 UniProt (TrEMBL) Secondary ID(s) of Target Chain 29 UniProt (TrEMBL) Alternative ID(s) of Target Chain 29 BindingDB Target Chain Sequence 30 PDB ID(s) of Target Chain 30 UniProt (SwissProt) Recommended Name of Target Chain 30 UniProt (SwissProt) Entry Name of Target Chain 30 UniProt (SwissProt) Primary ID of Target Chain 30 UniProt (SwissProt) Secondary ID(s) of Target Chain 30 UniProt (SwissProt) Alternative ID(s) of Target Chain 30 UniProt (TrEMBL) Submitted Name of Target Chain 30 UniProt (TrEMBL) Entry Name of Target Chain 30 UniProt (TrEMBL) Primary ID of Target Chain 30 UniProt (TrEMBL) Secondary ID(s) of Target Chain 30 UniProt (TrEMBL) Alternative ID(s) of Target Chain 30 BindingDB Target Chain Sequence 31 PDB ID(s) of Target Chain 31 UniProt (SwissProt) Recommended Name of Target Chain 31 UniProt (SwissProt) Entry Name of Target Chain 31 UniProt (SwissProt) Primary ID of Target Chain 31 UniProt (SwissProt) Secondary ID(s) of Target Chain 31 UniProt (SwissProt) Alternative ID(s) of Target Chain 31 UniProt (TrEMBL) Submitted Name of Target Chain 31 UniProt (TrEMBL) Entry Name of Target Chain 31 UniProt (TrEMBL) Primary ID of Target Chain 31 UniProt (TrEMBL) Secondary ID(s) of Target Chain 31 UniProt (TrEMBL) Alternative ID(s) of Target Chain 31 BindingDB Target Chain Sequence 32 PDB ID(s) of Target Chain 32 UniProt (SwissProt) Recommended Name of Target Chain 32 UniProt (SwissProt) Entry Name of Target Chain 32 UniProt (SwissProt) Primary ID of Target Chain 32 UniProt (SwissProt) Secondary ID(s) of Target Chain 32 UniProt (SwissProt) Alternative ID(s) of Target Chain 32 UniProt (TrEMBL) Submitted Name of Target Chain 32 UniProt (TrEMBL) Entry Name of Target Chain 32 UniProt (TrEMBL) Primary ID of Target Chain 32 UniProt (TrEMBL) Secondary ID(s) of Target Chain 32 UniProt (TrEMBL) Alternative ID(s) of Target Chain 32 BindingDB Target Chain Sequence 33 PDB ID(s) of Target Chain 33 UniProt (SwissProt) Recommended Name of Target Chain 33 UniProt (SwissProt) Entry Name of Target Chain 33 UniProt (SwissProt) Primary ID of Target Chain 33 UniProt (SwissProt) Secondary ID(s) of Target Chain 33 UniProt (SwissProt) Alternative ID(s) of Target Chain 33 UniProt (TrEMBL) Submitted Name of Target Chain 33 UniProt (TrEMBL) Entry Name of Target Chain 33 UniProt (TrEMBL) Primary ID of Target Chain 33 UniProt (TrEMBL) Secondary ID(s) of Target Chain 33 UniProt (TrEMBL) Alternative ID(s) of Target Chain 33 BindingDB Target Chain Sequence 34 PDB ID(s) of Target Chain 34 UniProt (SwissProt) Recommended Name of Target Chain 34 UniProt (SwissProt) Entry Name of Target Chain 34 UniProt (SwissProt) Primary ID of Target Chain 34 UniProt (SwissProt) Secondary ID(s) of Target Chain 34 UniProt (SwissProt) Alternative ID(s) of Target Chain 34 UniProt (TrEMBL) Submitted Name of Target Chain 34 UniProt (TrEMBL) Entry Name of Target Chain 34 UniProt (TrEMBL) Primary ID of Target Chain 34 UniProt (TrEMBL) Secondary ID(s) of Target Chain 34 UniProt (TrEMBL) Alternative ID(s) of Target Chain 34 BindingDB Target Chain Sequence 35 PDB ID(s) of Target Chain 35 UniProt (SwissProt) Recommended Name of Target Chain 35 UniProt (SwissProt) Entry Name of Target Chain 35 UniProt (SwissProt) Primary ID of Target Chain 35 UniProt (SwissProt) Secondary ID(s) of Target Chain 35 UniProt (SwissProt) Alternative ID(s) of Target Chain 35 UniProt (TrEMBL) Submitted Name of Target Chain 35 UniProt (TrEMBL) Entry Name of Target Chain 35 UniProt (TrEMBL) Primary ID of Target Chain 35 UniProt (TrEMBL) Secondary ID(s) of Target Chain 35 UniProt (TrEMBL) Alternative ID(s) of Target Chain 35 BindingDB Target Chain Sequence 36 PDB ID(s) of Target Chain 36 UniProt (SwissProt) Recommended Name of Target Chain 36 UniProt (SwissProt) Entry Name of Target Chain 36 UniProt (SwissProt) Primary ID of Target Chain 36 UniProt (SwissProt) Secondary ID(s) of Target Chain 36 UniProt (SwissProt) Alternative ID(s) of Target Chain 36 UniProt (TrEMBL) Submitted Name of Target Chain 36 UniProt (TrEMBL) Entry Name of Target Chain 36 UniProt (TrEMBL) Primary ID of Target Chain 36 UniProt (TrEMBL) Secondary ID(s) of Target Chain 36 UniProt (TrEMBL) Alternative ID(s) of Target Chain 36 BindingDB Target Chain Sequence 37 PDB ID(s) of Target Chain 37 UniProt (SwissProt) Recommended Name of Target Chain 37 UniProt (SwissProt) Entry Name of Target Chain 37 UniProt (SwissProt) Primary ID of Target Chain 37 UniProt (SwissProt) Secondary ID(s) of Target Chain 37 UniProt (SwissProt) Alternative ID(s) of Target Chain 37 UniProt (TrEMBL) Submitted Name of Target Chain 37 UniProt (TrEMBL) Entry Name of Target Chain 37 UniProt (TrEMBL) Primary ID of Target Chain 37 UniProt (TrEMBL) Secondary ID(s) of Target Chain 37 UniProt (TrEMBL) Alternative ID(s) of Target Chain 37 BindingDB Target Chain Sequence 38 PDB ID(s) of Target Chain 38 UniProt (SwissProt) Recommended Name of Target Chain 38 UniProt (SwissProt) Entry Name of Target Chain 38 UniProt (SwissProt) Primary ID of Target Chain 38 UniProt (SwissProt) Secondary ID(s) of Target Chain 38 UniProt (SwissProt) Alternative ID(s) of Target Chain 38 UniProt (TrEMBL) Submitted Name of Target Chain 38 UniProt (TrEMBL) Entry Name of Target Chain 38 UniProt (TrEMBL) Primary ID of Target Chain 38 UniProt (TrEMBL) Secondary ID(s) of Target Chain 38 UniProt (TrEMBL) Alternative ID(s) of Target Chain 38 BindingDB Target Chain Sequence 39 PDB ID(s) of Target Chain 39 UniProt (SwissProt) Recommended Name of Target Chain 39 UniProt (SwissProt) Entry Name of Target Chain 39 UniProt (SwissProt) Primary ID of Target Chain 39 UniProt (SwissProt) Secondary ID(s) of Target Chain 39 UniProt (SwissProt) Alternative ID(s) of Target Chain 39 UniProt (TrEMBL) Submitted Name of Target Chain 39 UniProt (TrEMBL) Entry Name of Target Chain 39 UniProt (TrEMBL) Primary ID of Target Chain 39 UniProt (TrEMBL) Secondary ID(s) of Target Chain 39 UniProt (TrEMBL) Alternative ID(s) of Target Chain 39 BindingDB Target Chain Sequence 40 PDB ID(s) of Target Chain 40 UniProt (SwissProt) Recommended Name of Target Chain 40 UniProt (SwissProt) Entry Name of Target Chain 40 UniProt (SwissProt) Primary ID of Target Chain 40 UniProt (SwissProt) Secondary ID(s) of Target Chain 40 UniProt (SwissProt) Alternative ID(s) of Target Chain 40 UniProt (TrEMBL) Submitted Name of Target Chain 40 UniProt (TrEMBL) Entry Name of Target Chain 40 UniProt (TrEMBL) Primary ID of Target Chain 40 UniProt (TrEMBL) Secondary ID(s) of Target Chain 40 UniProt (TrEMBL) Alternative ID(s) of Target Chain 40 BindingDB Target Chain Sequence 41 PDB ID(s) of Target Chain 41 UniProt (SwissProt) Recommended Name of Target Chain 41 UniProt (SwissProt) Entry Name of Target Chain 41 UniProt (SwissProt) Primary ID of Target Chain 41 UniProt (SwissProt) Secondary ID(s) of Target Chain 41 UniProt (SwissProt) Alternative ID(s) of Target Chain 41 UniProt (TrEMBL) Submitted Name of Target Chain 41 UniProt (TrEMBL) Entry Name of Target Chain 41 UniProt (TrEMBL) Primary ID of Target Chain 41 UniProt (TrEMBL) Secondary ID(s) of Target Chain 41 UniProt (TrEMBL) Alternative ID(s) of Target Chain 41 BindingDB Target Chain Sequence 42 PDB ID(s) of Target Chain 42 UniProt (SwissProt) Recommended Name of Target Chain 42 UniProt (SwissProt) Entry Name of Target Chain 42 UniProt (SwissProt) Primary ID of Target Chain 42 UniProt (SwissProt) Secondary ID(s) of Target Chain 42 UniProt (SwissProt) Alternative ID(s) of Target Chain 42 UniProt (TrEMBL) Submitted Name of Target Chain 42 UniProt (TrEMBL) Entry Name of Target Chain 42 UniProt (TrEMBL) Primary ID of Target Chain 42 UniProt (TrEMBL) Secondary ID(s) of Target Chain 42 UniProt (TrEMBL) Alternative ID(s) of Target Chain 42 BindingDB Target Chain Sequence 43 PDB ID(s) of Target Chain 43 UniProt (SwissProt) Recommended Name of Target Chain 43 UniProt (SwissProt) Entry Name of Target Chain 43 UniProt (SwissProt) Primary ID of Target Chain 43 UniProt (SwissProt) Secondary ID(s) of Target Chain 43 UniProt (SwissProt) Alternative ID(s) of Target Chain 43 UniProt (TrEMBL) Submitted Name of Target Chain 43 UniProt (TrEMBL) Entry Name of Target Chain 43 UniProt (TrEMBL) Primary ID of Target Chain 43 UniProt (TrEMBL) Secondary ID(s) of Target Chain 43 UniProt (TrEMBL) Alternative ID(s) of Target Chain 43 BindingDB Target Chain Sequence 44 PDB ID(s) of Target Chain 44 UniProt (SwissProt) Recommended Name of Target Chain 44 UniProt (SwissProt) Entry Name of Target Chain 44 UniProt (SwissProt) Primary ID of Target Chain 44 UniProt (SwissProt) Secondary ID(s) of Target Chain 44 UniProt (SwissProt) Alternative ID(s) of Target Chain 44 UniProt (TrEMBL) Submitted Name of Target Chain 44 UniProt (TrEMBL) Entry Name of Target Chain 44 UniProt (TrEMBL) Primary ID of Target Chain 44 UniProt (TrEMBL) Secondary ID(s) of Target Chain 44 UniProt (TrEMBL) Alternative ID(s) of Target Chain 44 BindingDB Target Chain Sequence 45 PDB ID(s) of Target Chain 45 UniProt (SwissProt) Recommended Name of Target Chain 45 UniProt (SwissProt) Entry Name of Target Chain 45 UniProt (SwissProt) Primary ID of Target Chain 45 UniProt (SwissProt) Secondary ID(s) of Target Chain 45 UniProt (SwissProt) Alternative ID(s) of Target Chain 45 UniProt (TrEMBL) Submitted Name of Target Chain 45 UniProt (TrEMBL) Entry Name of Target Chain 45 UniProt (TrEMBL) Primary ID of Target Chain 45 UniProt (TrEMBL) Secondary ID(s) of Target Chain 45 UniProt (TrEMBL) Alternative ID(s) of Target Chain 45 BindingDB Target Chain Sequence 46 PDB ID(s) of Target Chain 46 UniProt (SwissProt) Recommended Name of Target Chain 46 UniProt (SwissProt) Entry Name of Target Chain 46 UniProt (SwissProt) Primary ID of Target Chain 46 UniProt (SwissProt) Secondary ID(s) of Target Chain 46 UniProt (SwissProt) Alternative ID(s) of Target Chain 46 UniProt (TrEMBL) Submitted Name of Target Chain 46 UniProt (TrEMBL) Entry Name of Target Chain 46 UniProt (TrEMBL) Primary ID of Target Chain 46 UniProt (TrEMBL) Secondary ID(s) of Target Chain 46 UniProt (TrEMBL) Alternative ID(s) of Target Chain 46 BindingDB Target Chain Sequence 47 PDB ID(s) of Target Chain 47 UniProt (SwissProt) Recommended Name of Target Chain 47 UniProt (SwissProt) Entry Name of Target Chain 47 UniProt (SwissProt) Primary ID of Target Chain 47 UniProt (SwissProt) Secondary ID(s) of Target Chain 47 UniProt (SwissProt) Alternative ID(s) of Target Chain 47 UniProt (TrEMBL) Submitted Name of Target Chain 47 UniProt (TrEMBL) Entry Name of Target Chain 47 UniProt (TrEMBL) Primary ID of Target Chain 47 UniProt (TrEMBL) Secondary ID(s) of Target Chain 47 UniProt (TrEMBL) Alternative ID(s) of Target Chain 47 BindingDB Target Chain Sequence 48 PDB ID(s) of Target Chain 48 UniProt (SwissProt) Recommended Name of Target Chain 48 UniProt (SwissProt) Entry Name of Target Chain 48 UniProt (SwissProt) Primary ID of Target Chain 48 UniProt (SwissProt) Secondary ID(s) of Target Chain 48 UniProt (SwissProt) Alternative ID(s) of Target Chain 48 UniProt (TrEMBL) Submitted Name of Target Chain 48 UniProt (TrEMBL) Entry Name of Target Chain 48 UniProt (TrEMBL) Primary ID of Target Chain 48 UniProt (TrEMBL) Secondary ID(s) of Target Chain 48 UniProt (TrEMBL) Alternative ID(s) of Target Chain 48 BindingDB Target Chain Sequence 49 PDB ID(s) of Target Chain 49 UniProt (SwissProt) Recommended Name of Target Chain 49 UniProt (SwissProt) Entry Name of Target Chain 49 UniProt (SwissProt) Primary ID of Target Chain 49 UniProt (SwissProt) Secondary ID(s) of Target Chain 49 UniProt (SwissProt) Alternative ID(s) of Target Chain 49 UniProt (TrEMBL) Submitted Name of Target Chain 49 UniProt (TrEMBL) Entry Name of Target Chain 49 UniProt (TrEMBL) Primary ID of Target Chain 49 UniProt (TrEMBL) Secondary ID(s) of Target Chain 49 UniProt (TrEMBL) Alternative ID(s) of Target Chain 49 BindingDB Target Chain Sequence 50 PDB ID(s) of Target Chain 50 UniProt (SwissProt) Recommended Name of Target Chain 50 UniProt (SwissProt) Entry Name of Target Chain 50 UniProt (SwissProt) Primary ID of Target Chain 50 UniProt (SwissProt) Secondary ID(s) of Target Chain 50 UniProt (SwissProt) Alternative ID(s) of Target Chain 50 UniProt (TrEMBL) Submitted Name of Target Chain 50 UniProt (TrEMBL) Entry Name of Target Chain 50 UniProt (TrEMBL) Primary ID of Target Chain 50 UniProt (TrEMBL) Secondary ID(s) of Target Chain 50 UniProt (TrEMBL) Alternative ID(s) of Target Chain 50 1199905 Fc1cc(ccc1N1CCC(F)(F)CC1)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O2/c15-10-7-9(11-8-22-13(21)19-18-11)1-2-12(10)20-5-3-14(16,17)4-6-20/h1-2,7H,3-6,8H2,(H,19,21) IAOAVCNNXDYQHL-UHFFFAOYSA-N 568562 5-[4-(4,4-Difluoropiperidin-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 1 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 275 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568562 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568562&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462999 473129876 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199906 Fc1cc(ccc1N1CCC(F)(F)CC1)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O2/c15-10-7-9(11-8-22-13(21)19-18-11)1-2-12(10)20-5-3-14(16,17)4-6-20/h1-2,7H,3-6,8H2,(H,19,21) IAOAVCNNXDYQHL-UHFFFAOYSA-N 568562 5-[4-(4,4-Difluoropiperidin-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 1 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 173 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568562 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568562&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462999 473129876 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199907 Fc1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) SMFWRPQNFNKFCN-UHFFFAOYSA-N 568563 5-[4′-Fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 3 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 285 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568563 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568563&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462948 473129877 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199908 Fc1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) SMFWRPQNFNKFCN-UHFFFAOYSA-N 568563 5-[4′-Fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 3 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 197 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568563 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568563&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462948 473129877 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199909 Fc1cc(ccc1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C13H14FN3O3/c14-10-7-9(11-8-20-13(18)16-15-11)1-2-12(10)17-3-5-19-6-4-17/h1-2,7H,3-6,8H2,(H,16,18) DNLCENYRYRBODW-UHFFFAOYSA-N 568564 5-[3-Fluoro-4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 4 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 203 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568564 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568564&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462706 473129878 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199910 Fc1cc(ccc1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C13H14FN3O3/c14-10-7-9(11-8-20-13(18)16-15-11)1-2-12(10)17-3-5-19-6-4-17/h1-2,7H,3-6,8H2,(H,16,18) DNLCENYRYRBODW-UHFFFAOYSA-N 568564 5-[3-Fluoro-4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 4 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 154 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568564 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568564&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462706 473129878 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199911 CC1(F)CCN(CC1)c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H17F2N3O2/c1-15(17)4-6-20(7-5-15)13-3-2-10(8-11(13)16)12-9-22-14(21)19-18-12/h2-3,8H,4-7,9H2,1H3,(H,19,21) QFISQTCTFMEIEA-UHFFFAOYSA-N 568565 5-[3-Fluoro-4-(4-fluoro-4-methylpiperidin-1-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 5 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 139 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568565 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568565&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462811 473129879 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199912 CC1(F)CCN(CC1)c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H17F2N3O2/c1-15(17)4-6-20(7-5-15)13-3-2-10(8-11(13)16)12-9-22-14(21)19-18-12/h2-3,8H,4-7,9H2,1H3,(H,19,21) QFISQTCTFMEIEA-UHFFFAOYSA-N 568565 5-[3-Fluoro-4-(4-fluoro-4-methylpiperidin-1-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 5 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 97.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568565 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568565&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462811 473129879 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199913 FC1CCN(CC1)c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H15F2N3O2/c15-10-3-5-19(6-4-10)13-2-1-9(7-11(13)16)12-8-21-14(20)18-17-12/h1-2,7,10H,3-6,8H2,(H,18,20) CIGVECSETGHGOE-UHFFFAOYSA-N 568566 5-[3-Fluoro-4-(4-fluoropiperidin-1-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 6 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568566 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568566&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462796 473129880 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199914 FC1CCN(CC1)c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H15F2N3O2/c15-10-3-5-19(6-4-10)13-2-1-9(7-11(13)16)12-8-21-14(20)18-17-12/h1-2,7,10H,3-6,8H2,(H,18,20) CIGVECSETGHGOE-UHFFFAOYSA-N 568566 5-[3-Fluoro-4-(4-fluoropiperidin-1-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 6 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568566 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568566&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462796 473129880 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199915 Cc1cc(ccc1-c1ccc(F)cc1)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-8-12(15-9-21-16(20)19-18-15)4-7-14(10)11-2-5-13(17)6-3-11/h2-8H,9H2,1H3,(H,19,20) YLUKCTBUOSXKSW-UHFFFAOYSA-N 568567 5-(4′-Fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 7 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568567 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568567&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462894 473129881 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199916 Cc1cc(ccc1-c1ccc(F)cc1)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-8-12(15-9-21-16(20)19-18-15)4-7-14(10)11-2-5-13(17)6-3-11/h2-8H,9H2,1H3,(H,19,20) YLUKCTBUOSXKSW-UHFFFAOYSA-N 568567 5-(4′-Fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 7 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568567 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568567&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462894 473129881 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199917 Cc1cc(ccc1-c1ccc(F)c(F)c1)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-6-11(15-8-22-16(21)20-19-15)2-4-12(9)10-3-5-13(17)14(18)7-10/h2-7H,8H2,1H3,(H,20,21) AIPYAMAXIWSKFZ-UHFFFAOYSA-N 568568 5-(3′,4′-Difluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 8 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568568 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568568&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462927 473129882 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199918 Cc1cc(ccc1-c1ccc(F)c(F)c1)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-6-11(15-8-22-16(21)20-19-15)2-4-12(9)10-3-5-13(17)14(18)7-10/h2-7H,8H2,1H3,(H,20,21) AIPYAMAXIWSKFZ-UHFFFAOYSA-N 568568 5-(3′,4′-Difluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 8 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 243 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568568 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568568&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462927 473129882 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199919 Cc1cc(F)ccc1-c1ccc(cc1C)C1=NNC(=O)OC1 InChI=1S/C17H15FN2O2/c1-10-7-12(16-9-22-17(21)20-19-16)3-5-14(10)15-6-4-13(18)8-11(15)2/h3-8H,9H2,1-2H3,(H,20,21) KFXQIFWQTIFMSH-UHFFFAOYSA-N 568569 5-(4′-Fluoro-2,2′-dimethylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 9 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 440 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568569 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568569&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463031 473129883 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199920 Cc1cc(F)ccc1-c1ccc(cc1C)C1=NNC(=O)OC1 InChI=1S/C17H15FN2O2/c1-10-7-12(16-9-22-17(21)20-19-16)3-5-14(10)15-6-4-13(18)8-11(15)2/h3-8H,9H2,1-2H3,(H,20,21) KFXQIFWQTIFMSH-UHFFFAOYSA-N 568569 5-(4′-Fluoro-2,2′-dimethylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 9 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568569 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568569&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463031 473129883 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199921 Cc1cc(ccc1C1=CCOCC1)C1=NNC(=O)OC1 InChI=1S/C15H16N2O3/c1-10-8-12(14-9-20-15(18)17-16-14)2-3-13(10)11-4-6-19-7-5-11/h2-4,8H,5-7,9H2,1H3,(H,17,18) FGQWFNHAMCLANG-UHFFFAOYSA-N 568570 5-[4-(3,6-Dihydro-2H-pyran-4-yl)-3-methylphenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 10 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568570 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568570&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462974 473129884 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199922 Cc1cc(ccc1C1=CCOCC1)C1=NNC(=O)OC1 InChI=1S/C15H16N2O3/c1-10-8-12(14-9-20-15(18)17-16-14)2-3-13(10)11-4-6-19-7-5-11/h2-4,8H,5-7,9H2,1H3,(H,17,18) FGQWFNHAMCLANG-UHFFFAOYSA-N 568570 5-[4-(3,6-Dihydro-2H-pyran-4-yl)-3-methylphenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 10 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 230 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568570 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568570&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462974 473129884 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199923 Cc1cc(ccc1-c1cn[nH]c1)C1=NNC(=O)OC1 InChI=1S/C13H12N4O2/c1-8-4-9(12-7-19-13(18)17-16-12)2-3-11(8)10-5-14-15-6-10/h2-6H,7H2,1H3,(H,14,15)(H,17,18) GZZCJPJEWUZDJO-UHFFFAOYSA-N 568571 5-[3-Methyl-4-(1H-pyrazol-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 11 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 84.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568571 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568571&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463001 473129885 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199924 Cc1cc(ccc1-c1cn[nH]c1)C1=NNC(=O)OC1 InChI=1S/C13H12N4O2/c1-8-4-9(12-7-19-13(18)17-16-12)2-3-11(8)10-5-14-15-6-10/h2-6H,7H2,1H3,(H,14,15)(H,17,18) GZZCJPJEWUZDJO-UHFFFAOYSA-N 568571 5-[3-Methyl-4-(1H-pyrazol-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 11 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568571 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568571&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463001 473129885 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199925 Cc1cc(ccc1-c1cccnc1)C1=NNC(=O)OC1 InChI=1S/C15H13N3O2/c1-10-7-11(14-9-20-15(19)18-17-14)4-5-13(10)12-3-2-6-16-8-12/h2-8H,9H2,1H3,(H,18,19) QXGXIMVUONSLBZ-UHFFFAOYSA-N 568572 5-[3-Methyl-4-(pyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 13 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568572 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568572&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462753 473129886 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199926 Cc1cc(ccc1-c1cccnc1)C1=NNC(=O)OC1 InChI=1S/C15H13N3O2/c1-10-7-11(14-9-20-15(19)18-17-14)4-5-13(10)12-3-2-6-16-8-12/h2-8H,9H2,1H3,(H,18,19) QXGXIMVUONSLBZ-UHFFFAOYSA-N 568572 5-[3-Methyl-4-(pyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 13 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 44.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568572 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568572&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462753 473129886 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199927 Cc1cc(ccc1-c1cccc(F)c1)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-7-12(15-9-21-16(20)19-18-15)5-6-14(10)11-3-2-4-13(17)8-11/h2-8H,9H2,1H3,(H,19,20) FWSBAFBJDFBZBA-UHFFFAOYSA-N 568573 5-(3′-Fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 15 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568573 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568573&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462707 473129887 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199928 Cc1cc(ccc1-c1cccc(F)c1)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-7-12(15-9-21-16(20)19-18-15)5-6-14(10)11-3-2-4-13(17)8-11/h2-8H,9H2,1H3,(H,19,20) FWSBAFBJDFBZBA-UHFFFAOYSA-N 568573 5-(3′-Fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 15 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568573 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568573&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462707 473129887 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199929 CC1OC(=O)NN=C1c1cc(F)c(N2CCOCC2)c(F)c1 InChI=1S/C14H15F2N3O3/c1-8-12(17-18-14(20)22-8)9-6-10(15)13(11(16)7-9)19-2-4-21-5-3-19/h6-8H,2-5H2,1H3,(H,18,20) DDUUYOMHMNPPCN-UHFFFAOYSA-N 568574 (rac)-5-[3,5-Difluoro-4-(morpholin-4-yl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 17 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 25.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568574 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568574&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462815 473129888 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199930 CC1OC(=O)NN=C1c1cc(F)c(N2CCOCC2)c(F)c1 InChI=1S/C14H15F2N3O3/c1-8-12(17-18-14(20)22-8)9-6-10(15)13(11(16)7-9)19-2-4-21-5-3-19/h6-8H,2-5H2,1H3,(H,18,20) DDUUYOMHMNPPCN-UHFFFAOYSA-N 568574 (rac)-5-[3,5-Difluoro-4-(morpholin-4-yl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 17 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 17.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568574 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568574&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462815 473129888 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199931 CC1CN(CCO1)c1c(F)cc(cc1F)C1=NNC(=O)OC1C InChI=1S/C15H17F2N3O3/c1-8-7-20(3-4-22-8)14-11(16)5-10(6-12(14)17)13-9(2)23-15(21)19-18-13/h5-6,8-9H,3-4,7H2,1-2H3,(H,19,21) LXBKJCJUKWFNBR-UHFFFAOYSA-N 568575 5-{3,5-Difluoro-4-[2-methylmorpholin-4-yl]phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (Mixture of stereoisomers)::US11427553, Example 18 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 450 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568575 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568575&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465183 473129889 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199932 CC1CN(CCO1)c1c(F)cc(cc1F)C1=NNC(=O)OC1C InChI=1S/C15H17F2N3O3/c1-8-7-20(3-4-22-8)14-11(16)5-10(6-12(14)17)13-9(2)23-15(21)19-18-13/h5-6,8-9H,3-4,7H2,1-2H3,(H,19,21) LXBKJCJUKWFNBR-UHFFFAOYSA-N 568575 5-{3,5-Difluoro-4-[2-methylmorpholin-4-yl]phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (Mixture of stereoisomers)::US11427553, Example 18 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568575 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568575&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465183 473129889 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199933 CC1OC(=O)NN=C1c1ccc(cc1)N1CCOCC1 InChI=1S/C14H17N3O3/c1-10-13(15-16-14(18)20-10)11-2-4-12(5-3-11)17-6-8-19-9-7-17/h2-5,10H,6-9H2,1H3,(H,16,18) ROZXHKUBWSBLBH-UHFFFAOYSA-N 568576 (rac)-6-Methyl-5-[4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 20 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568576 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568576&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462740 473129890 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199934 CC1OC(=O)NN=C1c1ccc(cc1)N1CCOCC1 InChI=1S/C14H17N3O3/c1-10-13(15-16-14(18)20-10)11-2-4-12(5-3-11)17-6-8-19-9-7-17/h2-5,10H,6-9H2,1H3,(H,16,18) ROZXHKUBWSBLBH-UHFFFAOYSA-N 568576 (rac)-6-Methyl-5-[4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 20 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568576 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568576&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462740 473129890 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199935 Fc1cc(cc(F)c1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C13H13F2N3O3/c14-9-5-8(11-7-21-13(19)17-16-11)6-10(15)12(9)18-1-3-20-4-2-18/h5-6H,1-4,7H2,(H,17,19) IPFPICKSUDOWFY-UHFFFAOYSA-N 568577 5-[3,5-Difluoro-4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 21 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 175 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568577 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568577&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462715 473129891 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199936 Fc1cc(cc(F)c1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C13H13F2N3O3/c14-9-5-8(11-7-21-13(19)17-16-11)6-10(15)12(9)18-1-3-20-4-2-18/h5-6H,1-4,7H2,(H,17,19) IPFPICKSUDOWFY-UHFFFAOYSA-N 568577 5-[3,5-Difluoro-4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 21 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 185 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568577 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568577&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462715 473129891 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199937 Clc1cc(cc(C#N)c1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C14H13ClN4O3/c15-11-6-9(12-8-22-14(20)18-17-12)5-10(7-16)13(11)19-1-3-21-4-2-19/h5-6H,1-4,8H2,(H,18,20) HKMIWVOZJIODIY-UHFFFAOYSA-N 568578 3-Chloro-2-(morpholin-4-yl)-5-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)benzonitrile::US11427553, Example 23 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 380 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568578 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568578&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462805 473129892 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199938 Clc1cc(cc(C#N)c1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C14H13ClN4O3/c15-11-6-9(12-8-22-14(20)18-17-12)5-10(7-16)13(11)19-1-3-21-4-2-19/h5-6H,1-4,8H2,(H,18,20) HKMIWVOZJIODIY-UHFFFAOYSA-N 568578 3-Chloro-2-(morpholin-4-yl)-5-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)benzonitrile::US11427553, Example 23 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 270 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568578 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568578&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462805 473129892 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199939 CC1CN(CC(C)O1)c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H18FN3O3/c1-9-6-19(7-10(2)22-9)14-4-3-11(5-12(14)16)13-8-21-15(20)18-17-13/h3-5,9-10H,6-8H2,1-2H3,(H,18,20) VRLMOKBQUKPIGM-UHFFFAOYSA-N 568579 5-{4-[2,6-Dimethylmorpholin-4-yl]-3-fluorophenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 24 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568579 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568579&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462952 473129893 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199940 CC1CN(CC(C)O1)c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H18FN3O3/c1-9-6-19(7-10(2)22-9)14-4-3-11(5-12(14)16)13-8-21-15(20)18-17-13/h3-5,9-10H,6-8H2,1-2H3,(H,18,20) VRLMOKBQUKPIGM-UHFFFAOYSA-N 568579 5-{4-[2,6-Dimethylmorpholin-4-yl]-3-fluorophenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 24 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568579 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568579&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462952 473129893 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199941 C[C@@H]1OC(=O)NN=C1c1ccc(N2CCOCC2)c(F)c1 InChI=1S/C14H16FN3O3/c1-9-13(16-17-14(19)21-9)10-2-3-12(11(15)8-10)18-4-6-20-7-5-18/h2-3,8-9H,4-7H2,1H3,(H,17,19)/t9-/m0/s1 CTSRYFMXFGZHJM-VIFPVBQESA-N 568580 (6S)-5-(3-Fluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 25-1 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 44.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568580 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568580&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462902 473129894 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199942 C[C@@H]1OC(=O)NN=C1c1ccc(N2CCOCC2)c(F)c1 InChI=1S/C14H16FN3O3/c1-9-13(16-17-14(19)21-9)10-2-3-12(11(15)8-10)18-4-6-20-7-5-18/h2-3,8-9H,4-7H2,1H3,(H,17,19)/t9-/m0/s1 CTSRYFMXFGZHJM-VIFPVBQESA-N 568580 (6S)-5-(3-Fluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 25-1 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 22.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568580 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568580&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462902 473129894 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199943 C[C@@H]1OC(=O)NN=C1c1cc(F)c(N2CCOCC2)c(F)c1 InChI=1S/C14H15F2N3O3/c1-8-12(17-18-14(20)22-8)9-6-10(15)13(11(16)7-9)19-2-4-21-5-3-19/h6-8H,2-5H2,1H3,(H,18,20)/t8-/m0/s1 DDUUYOMHMNPPCN-QMMMGPOBSA-N 568581 (6S)-5-(3,5-Difluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 25-2 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 17.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568581 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568581&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462907 473129895 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199944 C[C@@H]1OC(=O)NN=C1c1cc(F)c(N2CCOCC2)c(F)c1 InChI=1S/C14H15F2N3O3/c1-8-12(17-18-14(20)22-8)9-6-10(15)13(11(16)7-9)19-2-4-21-5-3-19/h6-8H,2-5H2,1H3,(H,18,20)/t8-/m0/s1 DDUUYOMHMNPPCN-QMMMGPOBSA-N 568581 (6S)-5-(3,5-Difluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 25-2 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 15.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568581 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568581&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462907 473129895 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199945 Fc1cc(ccc1N1CCC(F)(F)C1)C1=NNC(=O)OC1 InChI=1S/C13H12F3N3O2/c14-9-5-8(10-6-21-12(20)18-17-10)1-2-11(9)19-4-3-13(15,16)7-19/h1-2,5H,3-4,6-7H2,(H,18,20) FYUIZLZTWZQYCB-UHFFFAOYSA-N 568582 5-[4-(3,3-Difluoropyrrolidin-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 26 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 700 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568582 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568582&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463030 473129896 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199946 Fc1cc(ccc1N1CCC(F)(F)C1)C1=NNC(=O)OC1 InChI=1S/C13H12F3N3O2/c14-9-5-8(10-6-21-12(20)18-17-10)1-2-11(9)19-4-3-13(15,16)7-19/h1-2,5H,3-4,6-7H2,(H,18,20) FYUIZLZTWZQYCB-UHFFFAOYSA-N 568582 5-[4-(3,3-Difluoropyrrolidin-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 26 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 270 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568582 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568582&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463030 473129896 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199947 Cc1cc(ccc1-c1ccccc1)C1=NNC(=O)OC1 InChI=1S/C16H14N2O2/c1-11-9-13(15-10-20-16(19)18-17-15)7-8-14(11)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,18,19) NJUNBRBSKVGSOX-UHFFFAOYSA-N 568583 5-(2-Methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 27 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568583 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568583&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463395 473129897 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199948 Cc1cc(ccc1-c1ccccc1)C1=NNC(=O)OC1 InChI=1S/C16H14N2O2/c1-11-9-13(15-10-20-16(19)18-17-15)7-8-14(11)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,18,19) NJUNBRBSKVGSOX-UHFFFAOYSA-N 568583 5-(2-Methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 27 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568583 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568583&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463395 473129897 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199949 Cc1cc(ccc1-c1ccnn1C)C1=NNC(=O)OC1 InChI=1S/C14H14N4O2/c1-9-7-10(12-8-20-14(19)17-16-12)3-4-11(9)13-5-6-15-18(13)2/h3-7H,8H2,1-2H3,(H,17,19) PXWRPKUPRSBCAP-UHFFFAOYSA-N 568584 5-[3-Methyl-4-(1-methyl-1H-pyrazol-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 29 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 300 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568584 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568584&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462988 473129898 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199950 Cc1cc(ccc1-c1ccnn1C)C1=NNC(=O)OC1 InChI=1S/C14H14N4O2/c1-9-7-10(12-8-20-14(19)17-16-12)3-4-11(9)13-5-6-15-18(13)2/h3-7H,8H2,1-2H3,(H,17,19) PXWRPKUPRSBCAP-UHFFFAOYSA-N 568584 5-[3-Methyl-4-(1-methyl-1H-pyrazol-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 29 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 160 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568584 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568584&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462988 473129898 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199951 Fc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H10F2N2O2/c16-11-4-1-9(2-5-11)12-6-3-10(7-13(12)17)14-8-21-15(20)19-18-14/h1-7H,8H2,(H,19,20) UGUKSHRHUHJCCM-UHFFFAOYSA-N 568585 5-(2,4′-Difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 30 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 99.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568585 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568585&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463394 473129899 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199952 Fc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H10F2N2O2/c16-11-4-1-9(2-5-11)12-6-3-10(7-13(12)17)14-8-21-15(20)19-18-14/h1-7H,8H2,(H,19,20) UGUKSHRHUHJCCM-UHFFFAOYSA-N 568585 5-(2,4′-Difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 30 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 79.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568585 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568585&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463394 473129899 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199953 FC(F)(F)c1cc(ccc1-c1ccc(Cl)cc1)C1=NNC(=O)OC1 InChI=1S/C16H10ClF3N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) DHIKBGOJRIJXHN-UHFFFAOYSA-N 568586 5-[4′-Chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 31 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 310 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568586 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568586&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463027 473129900 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199954 FC(F)(F)c1cc(ccc1-c1ccc(Cl)cc1)C1=NNC(=O)OC1 InChI=1S/C16H10ClF3N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) DHIKBGOJRIJXHN-UHFFFAOYSA-N 568586 5-[4′-Chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 31 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 603 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568586 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568586&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463027 473129900 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199955 Cc1ccc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O2/c1-9-2-3-11(7-20-9)12-5-4-10(6-13(12)16(17,18)19)14-8-24-15(23)22-21-14/h2-7H,8H2,1H3,(H,22,23) MEDJPSFTFQXVKI-UHFFFAOYSA-N 568587 5-[4-(6-Methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 32 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 67.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568587 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568587&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462806 473129901 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199956 Cc1ccc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O2/c1-9-2-3-11(7-20-9)12-5-4-10(6-13(12)16(17,18)19)14-8-24-15(23)22-21-14/h2-7H,8H2,1H3,(H,22,23) MEDJPSFTFQXVKI-UHFFFAOYSA-N 568587 5-[4-(6-Methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 32 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568587 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568587&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462806 473129901 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199957 FC(F)(F)c1cc(ccc1-c1cccnc1)C1=NNC(=O)OC1 InChI=1S/C15H10F3N3O2/c16-15(17,18)12-6-9(13-8-23-14(22)21-20-13)3-4-11(12)10-2-1-5-19-7-10/h1-7H,8H2,(H,21,22) IYWJSJXNGBARFL-UHFFFAOYSA-N 568588 5-[4-(Pyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 33 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568588 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568588&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462777 473129902 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199958 FC(F)(F)c1cc(ccc1-c1cccnc1)C1=NNC(=O)OC1 InChI=1S/C15H10F3N3O2/c16-15(17,18)12-6-9(13-8-23-14(22)21-20-13)3-4-11(12)10-2-1-5-19-7-10/h1-7H,8H2,(H,21,22) IYWJSJXNGBARFL-UHFFFAOYSA-N 568588 5-[4-(Pyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 33 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 80.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568588 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568588&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462777 473129902 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199959 Nc1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O2/c17-16(18,19)13-7-10(14-8-24-15(23)22-21-14)3-6-12(13)9-1-4-11(20)5-2-9/h1-7H,8,20H2,(H,22,23) QDVQLLLMAQDCGV-UHFFFAOYSA-N 568589 5-[4′-Amino-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 34 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568589 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568589&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465178 473129903 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199960 Nc1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O2/c17-16(18,19)13-7-10(14-8-24-15(23)22-21-14)3-6-12(13)9-1-4-11(20)5-2-9/h1-7H,8,20H2,(H,22,23) QDVQLLLMAQDCGV-UHFFFAOYSA-N 568589 5-[4′-Amino-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 34 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568589 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568589&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465178 473129903 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199961 FC(F)(F)c1ccc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F6N3O2/c17-15(18,19)11-5-8(12-7-27-14(26)25-24-12)1-3-10(11)9-2-4-13(23-6-9)16(20,21)22/h1-6H,7H2,(H,25,26) VXXVFFRCOSADJW-UHFFFAOYSA-N 568590 5-{3-(Trifluoromethyl)-4-[6-(trifluoromethyl)pyridin-3-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 36 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 280 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568590 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568590&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462669 473129904 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199962 FC(F)(F)c1ccc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F6N3O2/c17-15(18,19)11-5-8(12-7-27-14(26)25-24-12)1-3-10(11)9-2-4-13(23-6-9)16(20,21)22/h1-6H,7H2,(H,25,26) VXXVFFRCOSADJW-UHFFFAOYSA-N 568590 5-{3-(Trifluoromethyl)-4-[6-(trifluoromethyl)pyridin-3-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 36 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 320 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568590 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568590&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462669 473129904 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199963 Oc1cc(ccc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O3/c17-12-4-2-8(6-14(12)23)10-3-1-9(5-11(10)16(18,19)20)13-7-25-15(24)22-21-13/h1-6,23H,7H2,(H,22,24) QYEIFDMKGKWJNH-UHFFFAOYSA-N 568591 5-[4′-Fluoro-3′-hydroxy-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 37 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568591 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568591&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462708 473129905 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199964 Oc1cc(ccc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O3/c17-12-4-2-8(6-14(12)23)10-3-1-9(5-11(10)16(18,19)20)13-7-25-15(24)22-21-13/h1-6,23H,7H2,(H,22,24) QYEIFDMKGKWJNH-UHFFFAOYSA-N 568591 5-[4′-Fluoro-3′-hydroxy-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 37 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568591 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568591&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462708 473129905 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199965 Nc1cc(c(F)cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F5N3O2/c17-11-5-12(18)13(22)4-9(11)8-2-1-7(3-10(8)16(19,20)21)14-6-26-15(25)24-23-14/h1-5H,6,22H2,(H,24,25) FRZBOWYWDPSOAO-UHFFFAOYSA-N 568592 5-[5′-Amino-2′,4′-difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 38 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568592 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568592&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462670 473129906 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199966 Nc1cc(c(F)cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F5N3O2/c17-11-5-12(18)13(22)4-9(11)8-2-1-7(3-10(8)16(19,20)21)14-6-26-15(25)24-23-14/h1-5H,6,22H2,(H,24,25) FRZBOWYWDPSOAO-UHFFFAOYSA-N 568592 5-[5′-Amino-2′,4′-difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 38 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 260 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568592 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568592&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462670 473129906 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199967 Nc1ccc(cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c17-12-6-8(2-4-13(12)21)10-3-1-9(5-11(10)16(18,19)20)14-7-25-15(24)23-22-14/h1-6H,7,21H2,(H,23,24) UWEGKTUSEURSJI-UHFFFAOYSA-N 568593 5-[4′-Amino-3′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 39 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 72.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568593 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568593&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462993 473129907 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199968 Nc1ccc(cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c17-12-6-8(2-4-13(12)21)10-3-1-9(5-11(10)16(18,19)20)14-7-25-15(24)23-22-14/h1-6H,7,21H2,(H,23,24) UWEGKTUSEURSJI-UHFFFAOYSA-N 568593 5-[4′-Amino-3′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 39 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568593 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568593&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462993 473129907 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199969 Nc1ccc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H11F3N4O2/c16-15(17,18)11-5-8(12-7-24-14(23)22-21-12)1-3-10(11)9-2-4-13(19)20-6-9/h1-6H,7H2,(H2,19,20)(H,22,23) GLCUUMCKSQUNDS-UHFFFAOYSA-N 568594 5-[4-(6-Aminopyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 40 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 42.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568594 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568594&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463011 473129908 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199970 Nc1ccc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H11F3N4O2/c16-15(17,18)11-5-8(12-7-24-14(23)22-21-12)1-3-10(11)9-2-4-13(19)20-6-9/h1-6H,7H2,(H2,19,20)(H,22,23) GLCUUMCKSQUNDS-UHFFFAOYSA-N 568594 5-[4-(6-Aminopyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 40 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 39.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568594 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568594&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463011 473129908 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199971 Nc1cc(ccc1Cl)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11ClF3N3O2/c17-12-4-2-8(6-13(12)21)10-3-1-9(5-11(10)16(18,19)20)14-7-25-15(24)23-22-14/h1-6H,7,21H2,(H,23,24) BXLHPCDHAJIGTG-UHFFFAOYSA-N 568595 5-[3′-Amino-4′-chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 41 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568595 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568595&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463012 473129909 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199972 Nc1cc(ccc1Cl)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11ClF3N3O2/c17-12-4-2-8(6-13(12)21)10-3-1-9(5-11(10)16(18,19)20)14-7-25-15(24)23-22-14/h1-6H,7,21H2,(H,23,24) BXLHPCDHAJIGTG-UHFFFAOYSA-N 568595 5-[3′-Amino-4′-chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 41 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568595 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568595&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463012 473129909 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199973 Cc1ccc(cc1N)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H14F3N3O2/c1-9-2-3-10(7-14(9)21)12-5-4-11(6-13(12)17(18,19)20)15-8-25-16(24)23-22-15/h2-7H,8,21H2,1H3,(H,23,24) FXNKURWXTPJDFG-UHFFFAOYSA-N 568596 5-[3′-Amino-4′-methyl-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 42 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568596 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568596&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463051 473129910 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199974 Cc1ccc(cc1N)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H14F3N3O2/c1-9-2-3-10(7-14(9)21)12-5-4-11(6-13(12)17(18,19)20)15-8-25-16(24)23-22-15/h2-7H,8,21H2,1H3,(H,23,24) FXNKURWXTPJDFG-UHFFFAOYSA-N 568596 5-[3′-Amino-4′-methyl-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 42 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568596 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568596&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463051 473129910 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199975 Nc1cccc(c1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c17-14-10(2-1-3-12(14)21)9-5-4-8(6-11(9)16(18,19)20)13-7-25-15(24)23-22-13/h1-6H,7,21H2,(H,23,24) ORYYWAHYOSMYHA-UHFFFAOYSA-N 568597 5-[3′-Amino-2′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 43 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 96.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568597 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568597&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462981 473129911 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199976 Nc1cccc(c1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c17-14-10(2-1-3-12(14)21)9-5-4-8(6-11(9)16(18,19)20)13-7-25-15(24)23-22-13/h1-6H,7,21H2,(H,23,24) ORYYWAHYOSMYHA-UHFFFAOYSA-N 568597 5-[3′-Amino-2′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 43 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 85.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568597 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568597&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462981 473129911 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199977 Cc1ccc(c(F)c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H12F4N2O2/c1-9-2-4-12(14(18)6-9)11-5-3-10(7-13(11)17(19,20)21)15-8-25-16(24)23-22-15/h2-7H,8H2,1H3,(H,23,24) OHSUCFFFEIBOTO-UHFFFAOYSA-N 568598 5-[4′-Amino-2′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 44 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 190 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568598 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568598&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475166 473129912 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199978 Cc1ccc(c(F)c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H12F4N2O2/c1-9-2-4-12(14(18)6-9)11-5-3-10(7-13(11)17(19,20)21)15-8-25-16(24)23-22-15/h2-7H,8H2,1H3,(H,23,24) OHSUCFFFEIBOTO-UHFFFAOYSA-N 568598 5-[4′-Amino-2′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 44 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568598 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568598&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475166 473129912 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199979 Cn1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H11F3N4O2/c1-21-6-9(5-18-21)10-3-2-8(4-11(10)14(15,16)17)12-7-23-13(22)20-19-12/h2-6H,7H2,1H3,(H,20,22) ZFEJMSPHRJVMRK-UHFFFAOYSA-N 568599 5-[4-(1-Methyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 45 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 43.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568599 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568599&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462955 473129913 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199980 Cn1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H11F3N4O2/c1-21-6-9(5-18-21)10-3-2-8(4-11(10)14(15,16)17)12-7-23-13(22)20-19-12/h2-6H,7H2,1H3,(H,20,22) ZFEJMSPHRJVMRK-UHFFFAOYSA-N 568599 5-[4-(1-Methyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 45 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 34.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568599 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568599&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462955 473129913 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199981 FC(F)(F)c1cc(ccc1-c1ccc2cn[nH]c2c1)C1=NNC(=O)OC1 InChI=1S/C17H11F3N4O2/c18-17(19,20)13-5-10(15-8-26-16(25)24-23-15)3-4-12(13)9-1-2-11-7-21-22-14(11)6-9/h1-7H,8H2,(H,21,22)(H,24,25) AXVZZJDZOPEJHI-UHFFFAOYSA-N 568600 5-[4-(1H-Indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 47 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 53.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568600 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568600&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462943 473129914 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199982 FC(F)(F)c1cc(ccc1-c1ccc2cn[nH]c2c1)C1=NNC(=O)OC1 InChI=1S/C17H11F3N4O2/c18-17(19,20)13-5-10(15-8-26-16(25)24-23-15)3-4-12(13)9-1-2-11-7-21-22-14(11)6-9/h1-7H,8H2,(H,21,22)(H,24,25) AXVZZJDZOPEJHI-UHFFFAOYSA-N 568600 5-[4-(1H-Indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 47 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 33.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568600 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568600&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462943 473129914 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199983 Cc1ncc(cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c1-8-13(17)5-10(6-21-8)11-3-2-9(4-12(11)16(18,19)20)14-7-25-15(24)23-22-14/h2-6H,7H2,1H3,(H,23,24) HFHRODZMIPNVBF-UHFFFAOYSA-N 568601 5-[4-(5-Fluoro-6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 48 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568601 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568601&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462810 473129915 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199984 Cc1ncc(cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c1-8-13(17)5-10(6-21-8)11-3-2-9(4-12(11)16(18,19)20)14-7-25-15(24)23-22-14/h2-6H,7H2,1H3,(H,23,24) HFHRODZMIPNVBF-UHFFFAOYSA-N 568601 5-[4-(5-Fluoro-6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 48 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568601 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568601&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462810 473129915 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199985 FC(F)(F)c1cc(ccc1-c1cnsc1)C1=NNC(=O)OC1 InChI=1S/C13H8F3N3O2S/c14-13(15,16)10-3-7(11-5-21-12(20)19-18-11)1-2-9(10)8-4-17-22-6-8/h1-4,6H,5H2,(H,19,20) UXFDFUDONSZQJT-UHFFFAOYSA-N 568602 5-[4-(1,2-Thiazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 49 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 230 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568602 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568602&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463211 473129916 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199986 FC(F)(F)c1cc(ccc1-c1cnsc1)C1=NNC(=O)OC1 InChI=1S/C13H8F3N3O2S/c14-13(15,16)10-3-7(11-5-21-12(20)19-18-11)1-2-9(10)8-4-17-22-6-8/h1-4,6H,5H2,(H,19,20) UXFDFUDONSZQJT-UHFFFAOYSA-N 568602 5-[4-(1,2-Thiazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 49 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 190 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568602 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568602&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463211 473129916 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199987 Cn1c(ccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C#N InChI=1S/C16H11F3N4O2/c1-23-10(7-20)3-5-14(23)11-4-2-9(6-12(11)16(17,18)19)13-8-25-15(24)22-21-13/h2-6H,8H2,1H3,(H,22,24) IZYSVRIYHUFQCY-UHFFFAOYSA-N 568603 1-Methyl-5-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]-1H-pyrrole-2-carbonitrile::US11427553, Example 50 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 260 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568603 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568603&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475707 473129917 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199988 Cn1c(ccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C#N InChI=1S/C16H11F3N4O2/c1-23-10(7-20)3-5-14(23)11-4-2-9(6-12(11)16(17,18)19)13-8-25-15(24)22-21-13/h2-6H,8H2,1H3,(H,22,24) IZYSVRIYHUFQCY-UHFFFAOYSA-N 568603 1-Methyl-5-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]-1H-pyrrole-2-carbonitrile::US11427553, Example 50 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568603 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568603&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475707 473129917 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199989 FC(F)(F)c1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H10F6N2O2/c18-16(19,20)11-4-1-9(2-5-11)12-6-3-10(7-13(12)17(21,22)23)14-8-27-15(26)25-24-14/h1-7H,8H2,(H,25,26) RBQVZFKUMXBDBA-UHFFFAOYSA-N 568604 5-[2,4′-Bis(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 51 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568604 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568604&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465180 473129918 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199990 FC(F)(F)c1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H10F6N2O2/c18-16(19,20)11-4-1-9(2-5-11)12-6-3-10(7-13(12)17(21,22)23)14-8-27-15(26)25-24-14/h1-7H,8H2,(H,25,26) RBQVZFKUMXBDBA-UHFFFAOYSA-N 568604 5-[2,4′-Bis(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 51 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568604 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568604&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465180 473129918 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199991 COc1nc(C)ccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H14F3N3O3/c1-9-3-5-12(15(21-9)25-2)11-6-4-10(7-13(11)17(18,19)20)14-8-26-16(24)23-22-14/h3-7H,8H2,1-2H3,(H,23,24) ZKSRRCLODFVPRY-UHFFFAOYSA-N 568605 5-[4-(2-Methoxy-6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 53 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 580 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568605 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568605&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462668 473129919 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199992 COc1nc(C)ccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H14F3N3O3/c1-9-3-5-12(15(21-9)25-2)11-6-4-10(7-13(11)17(18,19)20)14-8-26-16(24)23-22-14/h3-7H,8H2,1-2H3,(H,23,24) ZKSRRCLODFVPRY-UHFFFAOYSA-N 568605 5-[4-(2-Methoxy-6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 53 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 390 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568605 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568605&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462668 473129919 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199993 Cc1ncc(s1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H10F3N3O2S/c1-7-18-5-12(23-7)9-3-2-8(4-10(9)14(15,16)17)11-6-22-13(21)20-19-11/h2-5H,6H2,1H3,(H,20,21) VJZSMKRNZDWSIM-UHFFFAOYSA-N 568606 5-[4-(2-Methyl-1,3-thiazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 54 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568606 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568606&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462982 473129920 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199994 Cc1ncc(s1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H10F3N3O2S/c1-7-18-5-12(23-7)9-3-2-8(4-10(9)14(15,16)17)11-6-22-13(21)20-19-11/h2-5H,6H2,1H3,(H,20,21) VJZSMKRNZDWSIM-UHFFFAOYSA-N 568606 5-[4-(2-Methyl-1,3-thiazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 54 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 89.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568606 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568606&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462982 473129920 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199995 CNc1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H14F3N3O2/c1-21-12-5-2-10(3-6-12)13-7-4-11(8-14(13)17(18,19)20)15-9-25-16(24)23-22-15/h2-8,21H,9H2,1H3,(H,23,24) QVLQAKIOWIJYJW-UHFFFAOYSA-N 568607 5-[4′-(Methylamino)-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 55 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 280 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568607 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568607&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462992 473129921 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199996 CNc1ccc(cc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H14F3N3O2/c1-21-12-5-2-10(3-6-12)13-7-4-11(8-14(13)17(18,19)20)15-9-25-16(24)23-22-15/h2-8,21H,9H2,1H3,(H,23,24) QVLQAKIOWIJYJW-UHFFFAOYSA-N 568607 5-[4′-(Methylamino)-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 55 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568607 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568607&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462992 473129921 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199997 Nc1cc(ccc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c17-12-4-2-8(6-13(12)21)10-3-1-9(5-11(10)16(18,19)20)14-7-25-15(24)23-22-14/h1-6H,7,21H2,(H,23,24) BTWQOFCROOJGFV-UHFFFAOYSA-N 568608 5-[3′-Amino-4′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 56 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568608 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568608&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463005 473129922 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1199998 Nc1cc(ccc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O2/c17-12-4-2-8(6-13(12)21)10-3-1-9(5-11(10)16(18,19)20)14-7-25-15(24)23-22-14/h1-6H,7,21H2,(H,23,24) BTWQOFCROOJGFV-UHFFFAOYSA-N 568608 5-[3′-Amino-4′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 56 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 80.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568608 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568608&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463005 473129922 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1199999 Fc1cc(cc(F)c1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H8F6N2O2/c17-11-4-8(5-12(18)14(11)19)9-2-1-7(3-10(9)16(20,21)22)13-6-26-15(25)24-23-13/h1-5H,6H2,(H,24,25) JFMCGGKNFAUHRJ-UHFFFAOYSA-N 568609 5-[3′,4′,5′-Trifluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 58 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 310 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568609 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568609&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462910 473129923 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200000 Fc1cc(cc(F)c1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H8F6N2O2/c17-11-4-8(5-12(18)14(11)19)9-2-1-7(3-10(9)16(20,21)22)13-6-26-15(25)24-23-13/h1-5H,6H2,(H,24,25) JFMCGGKNFAUHRJ-UHFFFAOYSA-N 568609 5-[3′,4′,5′-Trifluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 58 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 570 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568609 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568609&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462910 473129923 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200001 Fc1ccc(F)c(c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F5N2O2/c17-9-2-4-13(18)11(6-9)10-3-1-8(5-12(10)16(19,20)21)14-7-25-15(24)23-22-14/h1-6H,7H2,(H,23,24) ONOBXOKMJSCRHY-UHFFFAOYSA-N 568610 5-[2′,5′-Difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 59 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568610 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568610&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463278 473129924 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200002 Fc1ccc(F)c(c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F5N2O2/c17-9-2-4-13(18)11(6-9)10-3-1-8(5-12(10)16(19,20)21)14-7-25-15(24)23-22-14/h1-6H,7H2,(H,23,24) ONOBXOKMJSCRHY-UHFFFAOYSA-N 568610 5-[2′,5′-Difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 59 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568610 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568610&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463278 473129924 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200003 Nc1cc(ccc1F)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O3/c17-11-4-2-8(5-12(11)21)10-3-1-9(6-14(10)26-16(18,19)20)13-7-25-15(24)23-22-13/h1-6H,7,21H2,(H,23,24) NNQKLHINZCYRDE-UHFFFAOYSA-N 568611 5-[3′-Amino-4′-fluoro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 60 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 270 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568611 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568611&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463056 473129925 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200004 Nc1cc(ccc1F)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H11F4N3O3/c17-11-4-2-8(5-12(11)21)10-3-1-9(6-14(10)26-16(18,19)20)13-7-25-15(24)23-22-13/h1-6H,7,21H2,(H,23,24) NNQKLHINZCYRDE-UHFFFAOYSA-N 568611 5-[3′-Amino-4′-fluoro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 60 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 510 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568611 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568611&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463056 473129925 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200005 Fc1ccc(cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F5N2O2/c17-12-4-2-8(6-13(12)18)10-3-1-9(5-11(10)16(19,20)21)14-7-25-15(24)23-22-14/h1-6H,7H2,(H,23,24) JSSQXOMPGFXVPL-UHFFFAOYSA-N 568612 5-[3′,4′-Difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 61 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 230 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568612 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568612&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463022 473129926 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200006 Fc1ccc(cc1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F5N2O2/c17-12-4-2-8(6-13(12)18)10-3-1-9(5-11(10)16(19,20)21)14-7-25-15(24)23-22-14/h1-6H,7H2,(H,23,24) JSSQXOMPGFXVPL-UHFFFAOYSA-N 568612 5-[3′,4′-Difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 61 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 320 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568612 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568612&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463022 473129926 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200007 FC(F)(F)c1cc(ccc1-c1ccc2cc[nH]c2c1)C1=NNC(=O)OC1 InChI=1S/C18H12F3N3O2/c19-18(20,21)14-7-12(16-9-26-17(25)24-23-16)3-4-13(14)11-2-1-10-5-6-22-15(10)8-11/h1-8,22H,9H2,(H,24,25) YLAALOFZOYCMGZ-UHFFFAOYSA-N 568613 5-[4-(1H-Indol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 62 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 85.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568613 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568613&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462714 473129927 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200008 FC(F)(F)c1cc(ccc1-c1ccc2cc[nH]c2c1)C1=NNC(=O)OC1 InChI=1S/C18H12F3N3O2/c19-18(20,21)14-7-12(16-9-26-17(25)24-23-16)3-4-13(14)11-2-1-10-5-6-22-15(10)8-11/h1-8,22H,9H2,(H,24,25) YLAALOFZOYCMGZ-UHFFFAOYSA-N 568613 5-[4-(1H-Indol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 62 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568613 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568613&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462714 473129927 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200009 CC(C)=Cc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F3N2O2/c1-8(2)5-9-3-4-10(6-11(9)14(15,16)17)12-7-21-13(20)19-18-12/h3-6H,7H2,1-2H3,(H,19,20) QBAOBQMAFUWUGE-UHFFFAOYSA-N 568614 5-[4-(2-Methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 63 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568614 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568614&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463400 473129928 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200010 CC(C)=Cc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F3N2O2/c1-8(2)5-9-3-4-10(6-11(9)14(15,16)17)12-7-21-13(20)19-18-12/h3-6H,7H2,1-2H3,(H,19,20) QBAOBQMAFUWUGE-UHFFFAOYSA-N 568614 5-[4-(2-Methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 63 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 33.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568614 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568614&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463400 473129928 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200011 Fc1cccc(c1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F5N2O2/c17-12-3-1-2-10(14(12)18)9-5-4-8(6-11(9)16(19,20)21)13-7-25-15(24)23-22-13/h1-6H,7H2,(H,23,24) UHZRXFSMCRRQMY-UHFFFAOYSA-N 568615 5-[2′,3′-Difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 64 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 221 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568615 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568615&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463096 473129929 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200012 Fc1cccc(c1F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H9F5N2O2/c17-12-3-1-2-10(14(12)18)9-5-4-8(6-11(9)16(19,20)21)13-7-25-15(24)23-22-13/h1-6H,7H2,(H,23,24) UHZRXFSMCRRQMY-UHFFFAOYSA-N 568615 5-[2′,3′-Difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 64 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 193 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568615 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568615&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463096 473129929 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200013 FC(F)(F)c1cc(ccc1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-7-9(11-8-23-13(21)19-18-11)1-2-12(10)20-3-5-22-6-4-20/h1-2,7H,3-6,8H2,(H,19,21) MVZPGGZBDKSDEM-UHFFFAOYSA-N 568616 5-[4-(Morpholin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 65 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 25.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568616 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568616&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462660 473129930 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200014 FC(F)(F)c1cc(ccc1N1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-7-9(11-8-23-13(21)19-18-11)1-2-12(10)20-3-5-22-6-4-20/h1-2,7H,3-6,8H2,(H,19,21) MVZPGGZBDKSDEM-UHFFFAOYSA-N 568616 5-[4-(Morpholin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 65 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 30.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568616 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568616&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462660 473129930 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200015 CCCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O2/c1-2-3-6-18-11-5-4-9(7-10(11)14(15,16)17)12-8-22-13(21)20-19-12/h4-5,7,18H,2-3,6,8H2,1H3,(H,20,21) MRIQPFHOMGBBNX-UHFFFAOYSA-N 568617 5-[4-(Butylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 66 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568617 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568617&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462918 473129931 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200016 CCCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O2/c1-2-3-6-18-11-5-4-9(7-10(11)14(15,16)17)12-8-22-13(21)20-19-12/h4-5,7,18H,2-3,6,8H2,1H3,(H,20,21) MRIQPFHOMGBBNX-UHFFFAOYSA-N 568617 5-[4-(Butylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 66 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 95.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568617 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568617&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462918 473129931 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200017 CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C12H12F3N3O2/c1-2-16-9-4-3-7(5-8(9)12(13,14)15)10-6-20-11(19)18-17-10/h3-5,16H,2,6H2,1H3,(H,18,19) LIIKVTQDEDSGKN-UHFFFAOYSA-N 568618 5-[4-(Ethylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 67 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 47.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568618 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568618&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462922 473129932 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200018 CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C12H12F3N3O2/c1-2-16-9-4-3-7(5-8(9)12(13,14)15)10-6-20-11(19)18-17-10/h3-5,16H,2,6H2,1H3,(H,18,19) LIIKVTQDEDSGKN-UHFFFAOYSA-N 568618 5-[4-(Ethylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 67 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 63.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568618 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568618&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462922 473129932 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200019 Cn1cc(cn1)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H11F3N4O3/c1-21-6-9(5-18-21)10-3-2-8(4-12(10)24-14(15,16)17)11-7-23-13(22)20-19-11/h2-6H,7H2,1H3,(H,20,22) YAFMRAKAYNROPY-UHFFFAOYSA-N 568619 5-[4-(1-Methyl-1H-pyrazol-4-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 68 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 81.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568619 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568619&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463057 473129933 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200020 Cn1cc(cn1)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H11F3N4O3/c1-21-6-9(5-18-21)10-3-2-8(4-12(10)24-14(15,16)17)11-7-23-13(22)20-19-11/h2-6H,7H2,1H3,(H,20,22) YAFMRAKAYNROPY-UHFFFAOYSA-N 568619 5-[4-(1-Methyl-1H-pyrazol-4-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 68 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 152 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568619 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568619&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463057 473129933 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200021 CCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O2/c1-2-5-17-10-4-3-8(6-9(10)13(14,15)16)11-7-21-12(20)19-18-11/h3-4,6,17H,2,5,7H2,1H3,(H,19,20) CAHDPRAPCFFDOO-UHFFFAOYSA-N 568620 5-[4-(Propylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 69 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568620 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568620&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463007 473129934 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200022 CCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O2/c1-2-5-17-10-4-3-8(6-9(10)13(14,15)16)11-7-21-12(20)19-18-11/h3-4,6,17H,2,5,7H2,1H3,(H,19,20) CAHDPRAPCFFDOO-UHFFFAOYSA-N 568620 5-[4-(Propylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 69 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 47.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568620 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568620&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463007 473129934 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200023 Cc1ccc(cn1)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O3/c1-9-2-3-11(7-20-9)12-5-4-10(6-14(12)25-16(17,18)19)13-8-24-15(23)22-21-13/h2-7H,8H2,1H3,(H,22,23) GUAPITJBDKTZCR-UHFFFAOYSA-N 568621 5-[4-(6-Methylpyridin-3-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 70 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568621 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568621&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462710 473129935 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200024 Cc1ccc(cn1)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O3/c1-9-2-3-11(7-20-9)12-5-4-10(6-14(12)25-16(17,18)19)13-8-24-15(23)22-21-13/h2-7H,8H2,1H3,(H,22,23) GUAPITJBDKTZCR-UHFFFAOYSA-N 568621 5-[4-(6-Methylpyridin-3-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 70 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568621 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568621&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462710 473129935 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200025 FC(F)(F)Oc1cc(ccc1-c1ccc(Cl)cc1)C1=NNC(=O)OC1 InChI=1S/C16H10ClF3N2O3/c17-11-4-1-9(2-5-11)12-6-3-10(7-14(12)25-16(18,19)20)13-8-24-15(23)22-21-13/h1-7H,8H2,(H,22,23) XAMCENTTYLLRGJ-UHFFFAOYSA-N 568622 5-[4′-Chloro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 71 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568622 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568622&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463013 473129936 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200026 FC(F)(F)Oc1cc(ccc1-c1ccc(Cl)cc1)C1=NNC(=O)OC1 InChI=1S/C16H10ClF3N2O3/c17-11-4-1-9(2-5-11)12-6-3-10(7-14(12)25-16(18,19)20)13-8-24-15(23)22-21-13/h1-7H,8H2,(H,22,23) XAMCENTTYLLRGJ-UHFFFAOYSA-N 568622 5-[4′-Chloro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 71 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568622 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568622&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463013 473129936 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200027 FC(F)(F)c1cc(ccc1N1CCC1)C1=NNC(=O)OC1 InChI=1S/C13H12F3N3O2/c14-13(15,16)9-6-8(10-7-21-12(20)18-17-10)2-3-11(9)19-4-1-5-19/h2-3,6H,1,4-5,7H2,(H,18,20) ZPYHYTCGOWHJGS-UHFFFAOYSA-N 568623 5-[4-(Azetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 72 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 74.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568623 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568623&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462970 473129937 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200028 FC(F)(F)c1cc(ccc1N1CCC1)C1=NNC(=O)OC1 InChI=1S/C13H12F3N3O2/c14-13(15,16)9-6-8(10-7-21-12(20)18-17-10)2-3-11(9)19-4-1-5-19/h2-3,6H,1,4-5,7H2,(H,18,20) ZPYHYTCGOWHJGS-UHFFFAOYSA-N 568623 5-[4-(Azetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 72 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568623 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568623&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462970 473129937 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200029 CCCCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O2/c1-2-3-4-7-19-12-6-5-10(8-11(12)15(16,17)18)13-9-23-14(22)21-20-13/h5-6,8,19H,2-4,7,9H2,1H3,(H,21,22) JSQKWWINDLUYHP-UHFFFAOYSA-N 568624 5-[4-(Pentylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 74 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 42.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568624 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568624&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462966 473129938 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200030 CCCCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O2/c1-2-3-4-7-19-12-6-5-10(8-11(12)15(16,17)18)13-9-23-14(22)21-20-13/h5-6,8,19H,2-4,7,9H2,1H3,(H,21,22) JSQKWWINDLUYHP-UHFFFAOYSA-N 568624 5-[4-(Pentylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 74 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568624 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568624&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462966 473129938 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200031 Fc1ccc(cc1)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O3/c17-11-4-1-9(2-5-11)12-6-3-10(7-14(12)25-16(18,19)20)13-8-24-15(23)22-21-13/h1-7H,8H2,(H,22,23) PUCGWGCNMBGUKW-UHFFFAOYSA-N 568625 5-[4′-Fluoro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 76 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 225 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568625 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568625&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462731 473129939 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200032 Fc1ccc(cc1)-c1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O3/c17-11-4-1-9(2-5-11)12-6-3-10(7-14(12)25-16(18,19)20)13-8-24-15(23)22-21-13/h1-7H,8H2,(H,22,23) PUCGWGCNMBGUKW-UHFFFAOYSA-N 568625 5-[4′-Fluoro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 76 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568625 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568625&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462731 473129939 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200033 Fc1ccc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H9F2N3O2/c15-11-5-8(12-7-21-14(20)19-18-12)1-3-10(11)9-2-4-13(16)17-6-9/h1-6H,7H2,(H,19,20) MBIDQVKJYXJFKY-UHFFFAOYSA-N 568626 5-[3-Fluoro-4-(6-fluoropyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 77 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 33.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568626 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568626&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462738 473129940 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200034 Fc1ccc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H9F2N3O2/c15-11-5-8(12-7-21-14(20)19-18-12)1-3-10(11)9-2-4-13(16)17-6-9/h1-6H,7H2,(H,19,20) MBIDQVKJYXJFKY-UHFFFAOYSA-N 568626 5-[3-Fluoro-4-(6-fluoropyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 77 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 83.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568626 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568626&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462738 473129940 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200035 Cc1cnccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-7-17-5-4-11(9)12-3-2-10(6-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) OPRASRLINQJDSK-UHFFFAOYSA-N 568627 5-[3-Fluoro-4-(3-methylpyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 78 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 29.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568627 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568627&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462976 473129941 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200036 Cc1cnccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-7-17-5-4-11(9)12-3-2-10(6-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) OPRASRLINQJDSK-UHFFFAOYSA-N 568627 5-[3-Fluoro-4-(3-methylpyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 78 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568627 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568627&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462976 473129941 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200037 Cc1cc(ccn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-6-10(4-5-17-9)12-3-2-11(7-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) QOGKRGJVBODBRF-UHFFFAOYSA-N 568628 5-[3-Fluoro-4-(2-methylpyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 79 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 29.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568628 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568628&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462937 473129942 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200038 Cc1cc(ccn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-6-10(4-5-17-9)12-3-2-11(7-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) QOGKRGJVBODBRF-UHFFFAOYSA-N 568628 5-[3-Fluoro-4-(2-methylpyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 79 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 71.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568628 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568628&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462937 473129942 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200039 Nc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c16-13-7-10(14-8-21-15(20)19-18-14)3-6-12(13)9-1-4-11(17)5-2-9/h1-7H,8,17H2,(H,19,20) KUNVDKXJWRLHHM-UHFFFAOYSA-N 568629 5-(4′-Amino-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 80 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 34.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568629 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568629&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463094 473129943 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200040 Nc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c16-13-7-10(14-8-21-15(20)19-18-14)3-6-12(13)9-1-4-11(17)5-2-9/h1-7H,8,17H2,(H,19,20) KUNVDKXJWRLHHM-UHFFFAOYSA-N 568629 5-(4′-Amino-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 80 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 87.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568629 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568629&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463094 473129943 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200041 Cc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-4-2-3-5-12(10)13-7-6-11(8-14(13)17)15-9-21-16(20)19-18-15/h2-8H,9H2,1H3,(H,19,20) OYOBMFJOKNXXHB-UHFFFAOYSA-N 568630 5-(2-Fluoro-2′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 81 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568630 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568630&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463257 473129944 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200042 Cc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-4-2-3-5-12(10)13-7-6-11(8-14(13)17)15-9-21-16(20)19-18-15/h2-8H,9H2,1H3,(H,19,20) OYOBMFJOKNXXHB-UHFFFAOYSA-N 568630 5-(2-Fluoro-2′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 81 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 270 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568630 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568630&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463257 473129944 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200043 Fc1ccc(c(Cl)c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9ClF2N2O2/c16-12-6-9(17)2-4-10(12)11-3-1-8(5-13(11)18)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) YIKPKUHGQLCORF-UHFFFAOYSA-N 568631 5-(2′-Chloro-2,4′-difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 82 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568631 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568631&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462934 473129945 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200044 Fc1ccc(c(Cl)c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9ClF2N2O2/c16-12-6-9(17)2-4-10(12)11-3-1-8(5-13(11)18)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) YIKPKUHGQLCORF-UHFFFAOYSA-N 568631 5-(2′-Chloro-2,4′-difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 82 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 320 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568631 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568631&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462934 473129945 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200045 Fc1cc(ccc1C1=CCCC1)C1=NNC(=O)OC1 InChI=1S/C14H13FN2O2/c15-12-7-10(13-8-19-14(18)17-16-13)5-6-11(12)9-3-1-2-4-9/h3,5-7H,1-2,4,8H2,(H,17,18) SUVQIVLAVXUFRQ-UHFFFAOYSA-N 568632 5-[4-(Cyclopent-1-en-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 83 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568632 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568632&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462658 473129946 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200046 Fc1cc(ccc1C1=CCCC1)C1=NNC(=O)OC1 InChI=1S/C14H13FN2O2/c15-12-7-10(13-8-19-14(18)17-16-13)5-6-11(12)9-3-1-2-4-9/h3,5-7H,1-2,4,8H2,(H,17,18) SUVQIVLAVXUFRQ-UHFFFAOYSA-N 568632 5-[4-(Cyclopent-1-en-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 83 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568632 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568632&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462658 473129946 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200047 CCc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C17H15FN2O2/c1-2-11-5-3-4-6-13(11)14-8-7-12(9-15(14)18)16-10-22-17(21)20-19-16/h3-9H,2,10H2,1H3,(H,20,21) QOMGREMTJKTUJZ-UHFFFAOYSA-N 568633 5-(2′-Ethyl-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 84 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568633 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568633&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462817 473129947 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200048 CCc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C17H15FN2O2/c1-2-11-5-3-4-6-13(11)14-8-7-12(9-15(14)18)16-10-22-17(21)20-19-16/h3-9H,2,10H2,1H3,(H,20,21) QOMGREMTJKTUJZ-UHFFFAOYSA-N 568633 5-(2′-Ethyl-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 84 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 320 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568633 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568633&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462817 473129947 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200049 COc1ccc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O3/c1-21-14-5-3-10(7-17-14)11-4-2-9(6-12(11)16)13-8-22-15(20)19-18-13/h2-7H,8H2,1H3,(H,19,20) QRSDOXXTCIPLJV-UHFFFAOYSA-N 568634 5-[3-Fluoro-4-(6-methoxypyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 85 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 33.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568634 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568634&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463079 473129948 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200050 COc1ccc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O3/c1-21-14-5-3-10(7-17-14)11-4-2-9(6-12(11)16)13-8-22-15(20)19-18-13/h2-7H,8H2,1H3,(H,19,20) QRSDOXXTCIPLJV-UHFFFAOYSA-N 568634 5-[3-Fluoro-4-(6-methoxypyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 85 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 78.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568634 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568634&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463079 473129948 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200051 Cc1cc(ccc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-6-10(3-5-13(9)17)12-4-2-11(7-14(12)18)15-8-22-16(21)20-19-15/h2-7H,8H2,1H3,(H,20,21) YHJZVZVMFFVSJC-UHFFFAOYSA-N 568635 5-(2,4′-Difluoro-3′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 86 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 84.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568635 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568635&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462897 473129949 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200052 Cc1cc(ccc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-6-10(3-5-13(9)17)12-4-2-11(7-14(12)18)15-8-22-16(21)20-19-15/h2-7H,8H2,1H3,(H,20,21) YHJZVZVMFFVSJC-UHFFFAOYSA-N 568635 5-(2,4′-Difluoro-3′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 86 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568635 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568635&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462897 473129949 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200053 Cc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-3-2-4-11(7-10)13-6-5-12(8-14(13)17)15-9-21-16(20)19-18-15/h2-8H,9H2,1H3,(H,19,20) VDIPEKVLVJPLFT-UHFFFAOYSA-N 568636 5-(2-Fluoro-3′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 87 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 81.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568636 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568636&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462959 473129950 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200054 Cc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-3-2-4-11(7-10)13-6-5-12(8-14(13)17)15-9-21-16(20)19-18-15/h2-8H,9H2,1H3,(H,19,20) VDIPEKVLVJPLFT-UHFFFAOYSA-N 568636 5-(2-Fluoro-3′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 87 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 230 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568636 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568636&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462959 473129950 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200055 Cc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-2-4-11(5-3-10)13-7-6-12(8-14(13)17)15-9-21-16(20)19-18-15/h2-8H,9H2,1H3,(H,19,20) NSYYSBQQCZLMPJ-UHFFFAOYSA-N 568637 5-(2-Fluoro-4′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 88 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568637 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568637&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462700 473129951 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200056 Cc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O2/c1-10-2-4-11(5-3-10)13-7-6-12(8-14(13)17)15-9-21-16(20)19-18-15/h2-8H,9H2,1H3,(H,19,20) NSYYSBQQCZLMPJ-UHFFFAOYSA-N 568637 5-(2-Fluoro-4′-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 88 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568637 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568637&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462700 473129951 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200057 Fc1cc(ccc1-c1ccccc1)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O2/c16-13-8-11(14-9-20-15(19)18-17-14)6-7-12(13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19) DYSZSRJIUGJHEZ-UHFFFAOYSA-N 568638 5-(2-Fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 89 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568638 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568638&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462846 473129952 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200058 Fc1cc(ccc1-c1ccccc1)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O2/c16-13-8-11(14-9-20-15(19)18-17-14)6-7-12(13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19) DYSZSRJIUGJHEZ-UHFFFAOYSA-N 568638 5-(2-Fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 89 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568638 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568638&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462846 473129952 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200059 Nc1cc(ccn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H11FN4O2/c15-11-5-9(12-7-21-14(20)19-18-12)1-2-10(11)8-3-4-17-13(16)6-8/h1-6H,7H2,(H2,16,17)(H,19,20) QDRVNGJVERBFSG-UHFFFAOYSA-N 568639 5-[4-(2-Aminopyridin-4-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 90 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 43.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568639 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568639&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463055 473129953 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200060 Nc1cc(ccn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H11FN4O2/c15-11-5-9(12-7-21-14(20)19-18-12)1-2-10(11)8-3-4-17-13(16)6-8/h1-6H,7H2,(H2,16,17)(H,19,20) QDRVNGJVERBFSG-UHFFFAOYSA-N 568639 5-[4-(2-Aminopyridin-4-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 90 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568639 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568639&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463055 473129953 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200061 Nc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c16-13-7-10(14-8-21-15(20)19-18-14)4-5-12(13)9-2-1-3-11(17)6-9/h1-7H,8,17H2,(H,19,20) SLCSFIUDWJVKRJ-UHFFFAOYSA-N 568640 5-[4-(3-Aminophenyl)-3-fluoro-phenyl]-3,6-dihydro-1,3,4-oxadiazin-2-one::US11427553, Example 91 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 68.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568640 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568640&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462733 473129954 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200062 Nc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c16-13-7-10(14-8-21-15(20)19-18-14)4-5-12(13)9-2-1-3-11(17)6-9/h1-7H,8,17H2,(H,19,20) SLCSFIUDWJVKRJ-UHFFFAOYSA-N 568640 5-[4-(3-Aminophenyl)-3-fluoro-phenyl]-3,6-dihydro-1,3,4-oxadiazin-2-one::US11427553, Example 91 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 85.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568640 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568640&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462733 473129954 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200063 FC(F)c1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H11F3N2O2/c17-13-7-11(14-8-23-16(22)21-20-14)5-6-12(13)9-1-3-10(4-2-9)15(18)19/h1-7,15H,8H2,(H,21,22) JQYSGSMLLAZEID-UHFFFAOYSA-N 568641 5-[4′-(Difluoromethyl)-2-fluoro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 92 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 68.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568641 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568641&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462748 473129955 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200064 FC(F)c1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H11F3N2O2/c17-13-7-11(14-8-23-16(22)21-20-14)5-6-12(13)9-1-3-10(4-2-9)15(18)19/h1-7,15H,8H2,(H,21,22) JQYSGSMLLAZEID-UHFFFAOYSA-N 568641 5-[4′-(Difluoromethyl)-2-fluoro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 92 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568641 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568641&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462748 473129955 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200065 Fc1cc(ccc1-c1ccncc1)C1=NNC(=O)OC1 InChI=1S/C14H10FN3O2/c15-12-7-10(13-8-20-14(19)18-17-13)1-2-11(12)9-3-5-16-6-4-9/h1-7H,8H2,(H,18,19) FFZYIGOAONVJSG-UHFFFAOYSA-N 568642 5-[3-Fluoro-4-(pyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 93 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 50.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568642 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568642&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463047 473129956 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200066 Fc1cc(ccc1-c1ccncc1)C1=NNC(=O)OC1 InChI=1S/C14H10FN3O2/c15-12-7-10(13-8-20-14(19)18-17-13)1-2-11(12)9-3-5-16-6-4-9/h1-7H,8H2,(H,18,19) FFZYIGOAONVJSG-UHFFFAOYSA-N 568642 5-[3-Fluoro-4-(pyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 93 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568642 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568642&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463047 473129956 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200067 Cc1ncc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H11FN4O2/c1-8-16-5-10(6-17-8)11-3-2-9(4-12(11)15)13-7-21-14(20)19-18-13/h2-6H,7H2,1H3,(H,19,20) HBMIGSHZRNJVGF-UHFFFAOYSA-N 568643 5-[3-Fluoro-4-(2-methylpyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 94 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 91.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568643 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568643&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463090 473129957 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200068 Cc1ncc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C14H11FN4O2/c1-8-16-5-10(6-17-8)11-3-2-9(4-12(11)15)13-7-21-14(20)19-18-13/h2-6H,7H2,1H3,(H,19,20) HBMIGSHZRNJVGF-UHFFFAOYSA-N 568643 5-[3-Fluoro-4-(2-methylpyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 94 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 280 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568643 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568643&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463090 473129957 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200069 Cc1ncccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-11(3-2-6-17-9)12-5-4-10(7-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) PIIHRXXNGHWZLD-UHFFFAOYSA-N 568644 5-[3-Fluoro-4-(2-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 96 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 50.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568644 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568644&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463204 473129958 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200070 Cc1ncccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-11(3-2-6-17-9)12-5-4-10(7-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) PIIHRXXNGHWZLD-UHFFFAOYSA-N 568644 5-[3-Fluoro-4-(2-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 96 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568644 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568644&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463204 473129958 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200071 Cc1ccc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-2-3-11(7-17-9)12-5-4-10(6-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) QJUYBFIOQQRFPO-UHFFFAOYSA-N 568645 5-[3-Fluoro-4-(6-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 97 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568645 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568645&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463304 473129959 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200072 Cc1ccc(cn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-2-3-11(7-17-9)12-5-4-10(6-13(12)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) QJUYBFIOQQRFPO-UHFFFAOYSA-N 568645 5-[3-Fluoro-4-(6-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 97 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568645 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568645&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463304 473129959 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200073 Fc1cc(F)c(cc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H8F4N2O2/c16-10-3-7(14-6-23-15(22)21-20-14)1-2-8(10)9-4-12(18)13(19)5-11(9)17/h1-5H,6H2,(H,21,22) JCQZGGSOUOKTLH-UHFFFAOYSA-N 568646 5-(2,2′,4′,5′-Tetrafluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 98 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568646 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568646&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463029 473129960 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200074 Fc1cc(F)c(cc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H8F4N2O2/c16-10-3-7(14-6-23-15(22)21-20-14)1-2-8(10)9-4-12(18)13(19)5-11(9)17/h1-5H,6H2,(H,21,22) JCQZGGSOUOKTLH-UHFFFAOYSA-N 568646 5-(2,2′,4′,5′-Tetrafluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 98 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568646 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568646&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463029 473129960 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200075 Fc1ccc(c(F)c1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H8F4N2O2/c16-10-4-3-9(13(18)14(10)19)8-2-1-7(5-11(8)17)12-6-23-15(22)21-20-12/h1-5H,6H2,(H,21,22) MIRFGQUBLUICOT-UHFFFAOYSA-N 568647 5-(2,2′,3′,4′-Tetrafluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 99 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 88.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568647 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568647&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463075 473129961 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200076 Fc1ccc(c(F)c1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H8F4N2O2/c16-10-4-3-9(13(18)14(10)19)8-2-1-7(5-11(8)17)12-6-23-15(22)21-20-12/h1-5H,6H2,(H,21,22) MIRFGQUBLUICOT-UHFFFAOYSA-N 568647 5-(2,2′,3′,4′-Tetrafluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 99 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568647 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568647&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463075 473129961 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200077 Fc1ccc(F)c(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-9-2-4-12(17)11(6-9)10-3-1-8(5-13(10)18)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) AVFAHSFFNADZBF-UHFFFAOYSA-N 568648 5-(2,2′,5′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 100 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568648 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568648&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463237 473129962 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200078 Fc1ccc(F)c(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-9-2-4-12(17)11(6-9)10-3-1-8(5-13(10)18)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) AVFAHSFFNADZBF-UHFFFAOYSA-N 568648 5-(2,2′,5′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 100 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568648 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568648&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463237 473129962 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200079 Fc1cc(ccc1-c1ccc(cc1)C#N)C1=NNC(=O)OC1 InChI=1S/C16H10FN3O2/c17-14-7-12(15-9-22-16(21)20-19-15)5-6-13(14)11-3-1-10(8-18)2-4-11/h1-7H,9H2,(H,20,21) MIBWFRCRSZLKHO-UHFFFAOYSA-N 568649 2′-Fluoro-4′-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)[1,1′-biphenyl]-4-carbonitrile::US11427553, Example 101 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 28.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568649 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568649&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463303 473129963 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200080 Fc1cc(ccc1-c1ccc(cc1)C#N)C1=NNC(=O)OC1 InChI=1S/C16H10FN3O2/c17-14-7-12(15-9-22-16(21)20-19-15)5-6-13(14)11-3-1-10(8-18)2-4-11/h1-7H,9H2,(H,20,21) MIBWFRCRSZLKHO-UHFFFAOYSA-N 568649 2′-Fluoro-4′-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)[1,1′-biphenyl]-4-carbonitrile::US11427553, Example 101 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 39.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568649 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568649&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463303 473129963 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200081 Nc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c16-12-7-9(14-8-21-15(20)19-18-14)5-6-10(12)11-3-1-2-4-13(11)17/h1-7H,8,17H2,(H,19,20) HKFUTHWNLJFNKH-UHFFFAOYSA-N 568650 5-(2′-Amino-2-fluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 102 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568650 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568650&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463312 473129964 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200082 Nc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c16-12-7-9(14-8-21-15(20)19-18-14)5-6-10(12)11-3-1-2-4-13(11)17/h1-7H,8,17H2,(H,19,20) HKFUTHWNLJFNKH-UHFFFAOYSA-N 568650 5-(2′-Amino-2-fluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 102 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 280 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568650 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568650&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463312 473129964 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200083 Cc1ccc(cc1N)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H14FN3O2/c1-9-2-3-10(7-14(9)18)12-5-4-11(6-13(12)17)15-8-22-16(21)20-19-15/h2-7H,8,18H2,1H3,(H,20,21) QZAGXZUIALCLGQ-UHFFFAOYSA-N 568651 5-(3′-Amino-2-fluoro-4′-methyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 103 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568651 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568651&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462721 473129965 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200084 Cc1ccc(cc1N)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H14FN3O2/c1-9-2-3-10(7-14(9)18)12-5-4-11(6-13(12)17)15-8-22-16(21)20-19-15/h2-7H,8,18H2,1H3,(H,20,21) QZAGXZUIALCLGQ-UHFFFAOYSA-N 568651 5-(3′-Amino-2-fluoro-4′-methyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 103 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568651 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568651&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462721 473129965 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200085 Oc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O3/c16-13-7-10(14-8-21-15(20)18-17-14)3-6-12(13)9-1-4-11(19)5-2-9/h1-7,19H,8H2,(H,18,20) KKAXRVSOWPINSF-UHFFFAOYSA-N 568652 5-(2-Fluoro-4′-hydroxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 105 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568652 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568652&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462735 473129966 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200086 Oc1ccc(cc1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O3/c16-13-7-10(14-8-21-15(20)18-17-14)3-6-12(13)9-1-4-11(19)5-2-9/h1-7,19H,8H2,(H,18,20) KKAXRVSOWPINSF-UHFFFAOYSA-N 568652 5-(2-Fluoro-4′-hydroxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 105 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568652 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568652&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462735 473129966 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200087 Oc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O3/c16-12-7-9(13-8-21-15(20)18-17-13)5-6-10(12)11-3-1-2-4-14(11)19/h1-7,19H,8H2,(H,18,20) XHCFHONQOIRNNN-UHFFFAOYSA-N 568653 5-(2-Fluoro-2′-hydroxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 106 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568653 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568653&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462743 473129967 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200088 Oc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O3/c16-12-7-9(13-8-21-15(20)18-17-13)5-6-10(12)11-3-1-2-4-14(11)19/h1-7,19H,8H2,(H,18,20) XHCFHONQOIRNNN-UHFFFAOYSA-N 568653 5-(2-Fluoro-2′-hydroxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 106 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568653 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568653&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462743 473129967 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200089 Fc1ccc(cc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-11-4-2-8(5-13(11)18)10-3-1-9(6-12(10)17)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) JQDCNNPSPGGZTR-UHFFFAOYSA-N 568654 5-(2,3′,4′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 107 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568654 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568654&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462762 473129968 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200090 Fc1ccc(cc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-11-4-2-8(5-13(11)18)10-3-1-9(6-12(10)17)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) JQDCNNPSPGGZTR-UHFFFAOYSA-N 568654 5-(2,3′,4′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 107 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 160 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568654 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568654&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462762 473129968 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200091 Fc1cc(ccc1-c1cccnc1)C1=NNC(=O)OC1 InChI=1S/C14H10FN3O2/c15-12-6-9(13-8-20-14(19)18-17-13)3-4-11(12)10-2-1-5-16-7-10/h1-7H,8H2,(H,18,19) UQYJCNPSDZVFDJ-UHFFFAOYSA-N 568655 5-[3-Fluoro-4-(pyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 108 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 26.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568655 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568655&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462720 473129969 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200092 Fc1cc(ccc1-c1cccnc1)C1=NNC(=O)OC1 InChI=1S/C14H10FN3O2/c15-12-6-9(13-8-20-14(19)18-17-13)3-4-11(12)10-2-1-5-16-7-10/h1-7H,8H2,(H,18,19) UQYJCNPSDZVFDJ-UHFFFAOYSA-N 568655 5-[3-Fluoro-4-(pyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 108 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 22.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568655 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568655&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462720 473129969 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200093 Fc1cccc(c1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-11-3-1-2-10(14(11)18)9-5-4-8(6-12(9)17)13-7-22-15(21)20-19-13/h1-6H,7H2,(H,20,21) YDEBOSSOBPCHNV-UHFFFAOYSA-N 568656 5-(2,2′,3′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 109 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 46.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568656 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568656&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463365 473129970 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200094 Fc1cccc(c1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-11-3-1-2-10(14(11)18)9-5-4-8(6-12(9)17)13-7-22-15(21)20-19-13/h1-6H,7H2,(H,20,21) YDEBOSSOBPCHNV-UHFFFAOYSA-N 568656 5-(2,2′,3′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 109 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 32.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568656 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568656&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463365 473129970 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200095 Fc1cc(F)cc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-10-3-9(4-11(17)6-10)12-2-1-8(5-13(12)18)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) AEARWUUISQMWCR-UHFFFAOYSA-N 568657 5-(2,3′,5′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 110 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568657 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568657&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463008 473129971 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200096 Fc1cc(F)cc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-10-3-9(4-11(17)6-10)12-2-1-8(5-13(12)18)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) AEARWUUISQMWCR-UHFFFAOYSA-N 568657 5-(2,3′,5′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 110 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568657 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568657&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463008 473129971 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200097 Fc1ccc(c(F)c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-9-2-4-11(13(18)6-9)10-3-1-8(5-12(10)17)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) QJFYCKBFYPZMDH-UHFFFAOYSA-N 568658 5-(2,2′,4′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 111 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 72.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568658 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568658&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463066 473129972 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200098 Fc1ccc(c(F)c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-9-2-4-11(13(18)6-9)10-3-1-8(5-12(10)17)14-7-22-15(21)20-19-14/h1-6H,7H2,(H,20,21) QJFYCKBFYPZMDH-UHFFFAOYSA-N 568658 5-(2,2′,4′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 111 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 81.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568658 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568658&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463066 473129972 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200099 Cc1ccc(c(C)c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C17H15FN2O2/c1-10-3-5-13(11(2)7-10)14-6-4-12(8-15(14)18)16-9-22-17(21)20-19-16/h3-8H,9H2,1-2H3,(H,20,21) CQDZPACGCIHVFS-UHFFFAOYSA-N 568659 5-(2-Fluoro-2′,4′-dimethyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 112 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568659 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568659&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462722 473129973 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200100 Cc1ccc(c(C)c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C17H15FN2O2/c1-10-3-5-13(11(2)7-10)14-6-4-12(8-15(14)18)16-9-22-17(21)20-19-16/h3-8H,9H2,1-2H3,(H,20,21) CQDZPACGCIHVFS-UHFFFAOYSA-N 568659 5-(2-Fluoro-2′,4′-dimethyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 112 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 230 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568659 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568659&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462722 473129973 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200101 Cc1ccc(cc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-2-3-10(6-13(9)17)12-5-4-11(7-14(12)18)15-8-22-16(21)20-19-15/h2-7H,8H2,1H3,(H,20,21) OBLHGHNTMNINGJ-UHFFFAOYSA-N 568660 5-(2,3′-Difluoro-4′-methyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 113 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568660 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568660&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462814 473129974 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200102 Cc1ccc(cc1F)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-2-3-10(6-13(9)17)12-5-4-11(7-14(12)18)15-8-22-16(21)20-19-15/h2-7H,8H2,1H3,(H,20,21) OBLHGHNTMNINGJ-UHFFFAOYSA-N 568660 5-(2,3′-Difluoro-4′-methyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 113 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 215 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568660 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568660&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462814 473129974 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200103 Fc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H10F2N2O2/c16-12-4-2-1-3-10(12)11-6-5-9(7-13(11)17)14-8-21-15(20)19-18-14/h1-7H,8H2,(H,19,20) RDQZKTAEKOWNIZ-UHFFFAOYSA-N 568661 5-(2,2′-Difluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 114 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 92.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568661 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568661&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462985 473129975 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200104 Fc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H10F2N2O2/c16-12-4-2-1-3-10(12)11-6-5-9(7-13(11)17)14-8-21-15(20)19-18-14/h1-7H,8H2,(H,19,20) RDQZKTAEKOWNIZ-UHFFFAOYSA-N 568661 5-(2,2′-Difluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 114 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568661 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568661&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462985 473129975 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200105 Fc1cccc(F)c1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-10-2-1-3-11(17)14(10)9-5-4-8(6-12(9)18)13-7-22-15(21)20-19-13/h1-6H,7H2,(H,20,21) VAZQJLOSRIGHJP-UHFFFAOYSA-N 568662 5-(2,2′,6′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 115 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 92.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568662 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568662&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462745 473129976 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200106 Fc1cccc(F)c1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H9F3N2O2/c16-10-2-1-3-11(17)14(10)9-5-4-8(6-12(9)18)13-7-22-15(21)20-19-13/h1-6H,7H2,(H,20,21) VAZQJLOSRIGHJP-UHFFFAOYSA-N 568662 5-(2,2′,6′-Trifluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 115 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568662 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568662&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462745 473129976 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200107 COc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O3/c1-21-15-5-3-2-4-12(15)11-7-6-10(8-13(11)17)14-9-22-16(20)19-18-14/h2-8H,9H2,1H3,(H,19,20) JLLUECMSUDEWAK-UHFFFAOYSA-N 568663 5-(2-Fluoro-2′-methoxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 116 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 79.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568663 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568663&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462861 473129977 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200108 COc1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H13FN2O3/c1-21-15-5-3-2-4-12(15)11-7-6-10(8-13(11)17)14-9-22-16(20)19-18-14/h2-8H,9H2,1H3,(H,19,20) JLLUECMSUDEWAK-UHFFFAOYSA-N 568663 5-(2-Fluoro-2′-methoxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 116 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 76.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568663 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568663&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462861 473129977 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200109 Fc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H10F2N2O2/c16-11-3-1-2-9(6-11)12-5-4-10(7-13(12)17)14-8-21-15(20)19-18-14/h1-7H,8H2,(H,19,20) JQMUTDUUJQXGBX-UHFFFAOYSA-N 568664 5-(2,3′-Difluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 117 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 77.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568664 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568664&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463307 473129978 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200110 Fc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H10F2N2O2/c16-11-3-1-2-9(6-11)12-5-4-10(7-13(12)17)14-8-21-15(20)19-18-14/h1-7H,8H2,(H,19,20) JQMUTDUUJQXGBX-UHFFFAOYSA-N 568664 5-(2,3′-Difluoro[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 117 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 95.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568664 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568664&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463307 473129978 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200111 Cc1ccncc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-4-5-17-7-12(9)11-3-2-10(6-13(11)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) SVWGAJXSIMTAQB-UHFFFAOYSA-N 568665 5-[3-Fluoro-4-(4-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 118 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 60.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568665 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568665&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463239 473129979 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200112 Cc1ccncc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O2/c1-9-4-5-17-7-12(9)11-3-2-10(6-13(11)16)14-8-21-15(20)19-18-14/h2-7H,8H2,1H3,(H,19,20) SVWGAJXSIMTAQB-UHFFFAOYSA-N 568665 5-[3-Fluoro-4-(4-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 118 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 64.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568665 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568665&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463239 473129979 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200113 CC1OC(=O)NN=C1c1ccc(N2CCOCC2)c(F)c1 InChI=1S/C14H16FN3O3/c1-9-13(16-17-14(19)21-9)10-2-3-12(11(15)8-10)18-4-6-20-7-5-18/h2-3,8-9H,4-7H2,1H3,(H,17,19) CTSRYFMXFGZHJM-UHFFFAOYSA-N 568666 (rac)-5-(3-Fluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 119 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 36.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568666 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568666&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462998 473129980 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200114 CC1OC(=O)NN=C1c1ccc(N2CCOCC2)c(F)c1 InChI=1S/C14H16FN3O3/c1-9-13(16-17-14(19)21-9)10-2-3-12(11(15)8-10)18-4-6-20-7-5-18/h2-3,8-9H,4-7H2,1H3,(H,17,19) CTSRYFMXFGZHJM-UHFFFAOYSA-N 568666 (rac)-5-(3-Fluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 119 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 13.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568666 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568666&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462998 473129980 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200115 C[C@@H]1OC(=O)NN=C1c1ccc(N2CCOCC2)c(C)c1 InChI=1S/C15H19N3O3/c1-10-9-12(14-11(2)21-15(19)17-16-14)3-4-13(10)18-5-7-20-8-6-18/h3-4,9,11H,5-8H2,1-2H3,(H,17,19)/t11-/m0/s1 IKINZRGKBOIIQP-NSHDSACASA-N 568667 (6S)-6-Methyl-5-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 120 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 6.00 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568667 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568667&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 155325994 473129981 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200116 C[C@@H]1OC(=O)NN=C1c1ccc(N2CCOCC2)c(C)c1 InChI=1S/C15H19N3O3/c1-10-9-12(14-11(2)21-15(19)17-16-14)3-4-13(10)18-5-7-20-8-6-18/h3-4,9,11H,5-8H2,1-2H3,(H,17,19)/t11-/m0/s1 IKINZRGKBOIIQP-NSHDSACASA-N 568667 (6S)-6-Methyl-5-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 120 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 4.00 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568667 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568667&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 155325994 473129981 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200117 C[C@@H]1OC(=O)NN=C1c1cc(Cl)c(N2CCOCC2)c(c1)C(F)(F)F InChI=1S/C15H15ClF3N3O3/c1-8-12(20-21-14(23)25-8)9-6-10(15(17,18)19)13(11(16)7-9)22-2-4-24-5-3-22/h6-8H,2-5H2,1H3,(H,21,23)/t8-/m0/s1 MILHWNGXHGLLTF-QMMMGPOBSA-N 568668 (6S)-5-(-[(3-Chloro-4-(morpholin-4-yl)-5-(trifluoromethyl)phenyl)-)]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 121 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568668 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568668&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475721 473129982 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200118 C[C@@H]1OC(=O)NN=C1c1cc(Cl)c(N2CCOCC2)c(c1)C(F)(F)F InChI=1S/C15H15ClF3N3O3/c1-8-12(20-21-14(23)25-8)9-6-10(15(17,18)19)13(11(16)7-9)22-2-4-24-5-3-22/h6-8H,2-5H2,1H3,(H,21,23)/t8-/m0/s1 MILHWNGXHGLLTF-QMMMGPOBSA-N 568668 (6S)-5-(-[(3-Chloro-4-(morpholin-4-yl)-5-(trifluoromethyl)phenyl)-)]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 121 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 299 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568668 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568668&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475721 473129982 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200119 CC1OC(=O)NN=C1c1ccc(N2CCOCC2)c(c1)C(F)(F)F InChI=1S/C15H16F3N3O3/c1-9-13(19-20-14(22)24-9)10-2-3-12(11(8-10)15(16,17)18)21-4-6-23-7-5-21/h2-3,8-9H,4-7H2,1H3,(H,20,22) VPFVSVYEZRQCSG-UHFFFAOYSA-N 568669 (rac)-6-Methyl-5-(4-morpholino-3-(trifluoromethyl)phenyl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 126 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 12.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568669 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568669&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462971 473129983 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200120 CC1OC(=O)NN=C1c1ccc(N2CCOCC2)c(c1)C(F)(F)F InChI=1S/C15H16F3N3O3/c1-9-13(19-20-14(22)24-9)10-2-3-12(11(8-10)15(16,17)18)21-4-6-23-7-5-21/h2-3,8-9H,4-7H2,1H3,(H,20,22) VPFVSVYEZRQCSG-UHFFFAOYSA-N 568669 (rac)-6-Methyl-5-(4-morpholino-3-(trifluoromethyl)phenyl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 126 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 8.00 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568669 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568669&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462971 473129983 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200121 CCn1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-2-22-7-10(6-19-22)11-4-3-9(5-12(11)15(16,17)18)13-8-24-14(23)21-20-13/h3-7H,2,8H2,1H3,(H,21,23) LKVAXYUHJKCXRX-UHFFFAOYSA-N 568670 5-[4-(1-Ethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 131 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 32.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568670 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568670&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463035 473129984 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200122 CCn1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-2-22-7-10(6-19-22)11-4-3-9(5-12(11)15(16,17)18)13-8-24-14(23)21-20-13/h3-7H,2,8H2,1H3,(H,21,23) LKVAXYUHJKCXRX-UHFFFAOYSA-N 568670 5-[4-(1-Ethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 131 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 42.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568670 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568670&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463035 473129984 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200123 CN(C1CCCC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H18F3N3O2/c1-22(11-4-2-3-5-11)14-7-6-10(8-12(14)16(17,18)19)13-9-24-15(23)21-20-13/h6-8,11H,2-5,9H2,1H3,(H,21,23) KNFYAEPYLBLULE-UHFFFAOYSA-N 568671 5-{4-[Cyclopentyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 132 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 260 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568671 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568671&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463009 473129985 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200124 CN(C1CCCC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H18F3N3O2/c1-22(11-4-2-3-5-11)14-7-6-10(8-12(14)16(17,18)19)13-9-24-15(23)21-20-13/h6-8,11H,2-5,9H2,1H3,(H,21,23) KNFYAEPYLBLULE-UHFFFAOYSA-N 568671 5-{4-[Cyclopentyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 132 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 450 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568671 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568671&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463009 473129985 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200125 CN1CCC(=CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H16F3N3O2/c1-22-6-4-10(5-7-22)12-3-2-11(8-13(12)16(17,18)19)14-9-24-15(23)21-20-14/h2-4,8H,5-7,9H2,1H3,(H,21,23) LFVIOVSORBCSRB-UHFFFAOYSA-N 568672 5-[4-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 133 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568672 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568672&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462801 473129986 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200126 CN1CCC(=CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H16F3N3O2/c1-22-6-4-10(5-7-22)12-3-2-11(8-13(12)16(17,18)19)14-9-24-15(23)21-20-14/h2-4,8H,5-7,9H2,1H3,(H,21,23) LFVIOVSORBCSRB-UHFFFAOYSA-N 568672 5-[4-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 133 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568672 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568672&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462801 473129986 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200127 CCCCN(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O2/c1-3-4-7-21(2)13-6-5-10(8-11(13)15(16,17)18)12-9-23-14(22)20-19-12/h5-6,8H,3-4,7,9H2,1-2H3,(H,20,22) XCLWOENOEKDGQK-UHFFFAOYSA-N 568673 5-{4-[Butyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 134 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 270 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568673 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568673&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463135 473129987 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200128 CCCCN(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O2/c1-3-4-7-21(2)13-6-5-10(8-11(13)15(16,17)18)12-9-23-14(22)20-19-12/h5-6,8H,3-4,7,9H2,1-2H3,(H,20,22) XCLWOENOEKDGQK-UHFFFAOYSA-N 568673 5-{4-[Butyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 134 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 580 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568673 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568673&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463135 473129987 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200129 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-4-7-13(14(8-11)17(19,20)21)10-2-5-12(18)6-3-10/h2-9H,1H3,(H,23,24)/t9-/m0/s1 JNTJTCXFIXNXDV-VIFPVBQESA-N 568674 (6S)-5-[4′-Fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 135 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 87.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568674 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568674&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465182 473129988 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200130 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-4-7-13(14(8-11)17(19,20)21)10-2-5-12(18)6-3-10/h2-9H,1H3,(H,23,24)/t9-/m0/s1 JNTJTCXFIXNXDV-VIFPVBQESA-N 568674 (6S)-5-[4′-Fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 135 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 50.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568674 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568674&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465182 473129988 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200131 FC(F)(F)c1cc(ccc1NC1CCCC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O2/c16-15(17,18)11-7-9(13-8-23-14(22)21-20-13)5-6-12(11)19-10-3-1-2-4-10/h5-7,10,19H,1-4,8H2,(H,21,22) NTTOFFAKCDYQOO-UHFFFAOYSA-N 568675 5-[4-(Cyclopentylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 136 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 32.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568675 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568675&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462768 473129989 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200132 FC(F)(F)c1cc(ccc1NC1CCCC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O2/c16-15(17,18)11-7-9(13-8-23-14(22)21-20-13)5-6-12(11)19-10-3-1-2-4-10/h5-7,10,19H,1-4,8H2,(H,21,22) NTTOFFAKCDYQOO-UHFFFAOYSA-N 568675 5-[4-(Cyclopentylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 136 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 27.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568675 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568675&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462768 473129989 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200133 CC(C)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O2/c1-7(2)17-10-4-3-8(5-9(10)13(14,15)16)11-6-21-12(20)19-18-11/h3-5,7,17H,6H2,1-2H3,(H,19,20) YORIIIRVDMNKSJ-UHFFFAOYSA-N 568676 5-[4-(Propan-2-ylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 137 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 52.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568676 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568676&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463128 473129990 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200134 CC(C)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O2/c1-7(2)17-10-4-3-8(5-9(10)13(14,15)16)11-6-21-12(20)19-18-11/h3-5,7,17H,6H2,1-2H3,(H,19,20) YORIIIRVDMNKSJ-UHFFFAOYSA-N 568676 5-[4-(Propan-2-ylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 137 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 88.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568676 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568676&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463128 473129990 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200135 Fc1cccc(c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O2/c17-11-3-1-2-9(6-11)12-5-4-10(7-13(12)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) WUBSOAMGZUHXEK-UHFFFAOYSA-N 568677 5-[3′-Fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 138 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568677 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568677&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463046 473129991 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200136 Fc1cccc(c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O2/c17-11-3-1-2-9(6-11)12-5-4-10(7-13(12)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) WUBSOAMGZUHXEK-UHFFFAOYSA-N 568677 5-[3′-Fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 138 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568677 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568677&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463046 473129991 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200137 Cc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C11H9F3N2O2/c1-6-2-3-7(4-8(6)11(12,13)14)9-5-18-10(17)16-15-9/h2-4H,5H2,1H3,(H,16,17) DEZBCGCLCOIZBU-UHFFFAOYSA-N 568678 5-[4-Methyl-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 139 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568678 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568678&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462829 473129992 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200138 Cc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C11H9F3N2O2/c1-6-2-3-7(4-8(6)11(12,13)14)9-5-18-10(17)16-15-9/h2-4H,5H2,1H3,(H,16,17) DEZBCGCLCOIZBU-UHFFFAOYSA-N 568678 5-[4-Methyl-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 139 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 310 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568678 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568678&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462829 473129992 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200139 COC\C=C\c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F3N2O3/c1-21-6-2-3-9-4-5-10(7-11(9)14(15,16)17)12-8-22-13(20)19-18-12/h2-5,7H,6,8H2,1H3,(H,19,20)/b3-2+ RYLLWGXEJSHWDG-NSCUHMNNSA-N 568679 5-{4-[3-Methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 140 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568679 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568679&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462804 473129993 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200140 COC\C=C\c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F3N2O3/c1-21-6-2-3-9-4-5-10(7-11(9)14(15,16)17)12-8-22-13(20)19-18-12/h2-5,7H,6,8H2,1H3,(H,19,20)/b3-2+ RYLLWGXEJSHWDG-NSCUHMNNSA-N 568679 5-{4-[3-Methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 140 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 80.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568679 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568679&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462804 473129993 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200141 OC1CCC(=CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H15F3N2O3/c17-16(18,19)13-7-10(14-8-24-15(23)21-20-14)3-6-12(13)9-1-4-11(22)5-2-9/h1,3,6-7,11,22H,2,4-5,8H2,(H,21,23) WKQXYWSYWAQGFJ-UHFFFAOYSA-N 568680 (rac)-5-[4′-Hydroxy-2-(trifluoromethyl)-2′,3′,4′,5′-tetrahydro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 141 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 13.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568680 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568680&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463058 473129994 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200142 OC1CCC(=CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H15F3N2O3/c17-16(18,19)13-7-10(14-8-24-15(23)21-20-14)3-6-12(13)9-1-4-11(22)5-2-9/h1,3,6-7,11,22H,2,4-5,8H2,(H,21,23) WKQXYWSYWAQGFJ-UHFFFAOYSA-N 568680 (rac)-5-[4′-Hydroxy-2-(trifluoromethyl)-2′,3′,4′,5′-tetrahydro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 141 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 27.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568680 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568680&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463058 473129994 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200143 FC(F)(F)c1cc(ccc1C1=CCCOC1)C1=NNC(=O)OC1 InChI=1S/C15H13F3N2O3/c16-15(17,18)12-6-9(13-8-23-14(21)20-19-13)3-4-11(12)10-2-1-5-22-7-10/h2-4,6H,1,5,7-8H2,(H,20,21) SUWNWKUDIYFSTN-UHFFFAOYSA-N 568681 5-[4-(5,6-Dihydro-2H-pyran-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 142 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 25.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568681 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568681&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462923 473129995 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200144 FC(F)(F)c1cc(ccc1C1=CCCOC1)C1=NNC(=O)OC1 InChI=1S/C15H13F3N2O3/c16-15(17,18)12-6-9(13-8-23-14(21)20-19-13)3-4-11(12)10-2-1-5-22-7-10/h2-4,6H,1,5,7-8H2,(H,20,21) SUWNWKUDIYFSTN-UHFFFAOYSA-N 568681 5-[4-(5,6-Dihydro-2H-pyran-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 142 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 47.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568681 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568681&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462923 473129995 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200145 FC(F)(F)c1cc(ccc1-c1ccc2nccn2c1)C1=NNC(=O)OC1 InChI=1S/C17H11F3N4O2/c18-17(19,20)13-7-10(14-9-26-16(25)23-22-14)1-3-12(13)11-2-4-15-21-5-6-24(15)8-11/h1-8H,9H2,(H,23,25) ZOARZGZEVRPIHO-UHFFFAOYSA-N 568682 5-[4-(Imidazo[1,2-a]pyridin-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 143 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 38.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568682 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568682&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465157 473129996 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200146 FC(F)(F)c1cc(ccc1-c1ccc2nccn2c1)C1=NNC(=O)OC1 InChI=1S/C17H11F3N4O2/c18-17(19,20)13-7-10(14-9-26-16(25)23-22-14)1-3-12(13)11-2-4-15-21-5-6-24(15)8-11/h1-8H,9H2,(H,23,25) ZOARZGZEVRPIHO-UHFFFAOYSA-N 568682 5-[4-(Imidazo[1,2-a]pyridin-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 143 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 83.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568682 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568682&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465157 473129996 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200147 CC(C)(C)\C=C\c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N2O2/c1-15(2,3)7-6-10-4-5-11(8-12(10)16(17,18)19)13-9-23-14(22)21-20-13/h4-8H,9H2,1-3H3,(H,21,22)/b7-6+ ULROFRBOPSXXEA-VOTSOKGWSA-N 568683 5-{4-[3,3-Dimethylbut-1-en-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 144 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 55.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568683 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568683&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462763 473129997 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200148 CC(C)(C)\C=C\c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N2O2/c1-15(2,3)7-6-10-4-5-11(8-12(10)16(17,18)19)13-9-23-14(22)21-20-13/h4-8H,9H2,1-3H3,(H,21,22)/b7-6+ ULROFRBOPSXXEA-VOTSOKGWSA-N 568683 5-{4-[3,3-Dimethylbut-1-en-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 144 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568683 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568683&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462763 473129997 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200149 FC(F)(F)c1cc(cs1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H8F6N2O2S/c16-14(17,18)10-3-7(11-5-25-13(24)23-22-11)1-2-9(10)8-4-12(26-6-8)15(19,20)21/h1-4,6H,5H2,(H,23,24) BLSQHANBUTYZBK-UHFFFAOYSA-N 568684 5-{3-(Trifluoromethyl)-4-[5-(trifluoromethyl)thiophen-3-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 145 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568684 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568684&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463117 473129998 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200150 FC(F)(F)c1cc(cs1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H8F6N2O2S/c16-14(17,18)10-3-7(11-5-25-13(24)23-22-11)1-2-9(10)8-4-12(26-6-8)15(19,20)21/h1-4,6H,5H2,(H,23,24) BLSQHANBUTYZBK-UHFFFAOYSA-N 568684 5-{3-(Trifluoromethyl)-4-[5-(trifluoromethyl)thiophen-3-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 145 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 410 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568684 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568684&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463117 473129998 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200151 FC(F)n1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H9F5N4O2/c15-12(16)23-5-8(4-20-23)9-2-1-7(3-10(9)14(17,18)19)11-6-25-13(24)22-21-11/h1-5,12H,6H2,(H,22,24) ABQOWYKZOMELPA-UHFFFAOYSA-N 568685 5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 146 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 40.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568685 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568685&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463037 473129999 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200152 FC(F)n1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H9F5N4O2/c15-12(16)23-5-8(4-20-23)9-2-1-7(3-10(9)14(17,18)19)11-6-25-13(24)22-21-11/h1-5,12H,6H2,(H,22,24) ABQOWYKZOMELPA-UHFFFAOYSA-N 568685 5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 146 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 80.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568685 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568685&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463037 473129999 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200153 CC(=C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H11F3N2O2/c1-7(2)9-4-3-8(5-10(9)13(14,15)16)11-6-20-12(19)18-17-11/h3-5H,1,6H2,2H3,(H,18,19) KJYJSTIRHYSKPR-UHFFFAOYSA-N 568686 5-[4-(Prop-1-en-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 147 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568686 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568686&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462812 473130000 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200154 CC(=C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H11F3N2O2/c1-7(2)9-4-3-8(5-10(9)13(14,15)16)11-6-20-12(19)18-17-11/h3-5H,1,6H2,2H3,(H,18,19) KJYJSTIRHYSKPR-UHFFFAOYSA-N 568686 5-[4-(Prop-1-en-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 147 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 310 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568686 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568686&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462812 473130000 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200155 FC(F)(F)c1cc(ccc1-c1cc2ccccc2s1)C1=NNC(=O)OC1 InChI=1S/C18H11F3N2O2S/c19-18(20,21)13-7-10(14-9-25-17(24)23-22-14)5-6-12(13)16-8-11-3-1-2-4-15(11)26-16/h1-8H,9H2,(H,23,24) DLDDNYHHOKSVRW-UHFFFAOYSA-N 568687 5-[4-(1-Benzothiophen-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 148 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 190 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568687 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568687&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465165 473130001 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200156 FC(F)(F)c1cc(ccc1-c1cc2ccccc2s1)C1=NNC(=O)OC1 InChI=1S/C18H11F3N2O2S/c19-18(20,21)13-7-10(14-9-25-17(24)23-22-14)5-6-12(13)16-8-11-3-1-2-4-15(11)26-16/h1-8H,9H2,(H,23,24) DLDDNYHHOKSVRW-UHFFFAOYSA-N 568687 5-[4-(1-Benzothiophen-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 148 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568687 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568687&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465165 473130001 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200157 FC(F)(F)c1cc(ccc1C1=CCOC1)C1=NNC(=O)OC1 InChI=1S/C14H11F3N2O3/c15-14(16,17)11-5-8(12-7-22-13(20)19-18-12)1-2-10(11)9-3-4-21-6-9/h1-3,5H,4,6-7H2,(H,19,20) KYCLFGAQDWJRRK-UHFFFAOYSA-N 568688 5-[4-(2,5-Dihydrofuran-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 149 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 163 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568688 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568688&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462883 473130002 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200158 FC(F)(F)c1cc(ccc1C1=CCOC1)C1=NNC(=O)OC1 InChI=1S/C14H11F3N2O3/c15-14(16,17)11-5-8(12-7-22-13(20)19-18-12)1-2-10(11)9-3-4-21-6-9/h1-3,5H,4,6-7H2,(H,19,20) KYCLFGAQDWJRRK-UHFFFAOYSA-N 568688 5-[4-(2,5-Dihydrofuran-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 149 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 132 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568688 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568688&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462883 473130002 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200159 FC(F)(F)c1cc(ccc1C1=CCCC1)C1=NNC(=O)OC1 InChI=1S/C15H13F3N2O2/c16-15(17,18)12-7-10(13-8-22-14(21)20-19-13)5-6-11(12)9-3-1-2-4-9/h3,5-7H,1-2,4,8H2,(H,20,21) RXGAKYWPFQJGPD-UHFFFAOYSA-N 568689 5-[4-(Cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 150 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568689 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568689&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462940 473130003 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200160 FC(F)(F)c1cc(ccc1C1=CCCC1)C1=NNC(=O)OC1 InChI=1S/C15H13F3N2O2/c16-15(17,18)12-7-10(13-8-22-14(21)20-19-13)5-6-11(12)9-3-1-2-4-9/h3,5-7H,1-2,4,8H2,(H,20,21) RXGAKYWPFQJGPD-UHFFFAOYSA-N 568689 5-[4-(Cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 150 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568689 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568689&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462940 473130003 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200161 CCn1cnc(c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-2-22-6-12(19-8-22)10-4-3-9(5-11(10)15(16,17)18)13-7-24-14(23)21-20-13/h3-6,8H,2,7H2,1H3,(H,21,23) ZSDCPMJORZSDGS-UHFFFAOYSA-N 568690 5-[4-(1-Ethyl-1H-imidazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 151 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 69.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568690 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568690&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463268 473130004 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200162 CCn1cnc(c1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-2-22-6-12(19-8-22)10-4-3-9(5-11(10)15(16,17)18)13-7-24-14(23)21-20-13/h3-6,8H,2,7H2,1H3,(H,21,23) ZSDCPMJORZSDGS-UHFFFAOYSA-N 568690 5-[4-(1-Ethyl-1H-imidazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 151 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 159 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568690 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568690&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463268 473130004 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200163 Cc1cc(sc1C#N)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F3N3O2S/c1-8-4-13(25-14(8)6-20)10-3-2-9(5-11(10)16(17,18)19)12-7-24-15(23)22-21-12/h2-5H,7H2,1H3,(H,22,23) HBUNMCPRHXBDCX-UHFFFAOYSA-N 568691 3-Methyl-5-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]thiophene-2-carbonitrile::US11427553, Example 152 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 63.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568691 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568691&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462659 473130005 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200164 Cc1cc(sc1C#N)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F3N3O2S/c1-8-4-13(25-14(8)6-20)10-3-2-9(5-11(10)16(17,18)19)12-7-24-15(23)22-21-12/h2-5H,7H2,1H3,(H,22,23) HBUNMCPRHXBDCX-UHFFFAOYSA-N 568691 3-Methyl-5-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]thiophene-2-carbonitrile::US11427553, Example 152 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 76.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568691 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568691&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462659 473130005 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200165 CC(C)n1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H15F3N4O2/c1-9(2)23-7-11(6-20-23)12-4-3-10(5-13(12)16(17,18)19)14-8-25-15(24)22-21-14/h3-7,9H,8H2,1-2H3,(H,22,24) SEOSKAFBLAKFPD-UHFFFAOYSA-N 568692 5-{4-[1-(Propan-2-yl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 153 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 15.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568692 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568692&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462671 473130006 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200166 CC(C)n1cc(cn1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H15F3N4O2/c1-9(2)23-7-11(6-20-23)12-4-3-10(5-13(12)16(17,18)19)14-8-25-15(24)22-21-14/h3-7,9H,8H2,1-2H3,(H,22,24) SEOSKAFBLAKFPD-UHFFFAOYSA-N 568692 5-{4-[1-(Propan-2-yl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 153 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 26.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568692 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568692&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462671 473130006 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200167 FC(F)(F)c1cc(ccc1C1=CC2CCC1C2)C1=NNC(=O)OC1 InChI=1S/C17H15F3N2O2/c18-17(19,20)14-7-11(15-8-24-16(23)22-21-15)3-4-12(14)13-6-9-1-2-10(13)5-9/h3-4,6-7,9-10H,1-2,5,8H2,(H,22,23) ZYBODMTUKDRWQM-UHFFFAOYSA-N 568693 (rac)-5-[4-(Bicyclo[2.2.1]hept-2-en-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 154 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 70.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568693 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568693&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462656 473130007 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200168 FC(F)(F)c1cc(ccc1C1=CC2CCC1C2)C1=NNC(=O)OC1 InChI=1S/C17H15F3N2O2/c18-17(19,20)14-7-11(15-8-24-16(23)22-21-15)3-4-12(14)13-6-9-1-2-10(13)5-9/h3-4,6-7,9-10H,1-2,5,8H2,(H,22,23) ZYBODMTUKDRWQM-UHFFFAOYSA-N 568693 (rac)-5-[4-(Bicyclo[2.2.1]hept-2-en-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 154 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568693 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568693&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462656 473130007 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200169 Fc1ccccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O2/c17-13-4-2-1-3-11(13)10-6-5-9(7-12(10)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) FEFXNCRFMIZZHK-UHFFFAOYSA-N 568694 5-[2′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 155 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 92.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568694 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568694&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463104 473130008 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200170 Fc1ccccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H10F4N2O2/c17-13-4-2-1-3-11(13)10-6-5-9(7-12(10)16(18,19)20)14-8-24-15(23)22-21-14/h1-7H,8H2,(H,22,23) FEFXNCRFMIZZHK-UHFFFAOYSA-N 568694 5-[2′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 155 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568694 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568694&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463104 473130008 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200171 FC(F)(F)c1ccc(s1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H8F6N2O2S/c16-14(17,18)9-5-7(10-6-25-13(24)23-22-10)1-2-8(9)11-3-4-12(26-11)15(19,20)21/h1-5H,6H2,(H,23,24) FFRNPLZIICTENM-UHFFFAOYSA-N 568695 5-{3-(Trifluoromethyl)-4-[5-(trifluoromethyl)thiophen-2-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 156 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 440 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568695 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568695&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462752 473130009 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200172 FC(F)(F)c1ccc(s1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H8F6N2O2S/c16-14(17,18)9-5-7(10-6-25-13(24)23-22-10)1-2-8(9)11-3-4-12(26-11)15(19,20)21/h1-5H,6H2,(H,23,24) FFRNPLZIICTENM-UHFFFAOYSA-N 568695 5-{3-(Trifluoromethyl)-4-[5-(trifluoromethyl)thiophen-2-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 156 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 650 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568695 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568695&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462752 473130009 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200173 Cc1ccc(nc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O2/c1-9-2-5-13(20-7-9)11-4-3-10(6-12(11)16(17,18)19)14-8-24-15(23)22-21-14/h2-7H,8H2,1H3,(H,22,23) DJMQVJUNBVJEPK-UHFFFAOYSA-N 568696 5-[4-(5-Methylpyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 157 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568696 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568696&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462744 473130010 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200174 Cc1ccc(nc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H12F3N3O2/c1-9-2-5-13(20-7-9)11-4-3-10(6-12(11)16(17,18)19)14-8-24-15(23)22-21-14/h2-7H,8H2,1H3,(H,22,23) DJMQVJUNBVJEPK-UHFFFAOYSA-N 568696 5-[4-(5-Methylpyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 157 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568696 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568696&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462744 473130010 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200175 Fc1ccc(nc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H9F4N3O2/c16-9-2-4-12(20-6-9)10-3-1-8(5-11(10)15(17,18)19)13-7-24-14(23)22-21-13/h1-6H,7H2,(H,22,23) NWFFCJBUMMVCRX-UHFFFAOYSA-N 568697 5-[4-(5-Fluoropyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 158 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 500 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568697 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568697&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462760 473130011 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200176 Fc1ccc(nc1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H9F4N3O2/c16-9-2-4-12(20-6-9)10-3-1-8(5-11(10)15(17,18)19)13-7-24-14(23)22-21-13/h1-6H,7H2,(H,22,23) NWFFCJBUMMVCRX-UHFFFAOYSA-N 568697 5-[4-(5-Fluoropyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 158 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 720 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568697 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568697&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462760 473130011 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200177 FC(F)(F)c1cc(ccc1-c1ccc(Cl)cn1)C1=NNC(=O)OC1 InChI=1S/C15H9ClF3N3O2/c16-9-2-4-12(20-6-9)10-3-1-8(5-11(10)15(17,18)19)13-7-24-14(23)22-21-13/h1-6H,7H2,(H,22,23) ZVJWTSJWSMDARQ-UHFFFAOYSA-N 568698 5-[4-(5-Chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 159 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568698 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568698&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463249 473130012 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200178 FC(F)(F)c1cc(ccc1-c1ccc(Cl)cn1)C1=NNC(=O)OC1 InChI=1S/C15H9ClF3N3O2/c16-9-2-4-12(20-6-9)10-3-1-8(5-11(10)15(17,18)19)13-7-24-14(23)22-21-13/h1-6H,7H2,(H,22,23) ZVJWTSJWSMDARQ-UHFFFAOYSA-N 568698 5-[4-(5-Chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 159 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568698 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568698&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463249 473130012 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200179 FC(F)(F)c1cc(ccc1-c1ccccn1)C1=NNC(=O)OC1 InChI=1S/C15H10F3N3O2/c16-15(17,18)11-7-9(13-8-23-14(22)21-20-13)4-5-10(11)12-3-1-2-6-19-12/h1-7H,8H2,(H,21,22) FUQINQITUBUYBR-UHFFFAOYSA-N 568699 5-[4-(Pyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 160 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568699 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568699&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465741 473130013 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200180 FC(F)(F)c1cc(ccc1-c1ccccn1)C1=NNC(=O)OC1 InChI=1S/C15H10F3N3O2/c16-15(17,18)11-7-9(13-8-23-14(22)21-20-13)4-5-10(11)12-3-1-2-6-19-12/h1-7H,8H2,(H,21,22) FUQINQITUBUYBR-UHFFFAOYSA-N 568699 5-[4-(Pyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 160 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568699 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568699&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465741 473130013 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200181 FC(F)c1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H11F3N2O2/c17-13-7-9(14-8-23-16(22)21-20-14)5-6-11(13)10-3-1-2-4-12(10)15(18)19/h1-7,15H,8H2,(H,21,22) LIFTWKZNLFUUPN-UHFFFAOYSA-N 568700 5-[2′-(Difluoromethyl)-2-fluoro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 161 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568700 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568700&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465166 473130014 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200182 FC(F)c1ccccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H11F3N2O2/c17-13-7-9(14-8-23-16(22)21-20-14)5-6-11(13)10-3-1-2-4-12(10)15(18)19/h1-7,15H,8H2,(H,21,22) LIFTWKZNLFUUPN-UHFFFAOYSA-N 568700 5-[2′-(Difluoromethyl)-2-fluoro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 161 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 49.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568700 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568700&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465166 473130014 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200183 Cc1cc(F)ccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-6-11(17)3-5-12(9)13-4-2-10(7-14(13)18)15-8-22-16(21)20-19-15/h2-7H,8H2,1H3,(H,20,21) PZFSVERLFTZCIW-UHFFFAOYSA-N 568701 5-(2,4′-Difluoro-2′-methyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 162 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568701 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568701&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462652 473130015 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200184 Cc1cc(F)ccc1-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C16H12F2N2O2/c1-9-6-11(17)3-5-12(9)13-4-2-10(7-14(13)18)15-8-22-16(21)20-19-15/h2-7H,8H2,1H3,(H,20,21) PZFSVERLFTZCIW-UHFFFAOYSA-N 568701 5-(2,4′-Difluoro-2′-methyl[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 162 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568701 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568701&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462652 473130015 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200185 Cc1cc(ccc1-c1ccc(cc1F)C1=NNC(=O)OC1)C#N InChI=1S/C17H12FN3O2/c1-10-6-11(8-19)2-4-13(10)14-5-3-12(7-15(14)18)16-9-23-17(22)21-20-16/h2-7H,9H2,1H3,(H,21,22) ITWAGLBJEGABEF-UHFFFAOYSA-N 568702 2′-Fluoro-2-methyl-4′-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)[1,1′-biphenyl]-4-carbonitrile::US11427553, Example 163 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 35.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568702 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568702&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462994 473130016 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200186 Cc1cc(ccc1-c1ccc(cc1F)C1=NNC(=O)OC1)C#N InChI=1S/C17H12FN3O2/c1-10-6-11(8-19)2-4-13(10)14-5-3-12(7-15(14)18)16-9-23-17(22)21-20-16/h2-7H,9H2,1H3,(H,21,22) ITWAGLBJEGABEF-UHFFFAOYSA-N 568702 2′-Fluoro-2-methyl-4′-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)[1,1′-biphenyl]-4-carbonitrile::US11427553, Example 163 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 51.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568702 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568702&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462994 473130016 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200187 CC(C)=Cc1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F3N2O3/c1-8(2)5-10-4-3-9(6-12(10)22-14(15,16)17)11-7-21-13(20)19-18-11/h3-6H,7H2,1-2H3,(H,19,20) QXWCJHGGVHVZFT-UHFFFAOYSA-N 568703 5-[4-(2-Methylprop-1-en-1-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 164 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 300 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568703 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568703&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463078 473130017 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200188 CC(C)=Cc1ccc(cc1OC(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F3N2O3/c1-8(2)5-10-4-3-9(6-12(10)22-14(15,16)17)11-7-21-13(20)19-18-11/h3-6H,7H2,1-2H3,(H,19,20) QXWCJHGGVHVZFT-UHFFFAOYSA-N 568703 5-[4-(2-Methylprop-1-en-1-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 164 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568703 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568703&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463078 473130017 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200189 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccnc(N)c2)c(c1)C(F)(F)F InChI=1S/C16H13F3N4O2/c1-8-14(22-23-15(24)25-8)10-2-3-11(12(6-10)16(17,18)19)9-4-5-21-13(20)7-9/h2-8H,1H3,(H2,20,21)(H,23,24)/t8-/m0/s1 XZVRWQQQWLPFRB-QMMMGPOBSA-N 568704 (6S)-5-[4-(2-Aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 165 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 77.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568704 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568704&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462899 473130018 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200190 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccnc(N)c2)c(c1)C(F)(F)F InChI=1S/C16H13F3N4O2/c1-8-14(22-23-15(24)25-8)10-2-3-11(12(6-10)16(17,18)19)9-4-5-21-13(20)7-9/h2-8H,1H3,(H2,20,21)(H,23,24)/t8-/m0/s1 XZVRWQQQWLPFRB-QMMMGPOBSA-N 568704 (6S)-5-[4-(2-Aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 165 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568704 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568704&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462899 473130018 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200191 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccncc2)c(c1)C(F)(F)F InChI=1S/C16H12F3N3O2/c1-9-14(21-22-15(23)24-9)11-2-3-12(10-4-6-20-7-5-10)13(8-11)16(17,18)19/h2-9H,1H3,(H,22,23)/t9-/m0/s1 KJJACMBDLFUVJV-VIFPVBQESA-N 568705 (6S)-6-Methyl-5-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 166 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 69.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568705 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568705&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462851 473130019 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200192 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccncc2)c(c1)C(F)(F)F InChI=1S/C16H12F3N3O2/c1-9-14(21-22-15(23)24-9)11-2-3-12(10-4-6-20-7-5-10)13(8-11)16(17,18)19/h2-9H,1H3,(H,22,23)/t9-/m0/s1 KJJACMBDLFUVJV-VIFPVBQESA-N 568705 (6S)-6-Methyl-5-[4-(pyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 166 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 42.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568705 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568705&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462851 473130019 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200193 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)nc2)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-3-4-12(8-21-9)13-6-5-11(7-14(13)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 RDPTWFYHEIZOBA-JTQLQIEISA-N 568706 (6S)-6-Methyl-5-[4-(6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 167 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 34.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568706 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568706&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463006 473130020 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200194 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)nc2)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-3-4-12(8-21-9)13-6-5-11(7-14(13)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 RDPTWFYHEIZOBA-JTQLQIEISA-N 568706 (6S)-6-Methyl-5-[4-(6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 167 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568706 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568706&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463006 473130020 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200195 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)cc2F)c(c1)C(F)(F)F InChI=1S/C18H14F4N2O2/c1-9-3-5-13(15(19)7-9)12-6-4-11(8-14(12)18(20,21)22)16-10(2)26-17(25)24-23-16/h3-8,10H,1-2H3,(H,24,25)/t10-/m0/s1 QDOZTHLINUJNET-JTQLQIEISA-N 568707 (6S)-5-[2′-Fluoro-4′-methyl-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 168 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568707 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568707&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462799 473130021 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200196 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)cc2F)c(c1)C(F)(F)F InChI=1S/C18H14F4N2O2/c1-9-3-5-13(15(19)7-9)12-6-4-11(8-14(12)18(20,21)22)16-10(2)26-17(25)24-23-16/h3-8,10H,1-2H3,(H,24,25)/t10-/m0/s1 QDOZTHLINUJNET-JTQLQIEISA-N 568707 (6S)-5-[2′-Fluoro-4′-methyl-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 168 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568707 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568707&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462799 473130021 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200197 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cc(F)c(F)cc2F)c(c1)C(F)(F)F InChI=1S/C17H10F6N2O2/c1-7-15(24-25-16(26)27-7)8-2-3-9(11(4-8)17(21,22)23)10-5-13(19)14(20)6-12(10)18/h2-7H,1H3,(H,25,26)/t7-/m0/s1 UTXFHGXBAUIRLZ-ZETCQYMHSA-N 568708 (6S)-6-Methyl-5-[2′,4′,5′-trifluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 169 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568708 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568708&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465190 473130022 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200198 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cc(F)c(F)cc2F)c(c1)C(F)(F)F InChI=1S/C17H10F6N2O2/c1-7-15(24-25-16(26)27-7)8-2-3-9(11(4-8)17(21,22)23)10-5-13(19)14(20)6-12(10)18/h2-7H,1H3,(H,25,26)/t7-/m0/s1 UTXFHGXBAUIRLZ-ZETCQYMHSA-N 568708 (6S)-6-Methyl-5-[2′,4′,5′-trifluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 169 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568708 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568708&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465190 473130022 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200199 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)c(F)c2F)c(c1)C(F)(F)F InChI=1S/C17H10F6N2O2/c1-7-15(24-25-16(26)27-7)8-2-3-9(11(6-8)17(21,22)23)10-4-5-12(18)14(20)13(10)19/h2-7H,1H3,(H,25,26)/t7-/m0/s1 KQIHCUMWNXFYMS-ZETCQYMHSA-N 568709 (6S)-6-Methyl-5-[2′,3′,4′-trifluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 170 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 190 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568709 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568709&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463052 473130023 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200200 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)c(F)c2F)c(c1)C(F)(F)F InChI=1S/C17H10F6N2O2/c1-7-15(24-25-16(26)27-7)8-2-3-9(11(6-8)17(21,22)23)10-4-5-12(18)14(20)13(10)19/h2-7H,1H3,(H,25,26)/t7-/m0/s1 KQIHCUMWNXFYMS-ZETCQYMHSA-N 568709 (6S)-6-Methyl-5-[2′,3′,4′-trifluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 170 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568709 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568709&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463052 473130023 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200201 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cc(F)ccc2F)c(c1)C(F)(F)F InChI=1S/C17H11F5N2O2/c1-8-15(23-24-16(25)26-8)9-2-4-11(13(6-9)17(20,21)22)12-7-10(18)3-5-14(12)19/h2-8H,1H3,(H,24,25)/t8-/m0/s1 NQRKCVDSWOZJKC-QMMMGPOBSA-N 568710 (6S)-5-[2′,5′-Difluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 171 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568710 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568710&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462729 473130024 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200202 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cc(F)ccc2F)c(c1)C(F)(F)F InChI=1S/C17H11F5N2O2/c1-8-15(23-24-16(25)26-8)9-2-4-11(13(6-9)17(20,21)22)12-7-10(18)3-5-14(12)19/h2-8H,1H3,(H,24,25)/t8-/m0/s1 NQRKCVDSWOZJKC-QMMMGPOBSA-N 568710 (6S)-5-[2′,5′-Difluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 171 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568710 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568710&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462729 473130024 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200203 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccccc2C#N)c(c1)C(F)(F)F InChI=1S/C18H12F3N3O2/c1-10-16(23-24-17(25)26-10)11-6-7-14(15(8-11)18(19,20)21)13-5-3-2-4-12(13)9-22/h2-8,10H,1H3,(H,24,25)/t10-/m0/s1 FBMGCPZJYYIWDP-JTQLQIEISA-N 568711 4′-[(6S)-6-Methyl-2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl]-2′-(trifluoromethyl)[1,1′-biphenyl]-2-carbonitrile::US11427553, Example 172 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 290 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568711&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462909 473130025 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200204 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccccc2C#N)c(c1)C(F)(F)F InChI=1S/C18H12F3N3O2/c1-10-16(23-24-17(25)26-10)11-6-7-14(15(8-11)18(19,20)21)13-5-3-2-4-12(13)9-22/h2-8,10H,1H3,(H,24,25)/t10-/m0/s1 FBMGCPZJYYIWDP-JTQLQIEISA-N 568711 4′-[(6S)-6-Methyl-2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl]-2′-(trifluoromethyl)[1,1′-biphenyl]-2-carbonitrile::US11427553, Example 172 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 520 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568711&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462909 473130025 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200205 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc3[nH]ccc3c2)c(c1)C(F)(F)F 568712 (6S)-5-[4-(1H-Indol-5-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 173 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568712&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465168 473130026 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200206 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc3[nH]ccc3c2)c(c1)C(F)(F)F 568712 (6S)-5-[4-(1H-Indol-5-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 173 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568712&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465168 473130026 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200207 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(O)cc2)c(c1)C(F)(F)F InChI=1S/C17H13F3N2O3/c1-9-15(21-22-16(24)25-9)11-4-7-13(14(8-11)17(18,19)20)10-2-5-12(23)6-3-10/h2-9,23H,1H3,(H,22,24)/t9-/m0/s1 QLSMQXDPLXXTTO-VIFPVBQESA-N 568713 (6S)-5-[4′-Hydroxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 174::US11427553, Example 188 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 27.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568713&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463122 473130027 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200208 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(O)cc2)c(c1)C(F)(F)F InChI=1S/C17H13F3N2O3/c1-9-15(21-22-16(24)25-9)11-4-7-13(14(8-11)17(18,19)20)10-2-5-12(23)6-3-10/h2-9,23H,1H3,(H,22,24)/t9-/m0/s1 QLSMQXDPLXXTTO-VIFPVBQESA-N 568713 (6S)-5-[4′-Hydroxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 174::US11427553, Example 188 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 16.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568713&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463122 473130027 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200209 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cccc(O)c2)c(c1)C(F)(F)F InChI=1S/C17H13F3N2O3/c1-9-15(21-22-16(24)25-9)11-5-6-13(14(8-11)17(18,19)20)10-3-2-4-12(23)7-10/h2-9,23H,1H3,(H,22,24)/t9-/m0/s1 MHLFBNHKEUUGDT-VIFPVBQESA-N 568714 (6S)-5-[3′-Hydroxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 175 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 26.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568714 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568714&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463406 473130028 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200210 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cccc(O)c2)c(c1)C(F)(F)F InChI=1S/C17H13F3N2O3/c1-9-15(21-22-16(24)25-9)11-5-6-13(14(8-11)17(18,19)20)10-3-2-4-12(23)7-10/h2-9,23H,1H3,(H,22,24)/t9-/m0/s1 MHLFBNHKEUUGDT-VIFPVBQESA-N 568714 (6S)-5-[3′-Hydroxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 175 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 24.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568714 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568714&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463406 473130028 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200211 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cccc(N)c2)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-15(22-23-16(24)25-9)11-5-6-13(14(8-11)17(18,19)20)10-3-2-4-12(21)7-10/h2-9H,21H2,1H3,(H,23,24)/t9-/m0/s1 GIHKNYQIKPLINP-VIFPVBQESA-N 568715 (6S)-5-[3′-Amino-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 176 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 37.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568715 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568715&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462956 473130029 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200212 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cccc(N)c2)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-15(22-23-16(24)25-9)11-5-6-13(14(8-11)17(18,19)20)10-3-2-4-12(21)7-10/h2-9H,21H2,1H3,(H,23,24)/t9-/m0/s1 GIHKNYQIKPLINP-VIFPVBQESA-N 568715 (6S)-5-[3′-Amino-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 176 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 35.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568715 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568715&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462956 473130029 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200213 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2F)c(c1)C(F)(F)F InChI=1S/C17H11F5N2O2/c1-8-15(23-24-16(25)26-8)9-2-4-11(13(6-9)17(20,21)22)12-5-3-10(18)7-14(12)19/h2-8H,1H3,(H,24,25)/t8-/m0/s1 WFZBHBLUCVRJNX-QMMMGPOBSA-N 568716 (6S)-5-[2′,4′-Difluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 177 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 160 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568716 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568716&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462657 473130030 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200214 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2F)c(c1)C(F)(F)F InChI=1S/C17H11F5N2O2/c1-8-15(23-24-16(25)26-8)9-2-4-11(13(6-9)17(20,21)22)12-5-3-10(18)7-14(12)19/h2-8H,1H3,(H,24,25)/t8-/m0/s1 WFZBHBLUCVRJNX-QMMMGPOBSA-N 568716 (6S)-5-[2′,4′-Difluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 177 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568716 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568716&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462657 473130030 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200215 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)c(F)c2)c(c1)C(F)(F)F InChI=1S/C18H14F4N2O2/c1-9-3-4-11(8-15(9)19)13-6-5-12(7-14(13)18(20,21)22)16-10(2)26-17(25)24-23-16/h3-8,10H,1-2H3,(H,24,25)/t10-/m0/s1 KQIQTSQHKHNYJY-JTQLQIEISA-N 568717 (6S)-5-[3′-Fluoro-4′-methyl-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 178 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568717 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568717&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463019 473130031 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200216 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)c(F)c2)c(c1)C(F)(F)F InChI=1S/C18H14F4N2O2/c1-9-3-4-11(8-15(9)19)13-6-5-12(7-14(13)18(20,21)22)16-10(2)26-17(25)24-23-16/h3-8,10H,1-2H3,(H,24,25)/t10-/m0/s1 KQIQTSQHKHNYJY-JTQLQIEISA-N 568717 (6S)-5-[3′-Fluoro-4′-methyl-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 178 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568717 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568717&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463019 473130031 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200217 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccccc2F)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)10-6-7-11(13(8-10)17(19,20)21)12-4-2-3-5-14(12)18/h2-9H,1H3,(H,23,24)/t9-/m0/s1 GVDRUTSKBXIUEW-VIFPVBQESA-N 568718 (6S)-5-[2′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 179 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568718 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568718&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462688 473130032 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200218 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccccc2F)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)10-6-7-11(13(8-10)17(19,20)21)12-4-2-3-5-14(12)18/h2-9H,1H3,(H,23,24)/t9-/m0/s1 GVDRUTSKBXIUEW-VIFPVBQESA-N 568718 (6S)-5-[2′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 179 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568718 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568718&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462688 473130032 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200219 COc1ccccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)O[C@H]1C InChI=1S/C18H15F3N2O3/c1-10-16(22-23-17(24)26-10)11-7-8-12(14(9-11)18(19,20)21)13-5-3-4-6-15(13)25-2/h3-10H,1-2H3,(H,23,24)/t10-/m0/s1 HCIDSTUOZLVOEQ-JTQLQIEISA-N 568719 (6S)-5-[2′-Methoxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 180 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568719 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568719&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462667 473130033 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200220 COc1ccccc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)O[C@H]1C InChI=1S/C18H15F3N2O3/c1-10-16(22-23-17(24)26-10)11-7-8-12(14(9-11)18(19,20)21)13-5-3-4-6-15(13)25-2/h3-10H,1-2H3,(H,23,24)/t10-/m0/s1 HCIDSTUOZLVOEQ-JTQLQIEISA-N 568719 (6S)-5-[2′-Methoxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 180 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568719 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568719&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462667 473130033 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200221 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cccc(F)c2)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-5-6-13(14(8-11)17(19,20)21)10-3-2-4-12(18)7-10/h2-9H,1H3,(H,23,24)/t9-/m0/s1 GLILTUPAPNTIBB-VIFPVBQESA-N 568720 (6S)-5-[3′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 181 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 74.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568720 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568720&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462935 473130034 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200222 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cccc(F)c2)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-5-6-13(14(8-11)17(19,20)21)10-3-2-4-12(18)7-10/h2-9H,1H3,(H,23,24)/t9-/m0/s1 GLILTUPAPNTIBB-VIFPVBQESA-N 568720 (6S)-5-[3′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 181 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 77.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568720 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568720&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462935 473130034 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200223 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cnccc2C)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-5-6-21-8-13(9)12-4-3-11(7-14(12)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 XFINUDQNQVAXQO-JTQLQIEISA-N 568721 (6S)-6-Methyl-5-[4-(4-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 182 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568721 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568721&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462969 473130035 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200224 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cnccc2C)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-5-6-21-8-13(9)12-4-3-11(7-14(12)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 XFINUDQNQVAXQO-JTQLQIEISA-N 568721 (6S)-6-Methyl-5-[4-(4-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 182 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 260 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568721 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568721&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462969 473130035 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200225 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccncc2C)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-8-21-6-5-12(9)13-4-3-11(7-14(13)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 QAMBZWUEYQFBKA-JTQLQIEISA-N 568722 (6S)-6-Methyl-5-[4-(3-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 183 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568722 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568722&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462961 473130036 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200226 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccncc2C)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-8-21-6-5-12(9)13-4-3-11(7-14(13)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 QAMBZWUEYQFBKA-JTQLQIEISA-N 568722 (6S)-6-Methyl-5-[4-(3-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 183 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568722 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568722&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462961 473130036 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200227 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccnc(C)c2)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-7-11(5-6-21-9)13-4-3-12(8-14(13)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 IPEVOPPPDXENKM-JTQLQIEISA-N 568723 (6S)-6-Methyl-5-[4-(2-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 184 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568723 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568723&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462808 473130037 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200228 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccnc(C)c2)c(c1)C(F)(F)F InChI=1S/C17H14F3N3O2/c1-9-7-11(5-6-21-9)13-4-3-12(8-14(13)17(18,19)20)15-10(2)25-16(24)23-22-15/h3-8,10H,1-2H3,(H,23,24)/t10-/m0/s1 IPEVOPPPDXENKM-JTQLQIEISA-N 568723 (6S)-6-Methyl-5-[4-(2-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 184 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 57.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568723 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568723&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462808 473130037 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200229 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc3cc[nH]c3c2)c(c1)C(F)(F)F 568724 (6S)-5-[4-(1H-Indol-6-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 185 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 49.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568724 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568724&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462973 473130038 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200230 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc3cc[nH]c3c2)c(c1)C(F)(F)F 568724 (6S)-5-[4-(1H-Indol-6-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 185 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568724 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568724&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462973 473130038 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200231 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(O)nc2)c(c1)C(F)(F)F InChI=1S/C16H12F3N3O3/c1-8-14(21-22-15(24)25-8)9-2-4-11(12(6-9)16(17,18)19)10-3-5-13(23)20-7-10/h2-8H,1H3,(H,20,23)(H,22,24)/t8-/m0/s1 YSRHPKPEFZMKRX-QMMMGPOBSA-N 568725 (6S)-5-[4-(6-Methoxypyridin-3-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 187 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 81.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568725 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568725&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475182 473130039 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200232 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(O)nc2)c(c1)C(F)(F)F InChI=1S/C16H12F3N3O3/c1-8-14(21-22-15(24)25-8)9-2-4-11(12(6-9)16(17,18)19)10-3-5-13(23)20-7-10/h2-8H,1H3,(H,20,23)(H,22,24)/t8-/m0/s1 YSRHPKPEFZMKRX-QMMMGPOBSA-N 568725 (6S)-5-[4-(6-Methoxypyridin-3-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 187 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568725 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568725&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475182 473130039 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200233 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(O)cc2)c(c1)C(F)(F)F InChI=1S/C17H13F3N2O3/c1-9-15(21-22-16(24)25-9)11-4-7-13(14(8-11)17(18,19)20)10-2-5-12(23)6-3-10/h2-9,23H,1H3,(H,22,24)/t9-/m0/s1 QLSMQXDPLXXTTO-VIFPVBQESA-N 568713 (6S)-5-[4′-Hydroxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 174::US11427553, Example 188 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 90.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568713&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463122 473130027 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200234 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(O)cc2)c(c1)C(F)(F)F InChI=1S/C17H13F3N2O3/c1-9-15(21-22-16(24)25-9)11-4-7-13(14(8-11)17(18,19)20)10-2-5-12(23)6-3-10/h2-9,23H,1H3,(H,22,24)/t9-/m0/s1 QLSMQXDPLXXTTO-VIFPVBQESA-N 568713 (6S)-5-[4′-Hydroxy-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 174::US11427553, Example 188 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568713&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463122 473130027 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200235 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)cc2)c(c1)C(F)(F)F InChI=1S/C18H15F3N2O2/c1-10-3-5-12(6-4-10)14-8-7-13(9-15(14)18(19,20)21)16-11(2)25-17(24)23-22-16/h3-9,11H,1-2H3,(H,23,24)/t11-/m0/s1 ARWVVDBWISSNEP-NSHDSACASA-N 568727 (6S)-6-Methyl-5-[4′-methyl-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 189 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 190 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568727 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568727&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463158 473130040 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200236 C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(C)cc2)c(c1)C(F)(F)F InChI=1S/C18H15F3N2O2/c1-10-3-5-12(6-4-10)14-8-7-13(9-15(14)18(19,20)21)16-11(2)25-17(24)23-22-16/h3-9,11H,1-2H3,(H,23,24)/t11-/m0/s1 ARWVVDBWISSNEP-NSHDSACASA-N 568727 (6S)-6-Methyl-5-[4′-methyl-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 189 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568727 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568727&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463158 473130040 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200237 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cnn(c2)C(F)F)c(c1)C(F)(F)F InChI=1S/C15H11F5N4O2/c1-7-12(22-23-14(25)26-7)8-2-3-10(11(4-8)15(18,19)20)9-5-21-24(6-9)13(16)17/h2-7,13H,1H3,(H,23,25)/t7-/m0/s1 GYOWSDLEDJOFED-ZETCQYMHSA-N 568728 (6S)-5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 190 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 38.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568728 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568728&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463020 473130041 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200238 C[C@@H]1OC(=O)NN=C1c1ccc(-c2cnn(c2)C(F)F)c(c1)C(F)(F)F InChI=1S/C15H11F5N4O2/c1-7-12(22-23-14(25)26-7)8-2-3-10(11(4-8)15(18,19)20)9-5-21-24(6-9)13(16)17/h2-7,13H,1H3,(H,23,25)/t7-/m0/s1 GYOWSDLEDJOFED-ZETCQYMHSA-N 568728 (6S)-5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 190 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 25.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568728 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568728&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463020 473130041 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200239 CC1OC(=O)NN=C1c1ccc(-c2cnn(c2)C(F)F)c(c1)C(F)(F)F InChI=1S/C15H11F5N4O2/c1-7-12(22-23-14(25)26-7)8-2-3-10(11(4-8)15(18,19)20)9-5-21-24(6-9)13(16)17/h2-7,13H,1H3,(H,23,25) GYOWSDLEDJOFED-UHFFFAOYSA-N 568729 (rac)-5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 191 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568729 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568729&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463016 473130042 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200240 CC1OC(=O)NN=C1c1ccc(-c2cnn(c2)C(F)F)c(c1)C(F)(F)F InChI=1S/C15H11F5N4O2/c1-7-12(22-23-14(25)26-7)8-2-3-10(11(4-8)15(18,19)20)9-5-21-24(6-9)13(16)17/h2-7,13H,1H3,(H,23,25) GYOWSDLEDJOFED-UHFFFAOYSA-N 568729 (rac)-5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 191 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 57.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568729 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568729&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463016 473130042 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200241 CC1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-4-7-13(14(8-11)17(19,20)21)10-2-5-12(18)6-3-10/h2-9H,1H3,(H,23,24) JNTJTCXFIXNXDV-UHFFFAOYSA-N 568730 (rac)-5-[4′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 192 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 320 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568730 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568730&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462886 473130043 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200242 CC1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2)c(c1)C(F)(F)F InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-4-7-13(14(8-11)17(19,20)21)10-2-5-12(18)6-3-10/h2-9H,1H3,(H,23,24) JNTJTCXFIXNXDV-UHFFFAOYSA-N 568730 (rac)-5-[4′-Fluoro-2-(trifluoromethyl)[1,1′-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 192 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568730 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568730&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462886 473130043 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200243 FC(F)n1cc(cn1)-c1c(F)cc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H8F6N4O2/c15-9-2-6(10-5-26-13(25)23-22-10)1-8(14(18,19)20)11(9)7-3-21-24(4-7)12(16)17/h1-4,12H,5H2,(H,23,25) PTJJQADRERZTSY-UHFFFAOYSA-N 568731 5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-fluoro-5-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 193 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 195 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568731 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568731&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462711 473130044 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200244 FC(F)n1cc(cn1)-c1c(F)cc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H8F6N4O2/c15-9-2-6(10-5-26-13(25)23-22-10)1-8(14(18,19)20)11(9)7-3-21-24(4-7)12(16)17/h1-4,12H,5H2,(H,23,25) PTJJQADRERZTSY-UHFFFAOYSA-N 568731 5-{4-[1-(Difluoromethyl)-1H-pyrazol-4-yl]-3-fluoro-5-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 193 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 215 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568731 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568731&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462711 473130044 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200245 FC(F)c1cc(ccc1-c1cnn(c1)C(F)F)C1=NNC(=O)OC1 InChI=1S/C14H10F4N4O2/c15-12(16)10-3-7(11-6-24-14(23)21-20-11)1-2-9(10)8-4-19-22(5-8)13(17)18/h1-5,12-13H,6H2,(H,21,23) VJHAQTKDSPEXPQ-UHFFFAOYSA-N 568732 5-{3-(Difluoromethyl)-4-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 195 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568732 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568732&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462651 473130045 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200246 FC(F)c1cc(ccc1-c1cnn(c1)C(F)F)C1=NNC(=O)OC1 InChI=1S/C14H10F4N4O2/c15-12(16)10-3-7(11-6-24-14(23)21-20-11)1-2-9(10)8-4-19-22(5-8)13(17)18/h1-5,12-13H,6H2,(H,21,23) VJHAQTKDSPEXPQ-UHFFFAOYSA-N 568732 5-{3-(Difluoromethyl)-4-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 195 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 77.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568732 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568732&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462651 473130045 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200247 C[C@@H]1OC(=O)NN=C1c1ccc(CN2CCOCC2)c(c1)C(F)(F)F InChI=1S/C16H18F3N3O3/c1-10-14(20-21-15(23)25-10)11-2-3-12(13(8-11)16(17,18)19)9-22-4-6-24-7-5-22/h2-3,8,10H,4-7,9H2,1H3,(H,21,23)/t10-/m0/s1 PFPFPCWJWPYXQM-JTQLQIEISA-N 568733 (6S)-6-Methyl-5-{4-[(morpholin-4-yl)methyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 196 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 810 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568733 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568733&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463200 473130046 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200248 C[C@@H]1OC(=O)NN=C1c1ccc(CN2CCOCC2)c(c1)C(F)(F)F InChI=1S/C16H18F3N3O3/c1-10-14(20-21-15(23)25-10)11-2-3-12(13(8-11)16(17,18)19)9-22-4-6-24-7-5-22/h2-3,8,10H,4-7,9H2,1H3,(H,21,23)/t10-/m0/s1 PFPFPCWJWPYXQM-JTQLQIEISA-N 568733 (6S)-6-Methyl-5-{4-[(morpholin-4-yl)methyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 196 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 790 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568733 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568733&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463200 473130046 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200249 FC(F)(F)c1cc(ccc1CN1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)12-7-10(13-9-24-14(22)20-19-13)1-2-11(12)8-21-3-5-23-6-4-21/h1-2,7H,3-6,8-9H2,(H,20,22) LWFOWEGIOLZSAB-UHFFFAOYSA-N 568734 5-{4-[(Morpholin-4-yl)methyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 197 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 650 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568734 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568734&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462761 473130047 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200250 FC(F)(F)c1cc(ccc1CN1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)12-7-10(13-9-24-14(22)20-19-13)1-2-11(12)8-21-3-5-23-6-4-21/h1-2,7H,3-6,8-9H2,(H,20,22) LWFOWEGIOLZSAB-UHFFFAOYSA-N 568734 5-{4-[(Morpholin-4-yl)methyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 197 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 803 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568734 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568734&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462761 473130047 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200251 FC(F)c1cc(ccc1-c1ccc(F)cc1)C1=NNC(=O)OC1 InChI=1S/C16H11F3N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)15(18)19)14-8-23-16(22)21-20-14/h1-7,15H,8H2,(H,21,22) FWYQCYVILNCMID-UHFFFAOYSA-N 568735 5-[2-(Difluoromethyl)-4′-fluoro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 198 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568735 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568735&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463261 473130048 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200252 FC(F)c1cc(ccc1-c1ccc(F)cc1)C1=NNC(=O)OC1 InChI=1S/C16H11F3N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)15(18)19)14-8-23-16(22)21-20-14/h1-7,15H,8H2,(H,21,22) FWYQCYVILNCMID-UHFFFAOYSA-N 568735 5-[2-(Difluoromethyl)-4′-fluoro[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 198 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568735 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568735&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463261 473130048 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200253 FC(F)c1cc(ccc1-c1ccc(Cl)cc1)C1=NNC(=O)OC1 InChI=1S/C16H11ClF2N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)15(18)19)14-8-23-16(22)21-20-14/h1-7,15H,8H2,(H,21,22) LKPHAELTCVRPDD-UHFFFAOYSA-N 568736 5-[4′-Chloro-2-(difluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 199 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568736 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568736&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462666 473130049 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200254 FC(F)c1cc(ccc1-c1ccc(Cl)cc1)C1=NNC(=O)OC1 InChI=1S/C16H11ClF2N2O2/c17-11-4-1-9(2-5-11)12-6-3-10(7-13(12)15(18)19)14-8-23-16(22)21-20-14/h1-7,15H,8H2,(H,21,22) LKPHAELTCVRPDD-UHFFFAOYSA-N 568736 5-[4′-Chloro-2-(difluoromethyl)[1,1′-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 199 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568736 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568736&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462666 473130049 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200255 Cc1ccc(cn1)-c1ccc(cc1C(F)F)C1=NNC(=O)OC1 InChI=1S/C16H13F2N3O2/c1-9-2-3-11(7-19-9)12-5-4-10(6-13(12)15(17)18)14-8-23-16(22)21-20-14/h2-7,15H,8H2,1H3,(H,21,22) UVPBMSDTJZLQJH-UHFFFAOYSA-N 568737 5-[3-(Difluoromethyl)-4-(6-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 200 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 34.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568737 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568737&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462958 473130050 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200256 Cc1ccc(cn1)-c1ccc(cc1C(F)F)C1=NNC(=O)OC1 InChI=1S/C16H13F2N3O2/c1-9-2-3-11(7-19-9)12-5-4-10(6-13(12)15(17)18)14-8-23-16(22)21-20-14/h2-7,15H,8H2,1H3,(H,21,22) UVPBMSDTJZLQJH-UHFFFAOYSA-N 568737 5-[3-(Difluoromethyl)-4-(6-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 200 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568737 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568737&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462958 473130050 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200257 FC(F)c1cc(ccc1C1=CCCC1)C1=NNC(=O)OC1 InChI=1S/C15H14F2N2O2/c16-14(17)12-7-10(13-8-21-15(20)19-18-13)5-6-11(12)9-3-1-2-4-9/h3,5-7,14H,1-2,4,8H2,(H,19,20) YQNZHHDYPPXVSY-UHFFFAOYSA-N 568738 5-[4-(Cyclopent-1-en-1-yl)-3-(difluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 201 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 86.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568738 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568738&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463132 473130051 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200258 FC(F)c1cc(ccc1C1=CCCC1)C1=NNC(=O)OC1 InChI=1S/C15H14F2N2O2/c16-14(17)12-7-10(13-8-21-15(20)19-18-13)5-6-11(12)9-3-1-2-4-9/h3,5-7,14H,1-2,4,8H2,(H,19,20) YQNZHHDYPPXVSY-UHFFFAOYSA-N 568738 5-[4-(Cyclopent-1-en-1-yl)-3-(difluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 201 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 77.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568738 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568738&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463132 473130051 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200259 FC(F)c1cc(ccc1-c1cn[nH]c1)C1=NNC(=O)OC1 InChI=1S/C13H10F2N4O2/c14-12(15)10-3-7(11-6-21-13(20)19-18-11)1-2-9(10)8-4-16-17-5-8/h1-5,12H,6H2,(H,16,17)(H,19,20) WXMGJIXCKGQRLA-UHFFFAOYSA-N 568739 5-[3-(Difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 202 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 76.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568739 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568739&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462991 473130052 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200260 FC(F)c1cc(ccc1-c1cn[nH]c1)C1=NNC(=O)OC1 InChI=1S/C13H10F2N4O2/c14-12(15)10-3-7(11-6-21-13(20)19-18-11)1-2-9(10)8-4-16-17-5-8/h1-5,12H,6H2,(H,16,17)(H,19,20) WXMGJIXCKGQRLA-UHFFFAOYSA-N 568739 5-[3-(Difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 202 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 63.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568739 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568739&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462991 473130052 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200261 CC1(O)CN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c1-13(22)6-20(7-13)11-3-2-8(4-9(11)14(15,16)17)10-5-23-12(21)19-18-10/h2-4,22H,5-7H2,1H3,(H,19,21) LKAOHDKDUDPAPP-UHFFFAOYSA-N 568740 5-[4-(3-Hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 203 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 37.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568740 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568740&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462827 473130053 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200262 CC1(O)CN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c1-13(22)6-20(7-13)11-3-2-8(4-9(11)14(15,16)17)10-5-23-12(21)19-18-10/h2-4,22H,5-7H2,1H3,(H,19,21) LKAOHDKDUDPAPP-UHFFFAOYSA-N 568740 5-[4-(3-Hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 203 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 88.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568740 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568740&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462827 473130053 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200263 OC(CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C(F)(F)F InChI=1S/C13H11F6N3O3/c14-12(15,16)7-3-6(9-5-25-11(24)22-21-9)1-2-8(7)20-4-10(23)13(17,18)19/h1-3,10,20,23H,4-5H2,(H,22,24) HETJACRWUIMVMX-UHFFFAOYSA-N 568741 (rac)-5-[4-{[3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 204 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 80.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568741 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568741&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462705 473130054 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200264 OC(CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C(F)(F)F InChI=1S/C13H11F6N3O3/c14-12(15,16)7-3-6(9-5-25-11(24)22-21-9)1-2-8(7)20-4-10(23)13(17,18)19/h1-3,10,20,23H,4-5H2,(H,22,24) HETJACRWUIMVMX-UHFFFAOYSA-N 568741 (rac)-5-[4-{[3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 204 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568741 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568741&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462705 473130054 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200265 FC(F)(F)c1cc(ccc1NC1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-7-9(13-8-24-14(22)21-20-13)1-2-12(11)19-10-3-5-23-6-4-10/h1-2,7,10,19H,3-6,8H2,(H,21,22) BRDRSCOFKHRZPN-UHFFFAOYSA-N 568742 5-{4-[(Oxan-4-yl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 205 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 53.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568742 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568742&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463024 473130055 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200266 FC(F)(F)c1cc(ccc1NC1CCOCC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-7-9(13-8-24-14(22)21-20-13)1-2-12(11)19-10-3-5-23-6-4-10/h1-2,7,10,19H,3-6,8H2,(H,21,22) BRDRSCOFKHRZPN-UHFFFAOYSA-N 568742 5-{4-[(Oxan-4-yl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 205 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 123 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568742 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568742&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463024 473130055 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200267 OC1CC(C1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-3-7(12-6-23-13(22)20-19-12)1-2-11(10)18-8-4-9(21)5-8/h1-3,8-9,18,21H,4-6H2,(H,20,22) FUBXNCIMMVKLIQ-UHFFFAOYSA-N 568743 (cis/trans)-5-[4-{[3-hydroxycyclobutyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 206 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 15.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568743 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568743&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463308 473130056 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200268 OC1CC(C1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-3-7(12-6-23-13(22)20-19-12)1-2-11(10)18-8-4-9(21)5-8/h1-3,8-9,18,21H,4-6H2,(H,20,22) FUBXNCIMMVKLIQ-UHFFFAOYSA-N 568743 (cis/trans)-5-[4-{[3-hydroxycyclobutyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 206 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 20.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568743 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568743&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463308 473130056 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200269 CC1CC(C)N1c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O2/c1-8-5-9(2)21(8)13-4-3-10(6-11(13)15(16,17)18)12-7-23-14(22)20-19-12/h3-4,6,8-9H,5,7H2,1-2H3,(H,20,22) LGMBOZFWFXOLRI-UHFFFAOYSA-N 568744 (rac)-5-{4-[2,4-Dimethylazetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 207 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 74.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568744 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568744&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475552 473130057 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200270 CC1CC(C)N1c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O2/c1-8-5-9(2)21(8)13-4-3-10(6-11(13)15(16,17)18)12-7-23-14(22)20-19-12/h3-4,6,8-9H,5,7H2,1-2H3,(H,20,22) LGMBOZFWFXOLRI-UHFFFAOYSA-N 568744 (rac)-5-{4-[2,4-Dimethylazetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 207 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568744 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568744&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475552 473130057 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200271 C[C@H]1C[C@H](C)N1c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O2/c1-8-5-9(2)21(8)13-4-3-10(6-11(13)15(16,17)18)12-7-23-14(22)20-19-12/h3-4,6,8-9H,5,7H2,1-2H3,(H,20,22)/t8-,9-/m0/s1 LGMBOZFWFXOLRI-IUCAKERBSA-N 568745 (cis or trans)-5-{4-[2,4-Dimethylazetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 208 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568745 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568745&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475371 473130058 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200272 C[C@H]1C[C@H](C)N1c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O2/c1-8-5-9(2)21(8)13-4-3-10(6-11(13)15(16,17)18)12-7-23-14(22)20-19-12/h3-4,6,8-9H,5,7H2,1-2H3,(H,20,22)/t8-,9-/m0/s1 LGMBOZFWFXOLRI-IUCAKERBSA-N 568745 (cis or trans)-5-{4-[2,4-Dimethylazetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 208 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568745 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568745&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475371 473130058 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200273 O[C@@H](CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C(F)(F)F InChI=1S/C13H11F6N3O3/c14-12(15,16)7-3-6(9-5-25-11(24)22-21-9)1-2-8(7)20-4-10(23)13(17,18)19/h1-3,10,20,23H,4-5H2,(H,22,24)/t10-/m0/s1 HETJACRWUIMVMX-JTQLQIEISA-N 568746 5-[4-{[3,3,3-Trifluoro-(2S)-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 209 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 275 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568746 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568746&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465174 473130059 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200274 O[C@@H](CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C(F)(F)F InChI=1S/C13H11F6N3O3/c14-12(15,16)7-3-6(9-5-25-11(24)22-21-9)1-2-8(7)20-4-10(23)13(17,18)19/h1-3,10,20,23H,4-5H2,(H,22,24)/t10-/m0/s1 HETJACRWUIMVMX-JTQLQIEISA-N 568746 5-[4-{[3,3,3-Trifluoro-(2S)-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 209 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 533 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568746 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568746&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465174 473130059 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200275 CC(C)(O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-13(2,22)7-18-10-4-3-8(5-9(10)14(15,16)17)11-6-23-12(21)20-19-11/h3-5,18,22H,6-7H2,1-2H3,(H,20,21) BQKWMVANZSMRQL-UHFFFAOYSA-N 568747 5-{4-[(2-Hydroxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 210 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568747 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568747&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462649 473130060 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200276 CC(C)(O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-13(2,22)7-18-10-4-3-8(5-9(10)14(15,16)17)11-6-23-12(21)20-19-11/h3-5,18,22H,6-7H2,1-2H3,(H,20,21) BQKWMVANZSMRQL-UHFFFAOYSA-N 568747 5-{4-[(2-Hydroxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 210 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 363 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568747 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568747&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462649 473130060 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200277 O[C@H]1CC[C@@H](CC1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H18F3N3O3/c17-16(18,19)12-7-9(14-8-25-15(24)22-21-14)1-6-13(12)20-10-2-4-11(23)5-3-10/h1,6-7,10-11,20,23H,2-5,8H2,(H,22,24)/t10-,11- FDFBRHLJGWWTPU-XYPYZODXSA-N 568748 (trans)-5-[4-{[4-Hydroxycyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 211 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 29.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568748 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568748&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463021 473130061 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200278 O[C@H]1CC[C@@H](CC1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H18F3N3O3/c17-16(18,19)12-7-9(14-8-25-15(24)22-21-14)1-6-13(12)20-10-2-4-11(23)5-3-10/h1,6-7,10-11,20,23H,2-5,8H2,(H,22,24)/t10-,11- FDFBRHLJGWWTPU-XYPYZODXSA-N 568748 (trans)-5-[4-{[4-Hydroxycyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 211 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 54.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568748 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568748&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463021 473130061 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200279 FC(F)(F)c1cc(ccc1NCC1CC1)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O2/c15-14(16,17)10-5-9(12-7-22-13(21)20-19-12)3-4-11(10)18-6-8-1-2-8/h3-5,8,18H,1-2,6-7H2,(H,20,21) DTAMDCMHGINZIZ-UHFFFAOYSA-N 568749 5-{4-[(Cyclopropylmethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 212 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 26.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568749 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568749&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462836 473130062 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200280 FC(F)(F)c1cc(ccc1NCC1CC1)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O2/c15-14(16,17)10-5-9(12-7-22-13(21)20-19-12)3-4-11(10)18-6-8-1-2-8/h3-5,8,18H,1-2,6-7H2,(H,20,21) DTAMDCMHGINZIZ-UHFFFAOYSA-N 568749 5-{4-[(Cyclopropylmethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 212 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 24.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568749 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568749&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462836 473130062 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200281 CC1(CNc2ccc(cc2C(F)(F)F)C2=NNC(=O)OC2)COC1 InChI=1S/C15H16F3N3O3/c1-14(7-23-8-14)6-19-11-3-2-9(4-10(11)15(16,17)18)12-5-24-13(22)21-20-12/h2-4,19H,5-8H2,1H3,(H,21,22) WHOPZHXSQBNYFL-UHFFFAOYSA-N 568750 5-[4-{[(3-Methyloxetan-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 213 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 68.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568750 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568750&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462841 473130063 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200282 CC1(CNc2ccc(cc2C(F)(F)F)C2=NNC(=O)OC2)COC1 InChI=1S/C15H16F3N3O3/c1-14(7-23-8-14)6-19-11-3-2-9(4-10(11)15(16,17)18)12-5-24-13(22)21-20-12/h2-4,19H,5-8H2,1H3,(H,21,22) WHOPZHXSQBNYFL-UHFFFAOYSA-N 568750 5-[4-{[(3-Methyloxetan-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 213 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 71.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568750 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568750&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462841 473130063 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200283 COCCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-22-6-2-5-18-11-4-3-9(7-10(11)14(15,16)17)12-8-23-13(21)20-19-12/h3-4,7,18H,2,5-6,8H2,1H3,(H,20,21) DVNBHVVAZHOSQT-UHFFFAOYSA-N 568751 5-{4-[(3-Methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 214 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 59.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568751 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568751&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463320 473130064 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200284 COCCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-22-6-2-5-18-11-4-3-9(7-10(11)14(15,16)17)12-8-23-13(21)20-19-12/h3-4,7,18H,2,5-6,8H2,1H3,(H,20,21) DVNBHVVAZHOSQT-UHFFFAOYSA-N 568751 5-{4-[(3-Methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 214 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 73.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568751 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568751&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463320 473130064 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200285 FC(F)(F)c1cc(ccc1NCC1CCCO1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(13-8-24-14(22)21-20-13)3-4-12(11)19-7-10-2-1-5-23-10/h3-4,6,10,19H,1-2,5,7-8H2,(H,21,22) WQZNIULOSVKZFL-UHFFFAOYSA-N 568752 (rac)-5-[4-({[Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 215 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568752 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568752&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462736 473130065 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200286 FC(F)(F)c1cc(ccc1NCC1CCCO1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(13-8-24-14(22)21-20-13)3-4-12(11)19-7-10-2-1-5-23-10/h3-4,6,10,19H,1-2,5,7-8H2,(H,21,22) WQZNIULOSVKZFL-UHFFFAOYSA-N 568752 (rac)-5-[4-({[Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 215 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568752 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568752&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462736 473130065 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200287 C[C@@H](O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O3/c1-7(20)5-17-10-3-2-8(4-9(10)13(14,15)16)11-6-22-12(21)19-18-11/h2-4,7,17,20H,5-6H2,1H3,(H,19,21)/t7-/m1/s1 CDJVHFYAUYOQBH-SSDOTTSWSA-N 568753 5-[4-{[(2R)-2-Hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 216 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 103 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568753 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568753&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465160 473130066 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200288 C[C@@H](O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O3/c1-7(20)5-17-10-3-2-8(4-9(10)13(14,15)16)11-6-22-12(21)19-18-11/h2-4,7,17,20H,5-6H2,1H3,(H,19,21)/t7-/m1/s1 CDJVHFYAUYOQBH-SSDOTTSWSA-N 568753 5-[4-{[(2R)-2-Hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 216 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 167 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568753 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568753&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465160 473130066 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200289 C[C@@H](O)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-8(21)4-5-18-11-3-2-9(6-10(11)14(15,16)17)12-7-23-13(22)20-19-12/h2-3,6,8,18,21H,4-5,7H2,1H3,(H,20,22)/t8-/m1/s1 JYNBAFJWVZPYHL-MRVPVSSYSA-N 568754 5-[4-{[(3R)-3-Hydroxybutyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 217 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568754 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568754&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462984 473130067 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200290 C[C@@H](O)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-8(21)4-5-18-11-3-2-9(6-10(11)14(15,16)17)12-7-23-13(22)20-19-12/h2-3,6,8,18,21H,4-5,7H2,1H3,(H,20,22)/t8-/m1/s1 JYNBAFJWVZPYHL-MRVPVSSYSA-N 568754 5-[4-{[(3R)-3-Hydroxybutyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 217 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568754 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568754&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462984 473130067 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200291 C[C@H](O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O3/c1-7(20)5-17-10-3-2-8(4-9(10)13(14,15)16)11-6-22-12(21)19-18-11/h2-4,7,17,20H,5-6H2,1H3,(H,19,21)/t7-/m0/s1 CDJVHFYAUYOQBH-ZETCQYMHSA-N 568755 5-[4-{[(2S)-2-Hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 218 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 35.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568755 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568755&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462941 473130068 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200292 C[C@H](O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O3/c1-7(20)5-17-10-3-2-8(4-9(10)13(14,15)16)11-6-22-12(21)19-18-11/h2-4,7,17,20H,5-6H2,1H3,(H,19,21)/t7-/m0/s1 CDJVHFYAUYOQBH-ZETCQYMHSA-N 568755 5-[4-{[(2S)-2-Hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 218 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 89.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568755 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568755&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462941 473130068 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200293 OC1(CNc2ccc(cc2C(F)(F)F)C2=NNC(=O)OC2)CCC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)10-6-9(12-7-24-13(22)21-20-12)2-3-11(10)19-8-14(23)4-1-5-14/h2-3,6,19,23H,1,4-5,7-8H2,(H,21,22) IWUNUHKQPDUGIK-UHFFFAOYSA-N 568756 5-[4-{[(1-Hydroxycyclobutyl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 219 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568756 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568756&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462930 473130069 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200294 OC1(CNc2ccc(cc2C(F)(F)F)C2=NNC(=O)OC2)CCC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)10-6-9(12-7-24-13(22)21-20-12)2-3-11(10)19-8-14(23)4-1-5-14/h2-3,6,19,23H,1,4-5,7-8H2,(H,21,22) IWUNUHKQPDUGIK-UHFFFAOYSA-N 568756 5-[4-{[(1-Hydroxycyclobutyl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 219 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 97.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568756 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568756&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462930 473130069 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200295 CC(C)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O2/c1-9(2)5-6-19-12-4-3-10(7-11(12)15(16,17)18)13-8-23-14(22)21-20-13/h3-4,7,9,19H,5-6,8H2,1-2H3,(H,21,22) FYVQHFOKZCWSQL-UHFFFAOYSA-N 568757 5-{4-[(3-Methylbutyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 220 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 90.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568757 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568757&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462905 473130070 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200296 CC(C)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O2/c1-9(2)5-6-19-12-4-3-10(7-11(12)15(16,17)18)13-8-23-14(22)21-20-13/h3-4,7,9,19H,5-6,8H2,1-2H3,(H,21,22) FYVQHFOKZCWSQL-UHFFFAOYSA-N 568757 5-{4-[(3-Methylbutyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 220 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 131 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568757 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568757&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462905 473130070 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200297 CC(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O2/c1-8(2)6-18-11-4-3-9(5-10(11)14(15,16)17)12-7-22-13(21)20-19-12/h3-5,8,18H,6-7H2,1-2H3,(H,20,21) UCSCXOFPNHJIGF-UHFFFAOYSA-N 568758 5-{4-[(2-Methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 221 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 28.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568758 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568758&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462650 473130071 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200298 CC(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O2/c1-8(2)6-18-11-4-3-9(5-10(11)14(15,16)17)12-7-22-13(21)20-19-12/h3-5,8,18H,6-7H2,1-2H3,(H,20,21) UCSCXOFPNHJIGF-UHFFFAOYSA-N 568758 5-{4-[(2-Methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 221 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 56.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568758 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568758&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462650 473130071 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200299 COCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O3/c1-21-5-4-17-10-3-2-8(6-9(10)13(14,15)16)11-7-22-12(20)19-18-11/h2-3,6,17H,4-5,7H2,1H3,(H,19,20) IBBJDXMABDCWFR-UHFFFAOYSA-N 568759 5-{4-[(2-Methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 222 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 76.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568759 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568759&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463036 473130072 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200300 COCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O3/c1-21-5-4-17-10-3-2-8(6-9(10)13(14,15)16)11-7-22-12(20)19-18-11/h2-3,6,17H,4-5,7H2,1H3,(H,19,20) IBBJDXMABDCWFR-UHFFFAOYSA-N 568759 5-{4-[(2-Methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 222 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568759 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568759&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463036 473130072 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200301 CCN(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O2/c1-3-19(2)11-5-4-8(6-9(11)13(14,15)16)10-7-21-12(20)18-17-10/h4-6H,3,7H2,1-2H3,(H,18,20) VBRPITHMSDKIQH-UHFFFAOYSA-N 568760 5-{4-[Ethyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 223 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568760 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568760&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462689 473130073 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200302 CCN(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O2/c1-3-19(2)11-5-4-8(6-9(11)13(14,15)16)10-7-21-12(20)18-17-10/h4-6H,3,7H2,1-2H3,(H,18,20) VBRPITHMSDKIQH-UHFFFAOYSA-N 568760 5-{4-[Ethyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 223 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568760 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568760&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462689 473130073 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200303 CC(C)(C)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O2/c1-13(2,3)18-10-5-4-8(6-9(10)14(15,16)17)11-7-22-12(21)20-19-11/h4-6,18H,7H2,1-3H3,(H,20,21) FSSROFZZQZTZML-UHFFFAOYSA-N 568761 5-[4-(tert-Butylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 224 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 165 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568761 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568761&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462859 473130074 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200304 CC(C)(C)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O2/c1-13(2,3)18-10-5-4-8(6-9(10)14(15,16)17)11-7-22-12(21)20-19-11/h4-6,18H,7H2,1-3H3,(H,20,21) FSSROFZZQZTZML-UHFFFAOYSA-N 568761 5-[4-(tert-Butylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 224 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568761 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568761&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462859 473130074 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200305 FC(F)(F)c1cc(ccc1NC[C@H]1CCCO1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(13-8-24-14(22)21-20-13)3-4-12(11)19-7-10-2-1-5-23-10/h3-4,6,10,19H,1-2,5,7-8H2,(H,21,22)/t10-/m1/s1 WQZNIULOSVKZFL-SNVBAGLBSA-N 568762 5-[4-({[(2R)-Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 225 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 45.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568762 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568762&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462654 473130075 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200306 FC(F)(F)c1cc(ccc1NC[C@H]1CCCO1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(13-8-24-14(22)21-20-13)3-4-12(11)19-7-10-2-1-5-23-10/h3-4,6,10,19H,1-2,5,7-8H2,(H,21,22)/t10-/m1/s1 WQZNIULOSVKZFL-SNVBAGLBSA-N 568762 5-[4-({[(2R)-Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 225 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568762 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568762&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462654 473130075 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200307 FC(F)(F)c1cc(ccc1NCc1cnccn1)C1=NNC(=O)OC1 InChI=1S/C15H12F3N5O2/c16-15(17,18)11-5-9(13-8-25-14(24)23-22-13)1-2-12(11)21-7-10-6-19-3-4-20-10/h1-6,21H,7-8H2,(H,23,24) FQPXYNARCNENKV-UHFFFAOYSA-N 568763 5-[4-{[(Pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 226 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 128 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568763 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568763&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463028 473130076 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200308 FC(F)(F)c1cc(ccc1NCc1cnccn1)C1=NNC(=O)OC1 InChI=1S/C15H12F3N5O2/c16-15(17,18)11-5-9(13-8-25-14(24)23-22-13)1-2-12(11)21-7-10-6-19-3-4-20-10/h1-6,21H,7-8H2,(H,23,24) FQPXYNARCNENKV-UHFFFAOYSA-N 568763 5-[4-{[(Pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 226 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 187 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568763 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568763&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463028 473130076 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200309 OC1CCN(CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-7-9(12-8-24-14(23)20-19-12)1-2-13(11)21-5-3-10(22)4-6-21/h1-2,7,10,22H,3-6,8H2,(H,20,23) BEMLSYVAFRQIIR-UHFFFAOYSA-N 568764 5-[4-(4-Hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 227 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 13.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568764 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568764&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462980 473130077 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200310 OC1CCN(CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-7-9(12-8-24-14(23)20-19-12)1-2-13(11)21-5-3-10(22)4-6-21/h1-2,7,10,22H,3-6,8H2,(H,20,23) BEMLSYVAFRQIIR-UHFFFAOYSA-N 568764 5-[4-(4-Hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 227 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 9.00 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568764 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568764&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462980 473130077 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200311 CC[C@@H](CO)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-2-9(6-21)18-11-4-3-8(5-10(11)14(15,16)17)12-7-23-13(22)20-19-12/h3-5,9,18,21H,2,6-7H2,1H3,(H,20,22)/t9-/m0/s1 IQHZVNOJYBEWSF-VIFPVBQESA-N 568765 5-[4-{[(2S)-1-Hydroxybutan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 228 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 400 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568765 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568765&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462834 473130078 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200312 CC[C@@H](CO)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-2-9(6-21)18-11-4-3-8(5-10(11)14(15,16)17)12-7-23-13(22)20-19-12/h3-5,9,18,21H,2,6-7H2,1H3,(H,20,22)/t9-/m0/s1 IQHZVNOJYBEWSF-VIFPVBQESA-N 568765 5-[4-{[(2S)-1-Hydroxybutan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 228 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 920 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568765 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568765&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462834 473130078 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200313 OC1CCCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(12-8-24-14(23)20-19-12)3-4-13(11)21-5-1-2-10(22)7-21/h3-4,6,10,22H,1-2,5,7-8H2,(H,20,23) IYOGBIHWMLYILM-UHFFFAOYSA-N 568766 (rac)-5-[4-(3-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 229 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 82.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568766 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568766&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463131 473130079 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200314 OC1CCCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(12-8-24-14(23)20-19-12)3-4-13(11)21-5-1-2-10(22)7-21/h3-4,6,10,22H,1-2,5,7-8H2,(H,20,23) IYOGBIHWMLYILM-UHFFFAOYSA-N 568766 (rac)-5-[4-(3-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 229 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 67.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568766 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568766&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463131 473130079 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200315 NC(=O)C1CCCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N4O3/c17-16(18,19)11-6-9(12-8-26-15(25)22-21-12)3-4-13(11)23-5-1-2-10(7-23)14(20)24/h3-4,6,10H,1-2,5,7-8H2,(H2,20,24)(H,22,25) JKERQASOWSAQGV-UHFFFAOYSA-N 568767 (rac)-1-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]piperidine-3-carboxamide::US11427553, Example 230 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568767 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568767&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463014 473130080 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200316 NC(=O)C1CCCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N4O3/c17-16(18,19)11-6-9(12-8-26-15(25)22-21-12)3-4-13(11)23-5-1-2-10(7-23)14(20)24/h3-4,6,10H,1-2,5,7-8H2,(H2,20,24)(H,22,25) JKERQASOWSAQGV-UHFFFAOYSA-N 568767 (rac)-1-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]piperidine-3-carboxamide::US11427553, Example 230 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568767 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568767&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463014 473130080 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200317 CC(C)(CO)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-14(2,8-22)7-19-11-4-3-9(5-10(11)15(16,17)18)12-6-24-13(23)21-20-12/h3-5,19,22H,6-8H2,1-2H3,(H,21,23) NVXQITVLIURHGR-UHFFFAOYSA-N 568768 5-{4-[(3-Hydroxy-2,2-dimethylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 231 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568768 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568768&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462911 473130081 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200318 CC(C)(CO)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-14(2,8-22)7-19-11-4-3-9(5-10(11)15(16,17)18)12-6-24-13(23)21-20-12/h3-5,19,22H,6-8H2,1-2H3,(H,21,23) NVXQITVLIURHGR-UHFFFAOYSA-N 568768 5-{4-[(3-Hydroxy-2,2-dimethylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 231 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568768 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568768&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462911 473130081 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200319 FC(F)(F)c1cc(ccc1N1CCC(F)(F)CC1)C1=NNC(=O)OC1 InChI=1S/C15H14F5N3O2/c16-14(17)3-5-23(6-4-14)12-2-1-9(7-10(12)15(18,19)20)11-8-25-13(24)22-21-11/h1-2,7H,3-6,8H2,(H,22,24) UUSSKISSJWVYTA-UHFFFAOYSA-N 568769 5-[4-(4,4-Difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 232 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 145 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568769 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568769&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462972 473130082 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200320 FC(F)(F)c1cc(ccc1N1CCC(F)(F)CC1)C1=NNC(=O)OC1 InChI=1S/C15H14F5N3O2/c16-14(17)3-5-23(6-4-14)12-2-1-9(7-10(12)15(18,19)20)11-8-25-13(24)22-21-11/h1-2,7H,3-6,8H2,(H,22,24) UUSSKISSJWVYTA-UHFFFAOYSA-N 568769 5-[4-(4,4-Difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 232 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 145 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568769 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568769&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462972 473130082 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200321 FC(F)(F)c1cc(ccc1N[C@@H]1CC2CCC1C2)C1=NNC(=O)OC1 InChI=1S/C17H18F3N3O2/c18-17(19,20)12-7-11(15-8-25-16(24)23-22-15)3-4-13(12)21-14-6-9-1-2-10(14)5-9/h3-4,7,9-10,14,21H,1-2,5-6,8H2,(H,23,24)/t9?,10?,14-/m1/s1 HNEZMCHBAPPBRA-RPFQZYLTSA-N 568770 5-[4-{[(1R,2R,4R)-Bicyclo[2.2.1]heptan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 233 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 86.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568770 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568770&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475387 473130083 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200322 FC(F)(F)c1cc(ccc1N[C@@H]1CC2CCC1C2)C1=NNC(=O)OC1 InChI=1S/C17H18F3N3O2/c18-17(19,20)12-7-11(15-8-25-16(24)23-22-15)3-4-13(12)21-14-6-9-1-2-10(14)5-9/h3-4,7,9-10,14,21H,1-2,5-6,8H2,(H,23,24)/t9?,10?,14-/m1/s1 HNEZMCHBAPPBRA-RPFQZYLTSA-N 568770 5-[4-{[(1R,2R,4R)-Bicyclo[2.2.1]heptan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 233 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 250 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568770 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568770&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475387 473130083 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200323 O[C@H]1CCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-5-8(11-7-23-13(22)19-18-11)1-2-12(10)20-4-3-9(21)6-20/h1-2,5,9,21H,3-4,6-7H2,(H,19,22)/t9-/m0/s1 ZPKKOLRJMZOATC-VIFPVBQESA-N 568771 5-{4-[(3S)-3-Hydroxypyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 234 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 78.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568771 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568771&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463317 473130084 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200324 O[C@H]1CCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-5-8(11-7-23-13(22)19-18-11)1-2-12(10)20-4-3-9(21)6-20/h1-2,5,9,21H,3-4,6-7H2,(H,19,22)/t9-/m0/s1 ZPKKOLRJMZOATC-VIFPVBQESA-N 568771 5-{4-[(3S)-3-Hydroxypyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 234 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 73.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568771 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568771&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463317 473130084 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200325 OCC(O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O4/c14-13(15,16)9-3-7(11-6-23-12(22)19-18-11)1-2-10(9)17-4-8(21)5-20/h1-3,8,17,20-21H,4-6H2,(H,19,22) QWVSHLZLMWKWAW-UHFFFAOYSA-N 568772 (rac)-5-{4-[(2-Hydroxy-3-methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 235 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568772 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568772&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475184 473130085 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200326 OCC(O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H14F3N3O4/c14-13(15,16)9-3-7(11-6-23-12(22)19-18-11)1-2-10(9)17-4-8(21)5-20/h1-3,8,17,20-21H,4-6H2,(H,19,22) QWVSHLZLMWKWAW-UHFFFAOYSA-N 568772 (rac)-5-{4-[(2-Hydroxy-3-methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 235 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568772 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568772&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475184 473130085 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200327 Cn1nccc1CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H14F3N5O2/c1-23-10(4-5-20-23)7-19-12-3-2-9(6-11(12)15(16,17)18)13-8-25-14(24)22-21-13/h2-6,19H,7-8H2,1H3,(H,22,24) BXJGRMQPXQFDQL-UHFFFAOYSA-N 568773 5-[4-{[(1-Methyl-1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 236 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 45.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568773 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568773&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463010 473130086 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200328 Cn1nccc1CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H14F3N5O2/c1-23-10(4-5-20-23)7-19-12-3-2-9(6-11(12)15(16,17)18)13-8-25-14(24)22-21-13/h2-6,19H,7-8H2,1H3,(H,22,24) BXJGRMQPXQFDQL-UHFFFAOYSA-N 568773 5-[4-{[(1-Methyl-1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 236 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 54.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568773 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568773&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463010 473130086 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200329 FC(F)(F)c1cc(ccc1NCc1cc[nH]n1)C1=NNC(=O)OC1 InChI=1S/C14H12F3N5O2/c15-14(16,17)10-5-8(12-7-24-13(23)22-21-12)1-2-11(10)18-6-9-3-4-19-20-9/h1-5,18H,6-7H2,(H,19,20)(H,22,23) ZCJNURSCOKBXIF-UHFFFAOYSA-N 568774 5-[4-{[(1H-Pyrazol-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 237 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568774 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568774&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463313 473130087 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200330 FC(F)(F)c1cc(ccc1NCc1cc[nH]n1)C1=NNC(=O)OC1 InChI=1S/C14H12F3N5O2/c15-14(16,17)10-5-8(12-7-24-13(23)22-21-12)1-2-11(10)18-6-9-3-4-19-20-9/h1-5,18H,6-7H2,(H,19,20)(H,22,23) ZCJNURSCOKBXIF-UHFFFAOYSA-N 568774 5-[4-{[(1H-Pyrazol-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 237 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568774 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568774&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463313 473130087 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200331 FC(F)(F)c1cc(ccc1NCCn1cccn1)C1=NNC(=O)OC1 InChI=1S/C15H14F3N5O2/c16-15(17,18)11-8-10(13-9-25-14(24)22-21-13)2-3-12(11)19-5-7-23-6-1-4-20-23/h1-4,6,8,19H,5,7,9H2,(H,22,24) STCOVSUSIUIOEK-UHFFFAOYSA-N 568775 5-[4-{[2-(1H-Pyrazol-1-yl)ethyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 238 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 88.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568775 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568775&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462890 473130088 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200332 FC(F)(F)c1cc(ccc1NCCn1cccn1)C1=NNC(=O)OC1 InChI=1S/C15H14F3N5O2/c16-15(17,18)11-8-10(13-9-25-14(24)22-21-13)2-3-12(11)19-5-7-23-6-1-4-20-23/h1-4,6,8,19H,5,7,9H2,(H,22,24) STCOVSUSIUIOEK-UHFFFAOYSA-N 568775 5-[4-{[2-(1H-Pyrazol-1-yl)ethyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 238 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 300 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568775 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568775&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462890 473130088 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200333 FC(F)(F)c1cc(ccc1N1CCC(CC1)C#N)C1=NNC(=O)OC1 InChI=1S/C16H15F3N4O2/c17-16(18,19)12-7-11(13-9-25-15(24)22-21-13)1-2-14(12)23-5-3-10(8-20)4-6-23/h1-2,7,10H,3-6,9H2,(H,22,24) HEXIGMPICOZSLA-UHFFFAOYSA-N 568776 1-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]piperidine-4-carbonitrile::US11427553, Example 239 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 27.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568776 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568776&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462727 473130089 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200334 FC(F)(F)c1cc(ccc1N1CCC(CC1)C#N)C1=NNC(=O)OC1 InChI=1S/C16H15F3N4O2/c17-16(18,19)12-7-11(13-9-25-15(24)22-21-13)1-2-14(12)23-5-3-10(8-20)4-6-23/h1-2,7,10H,3-6,9H2,(H,22,24) HEXIGMPICOZSLA-UHFFFAOYSA-N 568776 1-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]piperidine-4-carbonitrile::US11427553, Example 239 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 26.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568776 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568776&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462727 473130089 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200335 CC(Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C1CC1 InChI=1S/C15H16F3N3O2/c1-8(9-2-3-9)19-12-5-4-10(6-11(12)15(16,17)18)13-7-23-14(22)21-20-13/h4-6,8-9,19H,2-3,7H2,1H3,(H,21,22) VKNMOANIMSZWOT-UHFFFAOYSA-N 568777 (rac)-5-{4-[(1-cyclopropylethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 240 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568777 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568777&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462924 473130090 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200336 CC(Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C1CC1 InChI=1S/C15H16F3N3O2/c1-8(9-2-3-9)19-12-5-4-10(6-11(12)15(16,17)18)13-7-23-14(22)21-20-13/h4-6,8-9,19H,2-3,7H2,1H3,(H,21,22) VKNMOANIMSZWOT-UHFFFAOYSA-N 568777 (rac)-5-{4-[(1-cyclopropylethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 240 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 260 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568777 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568777&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462924 473130090 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200337 CCOC(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-3-23-9(2)7-19-12-5-4-10(6-11(12)15(16,17)18)13-8-24-14(22)21-20-13/h4-6,9,19H,3,7-8H2,1-2H3,(H,21,22) YKLKSMUTOVYNSM-UHFFFAOYSA-N 568778 (rac)-5-{4-[(2-Ethoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 241 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 66.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568778 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568778&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462895 473130091 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200338 CCOC(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-3-23-9(2)7-19-12-5-4-10(6-11(12)15(16,17)18)13-8-24-14(22)21-20-13/h4-6,9,19H,3,7-8H2,1-2H3,(H,21,22) YKLKSMUTOVYNSM-UHFFFAOYSA-N 568778 (rac)-5-{4-[(2-Ethoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 241 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568778 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568778&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462895 473130091 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200339 COC(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-8(22-2)6-18-11-4-3-9(5-10(11)14(15,16)17)12-7-23-13(21)20-19-12/h3-5,8,18H,6-7H2,1-2H3,(H,20,21) RHLKPHWSFKZMIP-UHFFFAOYSA-N 568779 (rac)-5-{4-[(2-Methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 242 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 92.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568779 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568779&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462712 473130092 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200340 COC(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-8(22-2)6-18-11-4-3-9(5-10(11)14(15,16)17)12-7-23-13(21)20-19-12/h3-5,8,18H,6-7H2,1-2H3,(H,20,21) RHLKPHWSFKZMIP-UHFFFAOYSA-N 568779 (rac)-5-{4-[(2-Methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 242 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568779 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568779&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462712 473130092 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200341 CCOC1CN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c1-2-23-10-6-21(7-10)13-4-3-9(5-11(13)15(16,17)18)12-8-24-14(22)20-19-12/h3-5,10H,2,6-8H2,1H3,(H,20,22) FWCZQOKJZOETPW-UHFFFAOYSA-N 568780 5-[4-(3-Ethoxyazetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 243 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568780 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568780&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462828 473130093 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200342 CCOC1CN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c1-2-23-10-6-21(7-10)13-4-3-9(5-11(13)15(16,17)18)12-8-24-14(22)20-19-12/h3-5,10H,2,6-8H2,1H3,(H,20,22) FWCZQOKJZOETPW-UHFFFAOYSA-N 568780 5-[4-(3-Ethoxyazetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 243 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568780 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568780&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462828 473130093 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200343 FC(F)(F)c1cc(ccc1NCc1ncccn1)C1=NNC(=O)OC1 InChI=1S/C15H12F3N5O2/c16-15(17,18)10-6-9(12-8-25-14(24)23-22-12)2-3-11(10)21-7-13-19-4-1-5-20-13/h1-6,21H,7-8H2,(H,23,24) PICPVDDPDQYUGM-UHFFFAOYSA-N 568781 5-[4-{[(Pyrimidin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 244 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568781 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568781&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462726 473130094 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200344 FC(F)(F)c1cc(ccc1NCc1ncccn1)C1=NNC(=O)OC1 InChI=1S/C15H12F3N5O2/c16-15(17,18)10-6-9(12-8-25-14(24)23-22-12)2-3-11(10)21-7-13-19-4-1-5-20-13/h1-6,21H,7-8H2,(H,23,24) PICPVDDPDQYUGM-UHFFFAOYSA-N 568781 5-[4-{[(Pyrimidin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 244 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568781 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568781&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462726 473130094 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200345 FC(F)(F)c1cc(ccc1NCC1CCOC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-5-10(13-8-24-14(22)21-20-13)1-2-12(11)19-6-9-3-4-23-7-9/h1-2,5,9,19H,3-4,6-8H2,(H,21,22) HBDIPQSEUCFYDV-UHFFFAOYSA-N 568782 (rac)-5-[4-{[(Oxolan-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 245 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568782 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568782&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463017 473130095 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200346 FC(F)(F)c1cc(ccc1NCC1CCOC1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-5-10(13-8-24-14(22)21-20-13)1-2-12(11)19-6-9-3-4-23-7-9/h1-2,5,9,19H,3-4,6-8H2,(H,21,22) HBDIPQSEUCFYDV-UHFFFAOYSA-N 568782 (rac)-5-[4-{[(Oxolan-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 245 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568782 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568782&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463017 473130095 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200347 C[C@@H](CCO)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-8(4-5-21)18-11-3-2-9(6-10(11)14(15,16)17)12-7-23-13(22)20-19-12/h2-3,6,8,18,21H,4-5,7H2,1H3,(H,20,22)/t8-/m0/s1 GRCVFQWWWBIXTN-QMMMGPOBSA-N 568783 5-[4-{[(2S)-4-Hydroxybutan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 246 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 95.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568783 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568783&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462960 473130096 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200348 C[C@@H](CCO)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-8(4-5-21)18-11-3-2-9(6-10(11)14(15,16)17)12-7-23-13(22)20-19-12/h2-3,6,8,18,21H,4-5,7H2,1H3,(H,20,22)/t8-/m0/s1 GRCVFQWWWBIXTN-QMMMGPOBSA-N 568783 5-[4-{[(2S)-4-Hydroxybutan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 246 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 210 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568783 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568783&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462960 473130096 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200349 FC(F)(F)c1cc(ccc1NCC1CCC(=O)NC1)C1=NNC(=O)OC1 InChI=1S/C16H17F3N4O3/c17-16(18,19)11-5-10(13-8-26-15(25)23-22-13)2-3-12(11)20-6-9-1-4-14(24)21-7-9/h2-3,5,9,20H,1,4,6-8H2,(H,21,24)(H,23,25) LOPLXFOPILLZKW-UHFFFAOYSA-N 568784 (rac)-5-[4-{[(6-Oxopiperidin-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 247 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568784 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568784&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462787 473130097 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200350 FC(F)(F)c1cc(ccc1NCC1CCC(=O)NC1)C1=NNC(=O)OC1 InChI=1S/C16H17F3N4O3/c17-16(18,19)11-5-10(13-8-26-15(25)23-22-13)2-3-12(11)20-6-9-1-4-14(24)21-7-9/h2-3,5,9,20H,1,4,6-8H2,(H,21,24)(H,23,25) LOPLXFOPILLZKW-UHFFFAOYSA-N 568784 (rac)-5-[4-{[(6-Oxopiperidin-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 247 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568784 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568784&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462787 473130097 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200351 CC1(C)CC1CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H18F3N3O2/c1-15(2)6-10(15)7-20-12-4-3-9(5-11(12)16(17,18)19)13-8-24-14(23)22-21-13/h3-5,10,20H,6-8H2,1-2H3,(H,22,23) QHAMCQNWQKUPPD-UHFFFAOYSA-N 568785 (rac)-5-[4-{[(2,2-Dimethylcyclopropyl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 248 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 61.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568785 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568785&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462672 473130098 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200352 CC1(C)CC1CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H18F3N3O2/c1-15(2)6-10(15)7-20-12-4-3-9(5-11(12)16(17,18)19)13-8-24-14(23)22-21-13/h3-5,10,20H,6-8H2,1-2H3,(H,22,23) QHAMCQNWQKUPPD-UHFFFAOYSA-N 568785 (rac)-5-[4-{[(2,2-Dimethylcyclopropyl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 248 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568785 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568785&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462672 473130098 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200353 OCC1(CNc2ccc(cc2C(F)(F)F)C2=NNC(=O)OC2)CCC1 InChI=1S/C16H18F3N3O3/c17-16(18,19)11-6-10(13-7-25-14(24)22-21-13)2-3-12(11)20-8-15(9-23)4-1-5-15/h2-3,6,20,23H,1,4-5,7-9H2,(H,22,24) KOGQRLQEEDTHCO-UHFFFAOYSA-N 568786 5-[4-({[1-(Hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 249 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568786 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568786&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462928 473130099 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200354 OCC1(CNc2ccc(cc2C(F)(F)F)C2=NNC(=O)OC2)CCC1 InChI=1S/C16H18F3N3O3/c17-16(18,19)11-6-10(13-7-25-14(24)22-21-13)2-3-12(11)20-8-15(9-23)4-1-5-15/h2-3,6,20,23H,1,4-5,7-9H2,(H,22,24) KOGQRLQEEDTHCO-UHFFFAOYSA-N 568786 5-[4-({[1-(Hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 249 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568786 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568786&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462928 473130099 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200355 OC[C@@H]1CCN1c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-5-8(11-7-23-13(22)19-18-11)1-2-12(10)20-4-3-9(20)6-21/h1-2,5,9,21H,3-4,6-7H2,(H,19,22)/t9-/m0/s1 HGYOZMPWRRSOIO-VIFPVBQESA-N 568787 5-{4-[(2S)-2-(Hydroxymethyl)azetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 250 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568787 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568787&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463070 473130100 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200356 OC[C@@H]1CCN1c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-5-8(11-7-23-13(22)19-18-11)1-2-12(10)20-4-3-9(20)6-21/h1-2,5,9,21H,3-4,6-7H2,(H,19,22)/t9-/m0/s1 HGYOZMPWRRSOIO-VIFPVBQESA-N 568787 5-{4-[(2S)-2-(Hydroxymethyl)azetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 250 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568787 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568787&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463070 473130100 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200357 CC1(CN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C#N InChI=1S/C15H13F3N4O2/c1-14(6-19)7-22(8-14)12-3-2-9(4-10(12)15(16,17)18)11-5-24-13(23)21-20-11/h2-4H,5,7-8H2,1H3,(H,21,23) DTXHZZLZPOYJPR-UHFFFAOYSA-N 568788 3-Methyl-1-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]azetidine-3-carbonitrile::US11427553, Example 251 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 61.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568788 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568788&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462938 473130101 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200358 CC1(CN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1)C#N InChI=1S/C15H13F3N4O2/c1-14(6-19)7-22(8-14)12-3-2-9(4-10(12)15(16,17)18)11-5-24-13(23)21-20-11/h2-4H,5,7-8H2,1H3,(H,21,23) DTXHZZLZPOYJPR-UHFFFAOYSA-N 568788 3-Methyl-1-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]azetidine-3-carbonitrile::US11427553, Example 251 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 97.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568788 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568788&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462938 473130101 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200359 FC(F)(F)c1cc(ccc1N1CC2CC2C1)C1=NNC(=O)OC1 InChI=1S/C15H14F3N3O2/c16-15(17,18)11-4-8(12-7-23-14(22)20-19-12)1-2-13(11)21-5-9-3-10(9)6-21/h1-2,4,9-10H,3,5-7H2,(H,20,22) CLDFKFVYDONGAQ-UHFFFAOYSA-N 568789 5-[4-(3-Azabicyclo[3.1.0]hexan-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 252 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568789 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568789&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462750 473130102 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200360 FC(F)(F)c1cc(ccc1N1CC2CC2C1)C1=NNC(=O)OC1 InChI=1S/C15H14F3N3O2/c16-15(17,18)11-4-8(12-7-23-14(22)20-19-12)1-2-13(11)21-5-9-3-10(9)6-21/h1-2,4,9-10H,3,5-7H2,(H,20,22) CLDFKFVYDONGAQ-UHFFFAOYSA-N 568789 5-[4-(3-Azabicyclo[3.1.0]hexan-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 252 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 86.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568789 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568789&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462750 473130102 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200361 CCC1(O)CCN(CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H20F3N3O3/c1-2-16(25)5-7-23(8-6-16)14-4-3-11(9-12(14)17(18,19)20)13-10-26-15(24)22-21-13/h3-4,9,25H,2,5-8,10H2,1H3,(H,22,24) BUNHELIDUGVLDJ-UHFFFAOYSA-N 568790 5-[4-(4-Ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 253 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 190 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568790 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568790&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462741 473130103 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200362 CCC1(O)CCN(CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H20F3N3O3/c1-2-16(25)5-7-23(8-6-16)14-4-3-11(9-12(14)17(18,19)20)13-10-26-15(24)22-21-13/h3-4,9,25H,2,5-8,10H2,1H3,(H,22,24) BUNHELIDUGVLDJ-UHFFFAOYSA-N 568790 5-[4-(4-Ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 253 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 155 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568790 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568790&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462741 473130103 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200363 FC(F)(F)c1cc(ccc1NCCCC#N)C1=NNC(=O)OC1 InChI=1S/C14H13F3N4O2/c15-14(16,17)10-7-9(12-8-23-13(22)21-20-12)3-4-11(10)19-6-2-1-5-18/h3-4,7,19H,1-2,6,8H2,(H,21,22) NQVSOQJHHOQSAO-UHFFFAOYSA-N 568791 4-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)anilino]butanenitrile::US11427553, Example 254 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 45.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568791 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568791&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462996 473130104 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200364 FC(F)(F)c1cc(ccc1NCCCC#N)C1=NNC(=O)OC1 InChI=1S/C14H13F3N4O2/c15-14(16,17)10-7-9(12-8-23-13(22)21-20-12)3-4-11(10)19-6-2-1-5-18/h3-4,7,19H,1-2,6,8H2,(H,21,22) NQVSOQJHHOQSAO-UHFFFAOYSA-N 568791 4-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)anilino]butanenitrile::US11427553, Example 254 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568791 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568791&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462996 473130104 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200365 FC(F)(F)c1cc(ccc1N1CC2(C1)CS(=O)C2)C1=NNC(=O)OC1 InChI=1S/C15H14F3N3O3S/c16-15(17,18)10-3-9(11-4-24-13(22)20-19-11)1-2-12(10)21-5-14(6-21)7-25(23)8-14/h1-3H,4-8H2,(H,20,22) CEUQVAZDOZDWNQ-UHFFFAOYSA-N 568792 6-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]-2λ6-thia-6-azaspiro[3.3]heptane-2,2-dione::US11427553, Example 255 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568792 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568792&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 155325988 473130105 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200366 FC(F)(F)c1cc(ccc1N1CC2(C1)CS(=O)C2)C1=NNC(=O)OC1 InChI=1S/C15H14F3N3O3S/c16-15(17,18)10-3-9(11-4-24-13(22)20-19-11)1-2-12(10)21-5-14(6-21)7-25(23)8-14/h1-3H,4-8H2,(H,20,22) CEUQVAZDOZDWNQ-UHFFFAOYSA-N 568792 6-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]-2λ6-thia-6-azaspiro[3.3]heptane-2,2-dione::US11427553, Example 255 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 76.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568792 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568792&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 155325988 473130105 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200367 NC(=O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C12H11F3N4O3/c13-12(14,15)7-3-6(9-5-22-11(21)19-18-9)1-2-8(7)17-4-10(16)20/h1-3,17H,4-5H2,(H2,16,20)(H,19,21) IIUNLYVOWWCNPU-UHFFFAOYSA-N 568793 N2-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]glycinamide::US11427553, Example 256 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568793 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568793&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463015 473130106 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200368 NC(=O)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C12H11F3N4O3/c13-12(14,15)7-3-6(9-5-22-11(21)19-18-9)1-2-8(7)17-4-10(16)20/h1-3,17H,4-5H2,(H2,16,20)(H,19,21) IIUNLYVOWWCNPU-UHFFFAOYSA-N 568793 N2-[4-(2-Oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]glycinamide::US11427553, Example 256 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 480 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568793 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568793&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463015 473130106 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200369 O[C@@H]1CCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-5-8(11-7-23-13(22)19-18-11)1-2-12(10)20-4-3-9(21)6-20/h1-2,5,9,21H,3-4,6-7H2,(H,19,22)/t9-/m1/s1 ZPKKOLRJMZOATC-SECBINFHSA-N 568794 5-{4-[(3R)-3-Hydroxypyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 257 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568794 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568794&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462945 473130107 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200370 O[C@@H]1CCN(C1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H14F3N3O3/c15-14(16,17)10-5-8(11-7-23-13(22)19-18-11)1-2-12(10)20-4-3-9(21)6-20/h1-2,5,9,21H,3-4,6-7H2,(H,19,22)/t9-/m1/s1 ZPKKOLRJMZOATC-SECBINFHSA-N 568794 5-{4-[(3R)-3-Hydroxypyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 257 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 120 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568794 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568794&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462945 473130107 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200371 COC(C)(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-14(2,23-3)8-19-11-5-4-9(6-10(11)15(16,17)18)12-7-24-13(22)21-20-12/h4-6,19H,7-8H2,1-3H3,(H,21,22) YSJARLQUFKSYBC-UHFFFAOYSA-N 568795 5-{4-[(2-Methoxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 258 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 41.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568795 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568795&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462728 473130108 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200372 COC(C)(C)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-14(2,23-3)8-19-11-5-4-9(6-10(11)15(16,17)18)12-7-24-13(22)21-20-12/h4-6,19H,7-8H2,1-3H3,(H,21,22) YSJARLQUFKSYBC-UHFFFAOYSA-N 568795 5-{4-[(2-Methoxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 258 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568795 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568795&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462728 473130108 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200373 FC(F)(F)c1cc(ccc1NC[C@@H]1CCCO1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(13-8-24-14(22)21-20-13)3-4-12(11)19-7-10-2-1-5-23-10/h3-4,6,10,19H,1-2,5,7-8H2,(H,21,22)/t10-/m0/s1 WQZNIULOSVKZFL-JTQLQIEISA-N 568796 5-[4-({[(2S)-Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 259 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 34.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568796 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568796&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462995 473130109 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200374 FC(F)(F)c1cc(ccc1NC[C@@H]1CCCO1)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)11-6-9(13-8-24-14(22)21-20-13)3-4-12(11)19-7-10-2-1-5-23-10/h3-4,6,10,19H,1-2,5,7-8H2,(H,21,22)/t10-/m0/s1 WQZNIULOSVKZFL-JTQLQIEISA-N 568796 5-[4-({[(2S)-Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 259 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568796 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568796&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462995 473130109 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200375 CCOCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-2-22-6-5-18-11-4-3-9(7-10(11)14(15,16)17)12-8-23-13(21)20-19-12/h3-4,7,18H,2,5-6,8H2,1H3,(H,20,21) ZYRDMKASOWZVBT-UHFFFAOYSA-N 568797 5-{4-[(2-Ethoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 260 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 48.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568797 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568797&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462813 473130110 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200376 CCOCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H16F3N3O3/c1-2-22-6-5-18-11-4-3-9(7-10(11)14(15,16)17)12-8-23-13(21)20-19-12/h3-4,7,18H,2,5-6,8H2,1H3,(H,20,21) ZYRDMKASOWZVBT-UHFFFAOYSA-N 568797 5-{4-[(2-Ethoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 260 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568797 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568797&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462813 473130110 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200377 O[C@@H]1CCC[C@@H]1Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)9-6-8(12-7-24-14(23)21-20-12)4-5-10(9)19-11-2-1-3-13(11)22/h4-6,11,13,19,22H,1-3,7H2,(H,21,23)/t11-,13+/m0/s1 SRIGIKUCXZBYPP-WCQYABFASA-N 568798 5-[4-{[(1S,2R)-2-Hydroxycyclopentyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 261 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 550 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568798 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568798&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462942 473130111 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200378 O[C@@H]1CCC[C@@H]1Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H16F3N3O3/c16-15(17,18)9-6-8(12-7-24-14(23)21-20-12)4-5-10(9)19-11-2-1-3-13(11)22/h4-6,11,13,19,22H,1-3,7H2,(H,21,23)/t11-,13+/m0/s1 SRIGIKUCXZBYPP-WCQYABFASA-N 568798 5-[4-{[(1S,2R)-2-Hydroxycyclopentyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 261 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 600 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568798 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568798&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462942 473130111 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200379 FC(F)(F)c1cc(ccc1NC1COC1)C1=NNC(=O)OC1 InChI=1S/C13H12F3N3O3/c14-13(15,16)9-3-7(11-6-22-12(20)19-18-11)1-2-10(9)17-8-4-21-5-8/h1-3,8,17H,4-6H2,(H,19,20) VYLPOWLHYCCFCV-UHFFFAOYSA-N 568799 5-{4-[(Oxetan-3-yl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 262 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 18.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568799 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568799&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462747 473130112 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200380 FC(F)(F)c1cc(ccc1NC1COC1)C1=NNC(=O)OC1 InChI=1S/C13H12F3N3O3/c14-13(15,16)9-3-7(11-6-22-12(20)19-18-11)1-2-10(9)17-8-4-21-5-8/h1-3,8,17H,4-6H2,(H,19,20) VYLPOWLHYCCFCV-UHFFFAOYSA-N 568799 5-{4-[(Oxetan-3-yl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 262 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 20.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568799 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568799&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462747 473130112 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200381 CC(C)n1cc(cn1)-c1ccc(cc1C(F)F)C1=NNC(=O)OC1 InChI=1S/C16H16F2N4O2/c1-9(2)22-7-11(6-19-22)12-4-3-10(5-13(12)15(17)18)14-8-24-16(23)21-20-14/h3-7,9,15H,8H2,1-2H3,(H,21,23) YMLGLUGDPPGSRF-UHFFFAOYSA-N 568800 5-{3-(Difluoromethyl)-4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 263 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 50.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568800 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568800&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462967 473130113 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200382 CC(C)n1cc(cn1)-c1ccc(cc1C(F)F)C1=NNC(=O)OC1 InChI=1S/C16H16F2N4O2/c1-9(2)22-7-11(6-19-22)12-4-3-10(5-13(12)15(17)18)14-8-24-16(23)21-20-14/h3-7,9,15H,8H2,1-2H3,(H,21,23) YMLGLUGDPPGSRF-UHFFFAOYSA-N 568800 5-{3-(Difluoromethyl)-4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 263 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 46.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568800 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568800&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462967 473130113 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200383 Fc1cc(cc(c1N1CCOCC1)C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F4N3O3/c15-10-6-8(11-7-24-13(22)20-19-11)5-9(14(16,17)18)12(10)21-1-3-23-4-2-21/h5-6H,1-4,7H2,(H,20,22) XGUUODBXXAGTHK-UHFFFAOYSA-N 568801 5-[3-Fluoro-4-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 264 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568801 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568801&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462809 473130114 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200384 Fc1cc(cc(c1N1CCOCC1)C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H13F4N3O3/c15-10-6-8(11-7-24-13(22)20-19-11)5-9(14(16,17)18)12(10)21-1-3-23-4-2-21/h5-6H,1-4,7H2,(H,20,22) XGUUODBXXAGTHK-UHFFFAOYSA-N 568801 5-[3-Fluoro-4-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 264 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 112 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568801 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568801&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462809 473130114 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200385 C[C@@H]1OC(=O)NN=C1c1ccc(c(c1)C(F)(F)F)-n1ccc(n1)C(F)(F)F InChI=1S/C15H10F6N4O2/c1-7-12(22-23-13(26)27-7)8-2-3-10(9(6-8)14(16,17)18)25-5-4-11(24-25)15(19,20)21/h2-7H,1H3,(H,23,26)/t7-/m0/s1 YRYSNJRREQGBOS-ZETCQYMHSA-N 568802 (6S)-6-Methyl-5-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 265 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 657 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568802 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568802&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462687 473130115 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200386 C[C@@H]1OC(=O)NN=C1c1ccc(c(c1)C(F)(F)F)-n1ccc(n1)C(F)(F)F InChI=1S/C15H10F6N4O2/c1-7-12(22-23-13(26)27-7)8-2-3-10(9(6-8)14(16,17)18)25-5-4-11(24-25)15(19,20)21/h2-7H,1H3,(H,23,26)/t7-/m0/s1 YRYSNJRREQGBOS-ZETCQYMHSA-N 568802 (6S)-6-Methyl-5-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 265 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 383 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568802 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568802&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462687 473130115 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200387 C[C@@H]1OC(=O)NN=C1c1ccc(c(c1)C(F)(F)F)-n1cnc(c1)C(F)(F)F InChI=1S/C15H10F6N4O2/c1-7-12(23-24-13(26)27-7)8-2-3-10(9(4-8)14(16,17)18)25-5-11(22-6-25)15(19,20)21/h2-7H,1H3,(H,24,26)/t7-/m0/s1 ORESZWAJGSQYQS-ZETCQYMHSA-N 568803 (6S)-6-Methyl-5-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 266 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568803 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568803&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462975 473130116 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200388 C[C@@H]1OC(=O)NN=C1c1ccc(c(c1)C(F)(F)F)-n1cnc(c1)C(F)(F)F InChI=1S/C15H10F6N4O2/c1-7-12(23-24-13(26)27-7)8-2-3-10(9(4-8)14(16,17)18)25-5-11(22-6-25)15(19,20)21/h2-7H,1H3,(H,24,26)/t7-/m0/s1 ORESZWAJGSQYQS-ZETCQYMHSA-N 568803 (6S)-6-Methyl-5-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 266 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 930 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568803 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568803&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462975 473130116 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200389 COCCCc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H15F3N2O3/c1-21-6-2-3-9-4-5-10(7-11(9)14(15,16)17)12-8-22-13(20)19-18-12/h4-5,7H,2-3,6,8H2,1H3,(H,19,20) YVXJGHZYRIMFBH-UHFFFAOYSA-N 568804 5-[4-(3-Methoxypropyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 267 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 145 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568804 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568804&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462730 473130117 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200390 COCCCc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H15F3N2O3/c1-21-6-2-3-9-4-5-10(7-11(9)14(15,16)17)12-8-22-13(20)19-18-12/h4-5,7H,2-3,6,8H2,1H3,(H,19,20) YVXJGHZYRIMFBH-UHFFFAOYSA-N 568804 5-[4-(3-Methoxypropyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 267 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 185 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568804 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568804&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462730 473130117 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200391 CC(C)Cc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H15F3N2O2/c1-8(2)5-9-3-4-10(6-11(9)14(15,16)17)12-7-21-13(20)19-18-12/h3-4,6,8H,5,7H2,1-2H3,(H,19,20) MIFBSBDNGQXZCA-UHFFFAOYSA-N 568805 5-[4-(2-Methylpropyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 268 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 138 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568805 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568805&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462949 473130118 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200392 CC(C)Cc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H15F3N2O2/c1-8(2)5-9-3-4-10(6-11(9)14(15,16)17)12-7-21-13(20)19-18-12/h3-4,6,8H,5,7H2,1-2H3,(H,19,20) MIFBSBDNGQXZCA-UHFFFAOYSA-N 568805 5-[4-(2-Methylpropyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 268 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 110 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568805 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568805&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462949 473130118 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200393 CC(C)(C)CCc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H19F3N2O2/c1-15(2,3)7-6-10-4-5-11(8-12(10)16(17,18)19)13-9-23-14(22)21-20-13/h4-5,8H,6-7,9H2,1-3H3,(H,21,22) SSHFGYIOGRHEIP-UHFFFAOYSA-N 568806 5-[4-(3,3-Dimethylbutyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 269 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 695 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568806 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568806&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462816 473130119 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200394 CC(C)(C)CCc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H19F3N2O2/c1-15(2,3)7-6-10-4-5-11(8-12(10)16(17,18)19)13-9-23-14(22)21-20-13/h4-5,8H,6-7,9H2,1-3H3,(H,21,22) SSHFGYIOGRHEIP-UHFFFAOYSA-N 568806 5-[4-(3,3-Dimethylbutyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 269 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 790 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568806 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568806&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462816 473130119 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200395 CC(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H13F3N2O2/c1-7(2)9-4-3-8(5-10(9)13(14,15)16)11-6-20-12(19)18-17-11/h3-5,7H,6H2,1-2H3,(H,18,19) VIQXQKBLUSBLCT-UHFFFAOYSA-N 568807 5-[4-(Propan-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 270 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 55.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568807 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568807&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462990 473130120 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200396 CC(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H13F3N2O2/c1-7(2)9-4-3-8(5-10(9)13(14,15)16)11-6-20-12(19)18-17-11/h3-5,7H,6H2,1-2H3,(H,18,19) VIQXQKBLUSBLCT-UHFFFAOYSA-N 568807 5-[4-(Propan-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 270 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 170 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568807 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568807&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462990 473130120 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200397 FC(F)(F)c1cc(ccc1C1CCCOC1)C1=NNC(=O)OC1 InChI=1S/C15H15F3N2O3/c16-15(17,18)12-6-9(13-8-23-14(21)20-19-13)3-4-11(12)10-2-1-5-22-7-10/h3-4,6,10H,1-2,5,7-8H2,(H,20,21) OJNOGIOWPRIKOY-UHFFFAOYSA-N 568808 (rac)-5-{4-[Oxan-3-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 271 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 27.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568808 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568808&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462916 473130121 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200398 FC(F)(F)c1cc(ccc1C1CCCOC1)C1=NNC(=O)OC1 InChI=1S/C15H15F3N2O3/c16-15(17,18)12-6-9(13-8-23-14(21)20-19-13)3-4-11(12)10-2-1-5-22-7-10/h3-4,6,10H,1-2,5,7-8H2,(H,20,21) OJNOGIOWPRIKOY-UHFFFAOYSA-N 568808 (rac)-5-{4-[Oxan-3-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 271 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 25.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568808 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568808&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462916 473130121 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200399 O[C@H]1CC[C@@H](CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N2O3/c17-16(18,19)13-7-10(14-8-24-15(23)21-20-14)3-6-12(13)9-1-4-11(22)5-2-9/h3,6-7,9,11,22H,1-2,4-5,8H2,(H,21,23)/t9-,11- DQYWGDBDHLHSCD-HOMQSWHASA-N 568809 (trans)-5-{4-[4-hydroxycyclohexyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 272 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 19.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568809 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568809&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462665 473130122 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200400 O[C@H]1CC[C@@H](CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N2O3/c17-16(18,19)13-7-10(14-8-24-15(23)21-20-14)3-6-12(13)9-1-4-11(22)5-2-9/h3,6-7,9,11,22H,1-2,4-5,8H2,(H,21,23)/t9-,11- DQYWGDBDHLHSCD-HOMQSWHASA-N 568809 (trans)-5-{4-[4-hydroxycyclohexyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 272 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 10.00 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568809 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568809&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462665 473130122 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200401 O[C@H]1CC[C@H](CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N2O3/c17-16(18,19)13-7-10(14-8-24-15(23)21-20-14)3-6-12(13)9-1-4-11(22)5-2-9/h3,6-7,9,11,22H,1-2,4-5,8H2,(H,21,23)/t9-,11+ DQYWGDBDHLHSCD-JGZJWPJOSA-N 568810 (cis)-5-{4-[4-Hydroxycyclohexyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 273 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 44.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568810 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568810&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462665 473130123 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200402 O[C@H]1CC[C@H](CC1)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H17F3N2O3/c17-16(18,19)13-7-10(14-8-24-15(23)21-20-14)3-6-12(13)9-1-4-11(22)5-2-9/h3,6-7,9,11,22H,1-2,4-5,8H2,(H,21,23)/t9-,11+ DQYWGDBDHLHSCD-JGZJWPJOSA-N 568810 (cis)-5-{4-[4-Hydroxycyclohexyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 273 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 53.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568810 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568810&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462665 473130123 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200403 NCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C12H13F3N4O2/c13-12(14,15)8-5-7(1-2-9(8)17-4-3-16)10-6-21-11(20)19-18-10/h1-2,5,17H,3-4,6,16H2,(H,19,20) MRAKZGZXMJKEHM-UHFFFAOYSA-N 568811 5-{4-[(2-Aminoethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one-salt with hydrochloric acid::US11427553, Example 274 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 300 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568811 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568811&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463026 473130124 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200404 NCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C12H13F3N4O2/c13-12(14,15)8-5-7(1-2-9(8)17-4-3-16)10-6-21-11(20)19-18-10/h1-2,5,17H,3-4,6,16H2,(H,19,20) MRAKZGZXMJKEHM-UHFFFAOYSA-N 568811 5-{4-[(2-Aminoethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one-salt with hydrochloric acid::US11427553, Example 274 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 400 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568811 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568811&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463026 473130124 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200405 NC12CC1CN(C2)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H15F3N4O2/c16-15(17,18)10-3-8(11-6-24-13(23)21-20-11)1-2-12(10)22-5-9-4-14(9,19)7-22/h1-3,9H,4-7,19H2,(H,21,23) QVTXTMRTSBKDKZ-UHFFFAOYSA-N 568812 (rac)-5-{4-[1-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one-salt with hydrochloric acid::US11427553, Example 275 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 29.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568812 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568812&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462957 473130125 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200406 NC12CC1CN(C2)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H15F3N4O2/c16-15(17,18)10-3-8(11-6-24-13(23)21-20-11)1-2-12(10)22-5-9-4-14(9,19)7-22/h1-3,9H,4-7,19H2,(H,21,23) QVTXTMRTSBKDKZ-UHFFFAOYSA-N 568812 (rac)-5-{4-[1-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one-salt with hydrochloric acid::US11427553, Example 275 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 64.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568812 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568812&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462957 473130125 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200407 CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C11H10F3N3O2/c1-15-8-3-2-6(4-7(8)11(12,13)14)9-5-19-10(18)17-16-9/h2-4,15H,5H2,1H3,(H,17,18) WPKVJCKKKHXAGS-UHFFFAOYSA-N 568813 5-[4-(Methylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 276 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 79.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568813 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568813&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462912 473130126 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200408 CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C11H10F3N3O2/c1-15-8-3-2-6(4-7(8)11(12,13)14)9-5-19-10(18)17-16-9/h2-4,15H,5H2,1H3,(H,17,18) WPKVJCKKKHXAGS-UHFFFAOYSA-N 568813 5-[4-(Methylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 276 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568813 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568813&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462912 473130126 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200409 C[C@@H]1OC(=O)NN=C1c1ccc(N2CCN(C)CC2)c(c1)C(F)(F)F InChI=1S/C16H19F3N4O2/c1-10-14(20-21-15(24)25-10)11-3-4-13(12(9-11)16(17,18)19)23-7-5-22(2)6-8-23/h3-4,9-10H,5-8H2,1-2H3,(H,21,24)/t10-/m0/s1 MOMGZCKRXOIAQX-JTQLQIEISA-N 568814 (6S)-6-Methyl-5-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 277 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568814 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568814&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465185 473130127 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200410 C[C@@H]1OC(=O)NN=C1c1ccc(N2CCN(C)CC2)c(c1)C(F)(F)F InChI=1S/C16H19F3N4O2/c1-10-14(20-21-15(24)25-10)11-3-4-13(12(9-11)16(17,18)19)23-7-5-22(2)6-8-23/h3-4,9-10H,5-8H2,1-2H3,(H,21,24)/t10-/m0/s1 MOMGZCKRXOIAQX-JTQLQIEISA-N 568814 (6S)-6-Methyl-5-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 277 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 87.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568814 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568814&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465185 473130127 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200411 CC(C)(O)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H13F3N2O3/c1-12(2,20)8-4-3-7(5-9(8)13(14,15)16)10-6-21-11(19)18-17-10/h3-5,20H,6H2,1-2H3,(H,18,19) RMVANUYVMJRYEJ-UHFFFAOYSA-N 568815 5-[4-(2-Hydroxypropan-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 278 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568815 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568815&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463003 473130128 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200412 CC(C)(O)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C13H13F3N2O3/c1-12(2,20)8-4-3-7(5-9(8)13(14,15)16)10-6-21-11(19)18-17-10/h3-5,20H,6H2,1-2H3,(H,18,19) RMVANUYVMJRYEJ-UHFFFAOYSA-N 568815 5-[4-(2-Hydroxypropan-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 278 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568815 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568815&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463003 473130128 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200413 C[C@@H]1OC(=O)NN=C1c1ccc(N2CC(F)(F)C2)c(c1)C(F)(F)F InChI=1S/C14H12F5N3O2/c1-7-11(20-21-12(23)24-7)8-2-3-10(9(4-8)14(17,18)19)22-5-13(15,16)6-22/h2-4,7H,5-6H2,1H3,(H,21,23)/t7-/m0/s1 ULPYSLWRIGQWTL-ZETCQYMHSA-N 568816 (6S)-5-[4-(3,3-Difluoroazetidin-1-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 279 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 20.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568816 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568816&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463002 473130129 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200414 C[C@@H]1OC(=O)NN=C1c1ccc(N2CC(F)(F)C2)c(c1)C(F)(F)F InChI=1S/C14H12F5N3O2/c1-7-11(20-21-12(23)24-7)8-2-3-10(9(4-8)14(17,18)19)22-5-13(15,16)6-22/h2-4,7H,5-6H2,1H3,(H,21,23)/t7-/m0/s1 ULPYSLWRIGQWTL-ZETCQYMHSA-N 568816 (6S)-5-[4-(3,3-Difluoroazetidin-1-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 279 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 23.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568816 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568816&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463002 473130129 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200415 C[C@@H]1OC(=O)NN=C1c1ccc(N2CC(C)(O)C2)c(c1)C(F)(F)F InChI=1S/C15H16F3N3O3/c1-8-12(19-20-13(22)24-8)9-3-4-11(10(5-9)15(16,17)18)21-6-14(2,23)7-21/h3-5,8,23H,6-7H2,1-2H3,(H,20,22)/t8-/m0/s1 BAPXKYZLOVJFOU-QMMMGPOBSA-N 568817 (6S)-5-[4-(3-Hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 280 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 11.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568817 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568817&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462746 473130130 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200416 C[C@@H]1OC(=O)NN=C1c1ccc(N2CC(C)(O)C2)c(c1)C(F)(F)F InChI=1S/C15H16F3N3O3/c1-8-12(19-20-13(22)24-8)9-3-4-11(10(5-9)15(16,17)18)21-6-14(2,23)7-21/h3-5,8,23H,6-7H2,1-2H3,(H,20,22)/t8-/m0/s1 BAPXKYZLOVJFOU-QMMMGPOBSA-N 568817 (6S)-5-[4-(3-Hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 280 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 9.00 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568817 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568817&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462746 473130130 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200417 FC(F)(F)c1cc(ccc1Cl)C1=NNC(=O)OC1 InChI=1S/C10H6ClF3N2O2/c11-7-2-1-5(3-6(7)10(12,13)14)8-4-18-9(17)16-15-8/h1-3H,4H2,(H,16,17) FMCYGJVBSFESNF-UHFFFAOYSA-N 568818 US11427553, Example Intermediate 64 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 610 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568818 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568818&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463156 473130131 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200418 FC(F)(F)c1cc(ccc1Cl)C1=NNC(=O)OC1 InChI=1S/C10H6ClF3N2O2/c11-7-2-1-5(3-6(7)10(12,13)14)8-4-18-9(17)16-15-8/h1-3H,4H2,(H,16,17) FMCYGJVBSFESNF-UHFFFAOYSA-N 568818 US11427553, Example Intermediate 64 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 490 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568818 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568818&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463156 473130131 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200419 Fc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C10H6F4N2O2/c11-7-2-1-5(3-6(7)10(12,13)14)8-4-18-9(17)16-15-8/h1-3H,4H2,(H,16,17) HVOQQQCHJMIBHR-UHFFFAOYSA-N 568819 US11427553, Example Intermediate 66 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568819 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568819&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462844 473130132 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200420 Fc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C10H6F4N2O2/c11-7-2-1-5(3-6(7)10(12,13)14)8-4-18-9(17)16-15-8/h1-3H,4H2,(H,16,17) HVOQQQCHJMIBHR-UHFFFAOYSA-N 568819 US11427553, Example Intermediate 66 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568819 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568819&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462844 473130132 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200421 CC1OC(=O)NN=C1c1ccc(Br)cc1 InChI=1S/C10H9BrN2O2/c1-6-9(12-13-10(14)15-6)7-2-4-8(11)5-3-7/h2-6H,1H3,(H,13,14) KNMKLBIEFWXRMO-UHFFFAOYSA-N 568820 US11427553, Example Intermediate 72 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 320 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568820 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568820&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463034 473130133 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200422 CC1OC(=O)NN=C1c1ccc(Br)cc1 InChI=1S/C10H9BrN2O2/c1-6-9(12-13-10(14)15-6)7-2-4-8(11)5-3-7/h2-6H,1H3,(H,13,14) KNMKLBIEFWXRMO-UHFFFAOYSA-N 568820 US11427553, Example Intermediate 72 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 400 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568820 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568820&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463034 473130133 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200423 FC(F)(F)Oc1cc(ccc1Cl)C1=NNC(=O)OC1 InChI=1S/C10H6ClF3N2O3/c11-6-2-1-5(3-8(6)19-10(12,13)14)7-4-18-9(17)16-15-7/h1-3H,4H2,(H,16,17) VASSUNOWJBRYCA-UHFFFAOYSA-N 568821 US11427553, Example Intermediate 73 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 720 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568821 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568821&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462709 473130134 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200424 FC(F)(F)Oc1cc(ccc1Cl)C1=NNC(=O)OC1 InChI=1S/C10H6ClF3N2O3/c11-6-2-1-5(3-8(6)19-10(12,13)14)7-4-18-9(17)16-15-7/h1-3H,4H2,(H,16,17) VASSUNOWJBRYCA-UHFFFAOYSA-N 568821 US11427553, Example Intermediate 73 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568821 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568821&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462709 473130134 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200425 C[C@@H]1OC(=O)NN=C1c1ccc(Cl)c(c1)C(F)(F)F InChI=1S/C11H8ClF3N2O2/c1-5-9(16-17-10(18)19-5)6-2-3-8(12)7(4-6)11(13,14)15/h2-5H,1H3,(H,17,18)/t5-/m0/s1 LHMCMBWRKRFIOH-YFKPBYRVSA-N 568822 US11427553, Example Intermediate 74 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 34.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568822 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568822&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463073 473130135 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200426 C[C@@H]1OC(=O)NN=C1c1ccc(Cl)c(c1)C(F)(F)F InChI=1S/C11H8ClF3N2O2/c1-5-9(16-17-10(18)19-5)6-2-3-8(12)7(4-6)11(13,14)15/h2-5H,1H3,(H,17,18)/t5-/m0/s1 LHMCMBWRKRFIOH-YFKPBYRVSA-N 568822 US11427553, Example Intermediate 74 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568822 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568822&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463073 473130135 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200427 C[C@@H]1OC(=O)NN=C1c1ccc(F)c(c1)C(F)(F)F InChI=1S/C11H8F4N2O2/c1-5-9(16-17-10(18)19-5)6-2-3-8(12)7(4-6)11(13,14)15/h2-5H,1H3,(H,17,18)/t5-/m0/s1 UDTISEFJVOGSFA-YFKPBYRVSA-N 568823 US11427553, Example Intermediate 75 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 240 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568823 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568823&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462818 473130136 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200428 C[C@@H]1OC(=O)NN=C1c1ccc(F)c(c1)C(F)(F)F InChI=1S/C11H8F4N2O2/c1-5-9(16-17-10(18)19-5)6-2-3-8(12)7(4-6)11(13,14)15/h2-5H,1H3,(H,17,18)/t5-/m0/s1 UDTISEFJVOGSFA-YFKPBYRVSA-N 568823 US11427553, Example Intermediate 75 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 710 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568823 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568823&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462818 473130136 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200429 Cc1cc(ccc1Cl)C1=NNC(=O)OC1 InChI=1S/C10H9ClN2O2/c1-6-4-7(2-3-8(6)11)9-5-15-10(14)13-12-9/h2-4H,5H2,1H3,(H,13,14) NDWZLHKAPOLXFO-UHFFFAOYSA-N 568824 US11427553, Example Intermediate 76 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 375 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568824 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568824&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462807 473130137 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200430 Cc1cc(ccc1Cl)C1=NNC(=O)OC1 InChI=1S/C10H9ClN2O2/c1-6-4-7(2-3-8(6)11)9-5-15-10(14)13-12-9/h2-4H,5H2,1H3,(H,13,14) NDWZLHKAPOLXFO-UHFFFAOYSA-N 568824 US11427553, Example Intermediate 76 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 130 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568824 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568824&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462807 473130137 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200431 FC(F)c1cc(ccc1Br)C1=NNC(=O)OC1 InChI=1S/C10H7BrF2N2O2/c11-7-2-1-5(3-6(7)9(12)13)8-4-17-10(16)15-14-8/h1-3,9H,4H2,(H,15,16) MGUDUVNCKFHWMQ-UHFFFAOYSA-N 568825 US11427553, Example Intermediate 77 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568825 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568825&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462674 473130138 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200432 FC(F)c1cc(ccc1Br)C1=NNC(=O)OC1 InChI=1S/C10H7BrF2N2O2/c11-7-2-1-5(3-6(7)9(12)13)8-4-17-10(16)15-14-8/h1-3,9H,4H2,(H,15,16) MGUDUVNCKFHWMQ-UHFFFAOYSA-N 568825 US11427553, Example Intermediate 77 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 330 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568825 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568825&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462674 473130138 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200433 FC(F)(F)c1cc(ccc1Br)C1=NNC(=O)OC1 InChI=1S/C10H6BrF3N2O2/c11-7-2-1-5(3-6(7)10(12,13)14)8-4-18-9(17)16-15-8/h1-3H,4H2,(H,16,17) KBFSLTNLANHPNF-UHFFFAOYSA-N 568826 US11427553, Example Intermediate 78 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 140 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568826 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568826&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462821 473130139 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200434 FC(F)(F)c1cc(ccc1Br)C1=NNC(=O)OC1 InChI=1S/C10H6BrF3N2O2/c11-7-2-1-5(3-6(7)10(12,13)14)8-4-18-9(17)16-15-8/h1-3H,4H2,(H,16,17) KBFSLTNLANHPNF-UHFFFAOYSA-N 568826 US11427553, Example Intermediate 78 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568826 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568826&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462821 473130139 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200435 CC(C)(C)OC(=O)NCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H21F3N4O4/c1-16(2,3)28-14(25)22-7-6-21-12-5-4-10(8-11(12)17(18,19)20)13-9-27-15(26)24-23-13/h4-5,8,21H,6-7,9H2,1-3H3,(H,22,25)(H,24,26) NWOMEEMLGNZVMK-UHFFFAOYSA-N 568827 US11427553, Example Intermediate 67 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 6.00 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568827 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568827&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475153 473130140 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200436 CC(C)(C)OC(=O)NCCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H21F3N4O4/c1-16(2,3)28-14(25)22-7-6-21-12-5-4-10(8-11(12)17(18,19)20)13-9-27-15(26)24-23-13/h4-5,8,21H,6-7,9H2,1-3H3,(H,22,25)(H,24,26) NWOMEEMLGNZVMK-UHFFFAOYSA-N 568827 US11427553, Example Intermediate 67 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 7.00 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568827 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568827&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475153 473130140 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200437 Cc1cc(ccc1-c1ccc(=O)[nH]c1)C1=NNC(=O)OC1 InChI=1S/C15H13N3O3/c1-9-6-10(13-8-21-15(20)18-17-13)2-4-12(9)11-3-5-14(19)16-7-11/h2-7H,8H2,1H3,(H,16,19)(H,18,20) CDFUCJZMUXBNKD-UHFFFAOYSA-N 568828 5-[3-Methyl-4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 12 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568828 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568828&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 165436726 473130141 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200438 Cc1cc(ccc1-c1ccc(=O)[nH]c1)C1=NNC(=O)OC1 InChI=1S/C15H13N3O3/c1-9-6-10(13-8-21-15(20)18-17-13)2-4-12(9)11-3-5-14(19)16-7-11/h2-7H,8H2,1H3,(H,16,19)(H,18,20) CDFUCJZMUXBNKD-UHFFFAOYSA-N 568828 5-[3-Methyl-4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 12 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 30.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568828 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568828&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 165436726 473130141 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200439 Cc1cc(ccc1-c1cncnc1)C1=NNC(=O)OC1 InChI=1S/C14H12N4O2/c1-9-4-10(13-7-20-14(19)18-17-13)2-3-12(9)11-5-15-8-16-6-11/h2-6,8H,7H2,1H3,(H,18,19) PPPBFWLLPXMPLW-UHFFFAOYSA-N 568829 5-[3-Methyl-4-(pyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 14 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 63.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568829 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568829&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463032 473130142 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200440 Cc1cc(ccc1-c1cncnc1)C1=NNC(=O)OC1 InChI=1S/C14H12N4O2/c1-9-4-10(13-7-20-14(19)18-17-13)2-3-12(9)11-5-15-8-16-6-11/h2-6,8H,7H2,1H3,(H,18,19) PPPBFWLLPXMPLW-UHFFFAOYSA-N 568829 5-[3-Methyl-4-(pyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 14 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 71.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568829 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568829&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463032 473130142 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200441 O=C1NN=C(CO1)c1ccc(N2CCOCC2)c(c1)C#N InChI=1S/C14H14N4O3/c15-8-11-7-10(12-9-21-14(19)17-16-12)1-2-13(11)18-3-5-20-6-4-18/h1-2,7H,3-6,9H2,(H,17,19) LOTIGKIRMOZROS-UHFFFAOYSA-N 568830 2-(Morpholin-4-yl)-5-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)benzonitrile::US11427553, Example 22 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 52.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568830 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568830&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462754 473130143 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200442 O=C1NN=C(CO1)c1ccc(N2CCOCC2)c(c1)C#N InChI=1S/C14H14N4O3/c15-8-11-7-10(12-9-21-14(19)17-16-12)1-2-13(11)18-3-5-20-6-4-18/h1-2,7H,3-6,9H2,(H,17,19) LOTIGKIRMOZROS-UHFFFAOYSA-N 568830 2-(Morpholin-4-yl)-5-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)benzonitrile::US11427553, Example 22 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 33.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568830 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568830&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462754 473130143 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200443 Cc1cc(ccc1-c1cnc(C)nc1)C1=NNC(=O)OC1 InChI=1S/C15H14N4O2/c1-9-5-11(14-8-21-15(20)19-18-14)3-4-13(9)12-6-16-10(2)17-7-12/h3-7H,8H2,1-2H3,(H,19,20) LWMHRSVMMMBCSM-UHFFFAOYSA-N 568831 5-[3-Methyl-4-(2-methylpyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 28 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568831 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568831&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462686 473130144 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200444 Cc1cc(ccc1-c1cnc(C)nc1)C1=NNC(=O)OC1 InChI=1S/C15H14N4O2/c1-9-5-11(14-8-21-15(20)19-18-14)3-4-13(9)12-6-16-10(2)17-7-12/h3-7H,8H2,1-2H3,(H,19,20) LWMHRSVMMMBCSM-UHFFFAOYSA-N 568831 5-[3-Methyl-4-(2-methylpyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 28 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 40.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568831 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568831&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462686 473130144 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200445 Cc1ccc(cc1O)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H13F3N2O3/c1-9-2-3-10(7-15(9)23)12-5-4-11(6-13(12)17(18,19)20)14-8-25-16(24)22-21-14/h2-7,23H,8H2,1H3,(H,22,24) ZDCVSMUGZRLHIC-UHFFFAOYSA-N 568832 5-[3′-Hydroxy-4′-methyl-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 35 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 79.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568832 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568832&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462826 473130145 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200446 Cc1ccc(cc1O)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C17H13F3N2O3/c1-9-2-3-10(7-15(9)23)12-5-4-11(6-13(12)17(18,19)20)14-8-25-16(24)22-21-14/h2-7,23H,8H2,1H3,(H,22,24) ZDCVSMUGZRLHIC-UHFFFAOYSA-N 568832 5-[3′-Hydroxy-4′-methyl-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 35 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 75.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568832 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568832&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462826 473130145 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200447 Cc1n[nH]cc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H11F3N4O2/c1-7-10(5-18-19-7)9-3-2-8(4-11(9)14(15,16)17)12-6-23-13(22)21-20-12/h2-5H,6H2,1H3,(H,18,19)(H,21,22) RDKWZSFOIKIBGB-UHFFFAOYSA-N 568833 5-[4-(3-Methyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 46 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 27.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568833 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568833&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463033 473130146 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200448 Cc1n[nH]cc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H11F3N4O2/c1-7-10(5-18-19-7)9-3-2-8(4-11(9)14(15,16)17)12-6-23-13(22)21-20-12/h2-5H,6H2,1H3,(H,18,19)(H,21,22) RDKWZSFOIKIBGB-UHFFFAOYSA-N 568833 5-[4-(3-Methyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 46 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 17.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568833 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568833&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463033 473130146 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200449 Cc1nn(C)cc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-8-11(6-22(2)21-8)10-4-3-9(5-12(10)15(16,17)18)13-7-24-14(23)20-19-13/h3-6H,7H2,1-2H3,(H,20,23) VNVFGFRFUNQJAK-UHFFFAOYSA-N 568834 5-[4-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 52 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 65.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568834 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568834&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462892 473130147 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200450 Cc1nn(C)cc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-8-11(6-22(2)21-8)10-4-3-9(5-12(10)15(16,17)18)13-7-24-14(23)20-19-13/h3-6H,7H2,1-2H3,(H,20,23) VNVFGFRFUNQJAK-UHFFFAOYSA-N 568834 5-[4-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 52 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 30.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568834 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568834&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462892 473130147 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200451 Cn1cnc2ccc(cc12)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-25-9-22-14-5-3-10(7-16(14)25)12-4-2-11(6-13(12)18(19,20)21)15-8-27-17(26)24-23-15/h2-7,9H,8H2,1H3,(H,24,26) JDKBPTVZQOWYLQ-UHFFFAOYSA-N 568835 5-[4-(1-Methyl-1H-benzimidazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 73 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 18.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568835 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568835&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463025 473130148 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200452 Cn1cnc2ccc(cc12)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-25-9-22-14-5-3-10(7-16(14)25)12-4-2-11(6-13(12)18(19,20)21)15-8-27-17(26)24-23-15/h2-7,9H,8H2,1H3,(H,24,26) JDKBPTVZQOWYLQ-UHFFFAOYSA-N 568835 5-[4-(1-Methyl-1H-benzimidazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 73 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 41.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568835 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568835&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463025 473130148 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200453 Cn1ncc2ccc(cc12)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-25-16-7-10(2-3-12(16)8-22-25)13-5-4-11(6-14(13)18(19,20)21)15-9-27-17(26)24-23-15/h2-8H,9H2,1H3,(H,24,26) UVQBFTYJPMGOJW-UHFFFAOYSA-N 568836 5-[4-(1-Methyl-1H-indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 75 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568836 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568836&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462946 473130149 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200454 Cn1ncc2ccc(cc12)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-25-16-7-10(2-3-12(16)8-22-25)13-5-4-11(6-14(13)18(19,20)21)15-9-27-17(26)24-23-15/h2-8H,9H2,1H3,(H,24,26) UVQBFTYJPMGOJW-UHFFFAOYSA-N 568836 5-[4-(1-Methyl-1H-indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 75 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 78.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568836 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568836&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462946 473130149 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200455 COc1cc(ccn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O3/c1-21-14-7-9(4-5-17-14)11-3-2-10(6-12(11)16)13-8-22-15(20)19-18-13/h2-7H,8H2,1H3,(H,19,20) MPLMOLGTXPCMIJ-UHFFFAOYSA-N 568837 5-[3-Fluoro-4-(2-methoxypyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 95 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 37.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568837 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568837&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462718 473130150 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200456 COc1cc(ccn1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H12FN3O3/c1-21-14-7-9(4-5-17-14)11-3-2-10(6-12(11)16)13-8-22-15(20)19-18-13/h2-7H,8H2,1H3,(H,19,20) MPLMOLGTXPCMIJ-UHFFFAOYSA-N 568837 5-[3-Fluoro-4-(2-methoxypyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 95 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 79.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568837 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568837&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462718 473130150 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200457 Oc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O3/c16-13-7-10(14-8-21-15(20)18-17-14)4-5-12(13)9-2-1-3-11(19)6-9/h1-7,19H,8H2,(H,18,20) JAQMNYDOINQFGV-UHFFFAOYSA-N 568838 5-(2-Fluoro-3′-hydroxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 104 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 35.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568838 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568838&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465159 473130151 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200458 Oc1cccc(c1)-c1ccc(cc1F)C1=NNC(=O)OC1 InChI=1S/C15H11FN2O3/c16-13-7-10(14-8-21-15(20)18-17-14)4-5-12(13)9-2-1-3-11(19)6-9/h1-7,19H,8H2,(H,18,20) JAQMNYDOINQFGV-UHFFFAOYSA-N 568838 5-(2-Fluoro-3′-hydroxy[1,1′-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 104 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 58.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568838 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568838&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465159 473130151 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200459 Cn1cc(c(n1)C(F)(F)F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H10F6N4O2/c1-25-5-9(12(24-25)15(19,20)21)8-3-2-7(4-10(8)14(16,17)18)11-6-27-13(26)23-22-11/h2-5H,6H2,1H3,(H,23,26) NNYVUXWGZYBGSC-UHFFFAOYSA-N 568839 5-{4-[1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 127 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 78.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568839 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568839&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462947 473130152 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200460 Cn1cc(c(n1)C(F)(F)F)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H10F6N4O2/c1-25-5-9(12(24-25)15(19,20)21)8-3-2-7(4-10(8)14(16,17)18)11-6-27-13(26)23-22-11/h2-5H,6H2,1H3,(H,23,26) NNYVUXWGZYBGSC-UHFFFAOYSA-N 568839 5-{4-[1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 127 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 31.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568839 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568839&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462947 473130152 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200461 Cc1n[nH]c(C)c1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-7-13(8(2)20-19-7)10-4-3-9(5-11(10)15(16,17)18)12-6-24-14(23)22-21-12/h3-5H,6H2,1-2H3,(H,19,20)(H,22,23) IBJVKSNORDBFND-UHFFFAOYSA-N 568840 5-[4-(3,5-Dimethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 128 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 280 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568840 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568840&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 165436727 473130153 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200462 Cc1n[nH]c(C)c1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H13F3N4O2/c1-7-13(8(2)20-19-7)10-4-3-9(5-11(10)15(16,17)18)12-6-24-14(23)22-21-12/h3-5H,6H2,1-2H3,(H,19,20)(H,22,23) IBJVKSNORDBFND-UHFFFAOYSA-N 568840 5-[4-(3,5-Dimethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 128 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 270 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568840 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568840&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 165436727 473130153 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200463 Cc1noc(C)c1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H12F3N3O3/c1-7-13(8(2)24-21-7)10-4-3-9(5-11(10)15(16,17)18)12-6-23-14(22)20-19-12/h3-5H,6H2,1-2H3,(H,20,22) OCOHVUNJBKXDTF-UHFFFAOYSA-N 568841 5-[4-(3,5-Dimethyl-1,2-oxazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 129 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 970 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568841 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568841&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462723 473130154 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200464 Cc1noc(C)c1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H12F3N3O3/c1-7-13(8(2)24-21-7)10-4-3-9(5-11(10)15(16,17)18)12-6-23-14(22)20-19-12/h3-5H,6H2,1-2H3,(H,20,22) OCOHVUNJBKXDTF-UHFFFAOYSA-N 568841 5-[4-(3,5-Dimethyl-1,2-oxazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 129 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 770 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568841 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568841&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462723 473130154 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200465 FC(F)(F)c1n[nH]cc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H8F6N4O2/c15-13(16,17)9-3-6(10-5-26-12(25)24-22-10)1-2-7(9)8-4-21-23-11(8)14(18,19)20/h1-4H,5H2,(H,21,23)(H,24,25) KSUZWMWMORSGOH-UHFFFAOYSA-N 568842 5-{3-(Trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 130 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 200 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568842 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568842&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 165436728 473130155 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200466 FC(F)(F)c1n[nH]cc1-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H8F6N4O2/c15-13(16,17)9-3-6(10-5-26-12(25)24-22-10)1-2-7(9)8-4-21-23-11(8)14(18,19)20/h1-4H,5H2,(H,21,23)(H,24,25) KSUZWMWMORSGOH-UHFFFAOYSA-N 568842 5-{3-(Trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 130 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 160 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568842 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568842&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 165436728 473130155 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200467 CC(C)(O)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-14(2,23)5-6-19-11-4-3-9(7-10(11)15(16,17)18)12-8-24-13(22)21-20-12/h3-4,7,19,23H,5-6,8H2,1-2H3,(H,21,22) VDEOMFCGPXASSB-UHFFFAOYSA-N 568843 5-{4-[(3-hydroxy-3-methylbutyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 319 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 70.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568843 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568843&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463227 473130156 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200468 CC(C)(O)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H18F3N3O3/c1-14(2,23)5-6-19-11-4-3-9(7-10(11)15(16,17)18)12-8-24-13(22)21-20-12/h3-4,7,19,23H,5-6,8H2,1-2H3,(H,21,22) VDEOMFCGPXASSB-UHFFFAOYSA-N 568843 5-{4-[(3-hydroxy-3-methylbutyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 319 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 180 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568843 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568843&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463227 473130156 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200469 NC1CCC(CC1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H19F3N4O2/c17-16(18,19)12-7-9(14-8-25-15(24)23-22-14)1-6-13(12)21-11-4-2-10(20)3-5-11/h1,6-7,10-11,21H,2-5,8,20H2,(H,23,24) RPZZZQHPDXCRLR-UHFFFAOYSA-N 568844 5-[4-{[4-aminocyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (mixture of stereoisomers)::US11427553, Example 320 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 76.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568844 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568844&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465179 473130157 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200470 NC1CCC(CC1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H19F3N4O2/c17-16(18,19)12-7-9(14-8-25-15(24)23-22-14)1-6-13(12)21-11-4-2-10(20)3-5-11/h1,6-7,10-11,21H,2-5,8,20H2,(H,23,24) RPZZZQHPDXCRLR-UHFFFAOYSA-N 568844 5-[4-{[4-aminocyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (mixture of stereoisomers)::US11427553, Example 320 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 220 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568844 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568844&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465179 473130157 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200471 CC(C)(N)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H17F3N4O2/c1-13(2,18)7-19-10-4-3-8(5-9(10)14(15,16)17)11-6-23-12(22)21-20-11/h3-5,19H,6-7,18H2,1-2H3,(H,21,22) VEGUHBPQHXUZNN-UHFFFAOYSA-N 568845 5-{4-[(2-amino-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 321 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 290 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568845 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568845&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465171 473130158 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200472 CC(C)(N)CNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H17F3N4O2/c1-13(2,18)7-19-10-4-3-8(5-9(10)14(15,16)17)11-6-23-12(22)21-20-11/h3-5,19H,6-7,18H2,1-2H3,(H,21,22) VEGUHBPQHXUZNN-UHFFFAOYSA-N 568845 5-{4-[(2-amino-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 321 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 500 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568845 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568845&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465171 473130158 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200473 NC1CCCC(C1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H19F3N4O2/c17-16(18,19)12-6-9(14-8-25-15(24)23-22-14)4-5-13(12)21-11-3-1-2-10(20)7-11/h4-6,10-11,21H,1-3,7-8,20H2,(H,23,24) RCDJAPNFKIPWFJ-UHFFFAOYSA-N 568846 5-[4-{[3-aminocyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (mixture of stereoisomers)::US11427553, Example 322 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 580 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568846 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568846&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462771 473130159 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200474 NC1CCCC(C1)Nc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C16H19F3N4O2/c17-16(18,19)12-6-9(14-8-25-15(24)23-22-14)4-5-13(12)21-11-3-1-2-10(20)7-11/h4-6,10-11,21H,1-3,7-8,20H2,(H,23,24) RCDJAPNFKIPWFJ-UHFFFAOYSA-N 568846 5-[4-{[3-aminocyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (mixture of stereoisomers)::US11427553, Example 322 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 780 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568846 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568846&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462771 473130159 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200475 CN(C)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H17F3N4O2/c1-21(2)6-5-18-11-4-3-9(7-10(11)14(15,16)17)12-8-23-13(22)20-19-12/h3-4,7,18H,5-6,8H2,1-2H3,(H,20,22) KEONFINAMASGKS-UHFFFAOYSA-N 568847 5-[4-{[2-(dimethylamino)ethyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 323 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >280 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568847 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568847&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463415 473130160 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200476 CN(C)CCNc1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C14H17F3N4O2/c1-21(2)6-5-18-11-4-3-9(7-10(11)14(15,16)17)12-8-23-13(22)20-19-12/h3-4,7,18H,5-6,8H2,1-2H3,(H,20,22) KEONFINAMASGKS-UHFFFAOYSA-N 568847 5-[4-{[2-(dimethylamino)ethyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 323 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >910 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568847 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568847&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463415 473130160 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200477 CN(C)CCN(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H19F3N4O2/c1-21(2)6-7-22(3)13-5-4-10(8-11(13)15(16,17)18)12-9-24-14(23)20-19-12/h4-5,8H,6-7,9H2,1-3H3,(H,20,23) CZKJUYUXIZJHGQ-UHFFFAOYSA-N 568848 5-[4-{[2-(dimethylamino)ethyl](methyl)amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 324 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568848 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568848&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463064 473130161 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200478 CN(C)CCN(C)c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C15H19F3N4O2/c1-21(2)6-7-22(3)13-5-4-10(8-11(13)15(16,17)18)12-9-24-14(23)20-19-12/h4-5,8H,6-7,9H2,1-3H3,(H,20,23) CZKJUYUXIZJHGQ-UHFFFAOYSA-N 568848 5-[4-{[2-(dimethylamino)ethyl](methyl)amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 324 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens >1000 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568848 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568848&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463064 473130161 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200479 Cc1nc2cc(ccc2s1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H12F3N3O2S/c1-9-22-14-7-10(3-5-16(14)27-9)12-4-2-11(6-13(12)18(19,20)21)15-8-26-17(25)24-23-15/h2-7H,8H2,1H3,(H,24,25) UNCBXDDOPODUKW-UHFFFAOYSA-N 568849 5-[4-(2-methyl-1,3-benzothiazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 325 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 56.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568849 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568849&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137463402 473130162 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200480 Cc1nc2cc(ccc2s1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H12F3N3O2S/c1-9-22-14-7-10(3-5-16(14)27-9)12-4-2-11(6-13(12)18(19,20)21)15-8-26-17(25)24-23-15/h2-7H,8H2,1H3,(H,24,25) UNCBXDDOPODUKW-UHFFFAOYSA-N 568849 5-[4-(2-methyl-1,3-benzothiazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 325 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 150 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568849 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568849&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137463402 473130162 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200481 Cc1nc2cc(ccc2[nH]1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-9-22-14-5-3-10(7-15(14)23-9)12-4-2-11(6-13(12)18(19,20)21)16-8-27-17(26)25-24-16/h2-7H,8H2,1H3,(H,22,23)(H,25,26) HYFPAHQYPCEVQA-UHFFFAOYSA-N 568850 5-[4-(2-methyl-1H-benzimidazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 326 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 17.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568850 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568850&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137462863 473130163 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200482 Cc1nc2cc(ccc2[nH]1)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-9-22-14-5-3-10(7-15(14)23-9)12-4-2-11(6-13(12)18(19,20)21)16-8-27-17(26)25-24-16/h2-7H,8H2,1H3,(H,22,23)(H,25,26) HYFPAHQYPCEVQA-UHFFFAOYSA-N 568850 5-[4-(2-methyl-1H-benzimidazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 326 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 30.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568850 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568850&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137462863 473130163 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200483 Cc1n[nH]c2cc(ccc12)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-9-12-4-2-10(7-15(12)23-22-9)13-5-3-11(6-14(13)18(19,20)21)16-8-27-17(26)25-24-16/h2-7H,8H2,1H3,(H,22,23)(H,25,26) QSBMBVZLGJUCDC-UHFFFAOYSA-N 568851 5-[4-(3-methyl-1H-indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 327 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 11.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568851 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568851&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475620 473130164 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200484 Cc1n[nH]c2cc(ccc12)-c1ccc(cc1C(F)(F)F)C1=NNC(=O)OC1 InChI=1S/C18H13F3N4O2/c1-9-12-4-2-10(7-15(12)23-22-9)13-5-3-11(6-14(13)18(19,20)21)16-8-27-17(26)25-24-16/h2-7H,8H2,1H3,(H,22,23)(H,25,26) QSBMBVZLGJUCDC-UHFFFAOYSA-N 568851 5-[4-(3-methyl-1H-indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 327 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 16.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568851 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568851&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475620 473130164 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200485 FC(F)(F)c1cc(ccc1C1=CCNCC1)C1=NNC(=O)OC1 InChI=1S/C15H14F3N3O2/c16-15(17,18)12-7-10(13-8-23-14(22)21-20-13)1-2-11(12)9-3-5-19-6-4-9/h1-3,7,19H,4-6,8H2,(H,21,22) PAZRQLIXJOYFLE-UHFFFAOYSA-N 568852 5-[4-(1,2,3,6-tetrahydropyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 328 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 74.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568852 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568852&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137465196 473130165 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200486 FC(F)(F)c1cc(ccc1C1=CCNCC1)C1=NNC(=O)OC1 InChI=1S/C15H14F3N3O2/c16-15(17,18)12-7-10(13-8-23-14(22)21-20-13)1-2-11(12)9-3-5-19-6-4-9/h1-3,7,19H,4-6,8H2,(H,21,22) PAZRQLIXJOYFLE-UHFFFAOYSA-N 568852 5-[4-(1,2,3,6-tetrahydropyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 328 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 91.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568852 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568852&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137465196 473130165 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4 1200487 FC(F)c1cc(ccc1C1=CCOC1)C1=NNC(=O)OC1 InChI=1S/C14H12F2N2O3/c15-13(16)11-5-8(12-7-21-14(19)18-17-12)1-2-10(11)9-3-4-20-6-9/h1-3,5,13H,4,6-7H2,(H,18,19) YFIACJYACJRKGF-UHFFFAOYSA-N 568853 5-[3-(difluoromethyl)-4-(2,5-dihydrofuran-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 329 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Homo sapiens 100.0 US Patent 10.7270/Q2280BTW aid1806766 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568853 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1570&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568853&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3A&column=ki&startPg=0&Increment=50&submit=Search 137475199 473130166 1 MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ 7EG0,7EG1,7EG4,7LRC,7LRD cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A PDE3A_HUMAN Q14432 O60865 Q13348 Q17RD1 1200488 FC(F)c1cc(ccc1C1=CCOC1)C1=NNC(=O)OC1 InChI=1S/C14H12F2N2O3/c15-13(16)11-5-8(12-7-21-14(19)18-17-12)1-2-10(11)9-3-4-20-6-9/h1-3,5,13H,4,6-7H2,(H,18,19) YFIACJYACJRKGF-UHFFFAOYSA-N 568853 5-[3-(difluoromethyl)-4-(2,5-dihydrofuran-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one::US11427553, Example 329 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Homo sapiens 93.0 US Patent 10.7270/Q2280BTW aid1806767 US11427553 Ellermann, M; Gradl, SN; Kopitz, CC; Lange, M; Tersteegen, A; Lienau, P; Hegele-Hartung, C; Sulzle, D; Lewis, TA; Greulich, H; Wu, X; Meyerson, M; Burgin, A 8/30/2022 11/7/2022 Bayer Aktiengesellschaft; Bayer Pharma Aktiengesellschaft; The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc. http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=568853 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=1571&target=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=568853&enzyme=cGMP-inhibited+3%27%2C5%27-cyclic+phosphodiesterase+3B&column=ki&startPg=0&Increment=50&submit=Search 137475199 473130166 1 MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE 1SO2,1SOJ cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B PDE3B_HUMAN Q13370 B7ZM37 O00639 Q14408 Q6SEI4